U.S. patent application number 16/100181 was filed with the patent office on 2019-01-17 for indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives.
This patent application is currently assigned to Hoffmann-La Roche Inc.. The applicant listed for this patent is Hoffmann-La Roche Inc.. Invention is credited to Hans Hilpert, Sabine Kolczewski, Anja Limberg, Theodor Stoll.
Application Number | 20190016719 16/100181 |
Document ID | / |
Family ID | 50735996 |
Filed Date | 2019-01-17 |
![](/patent/app/20190016719/US20190016719A1-20190117-C00001.png)
![](/patent/app/20190016719/US20190016719A1-20190117-C00002.png)
![](/patent/app/20190016719/US20190016719A1-20190117-C00003.png)
![](/patent/app/20190016719/US20190016719A1-20190117-C00004.png)
![](/patent/app/20190016719/US20190016719A1-20190117-C00005.png)
![](/patent/app/20190016719/US20190016719A1-20190117-C00006.png)
![](/patent/app/20190016719/US20190016719A1-20190117-C00007.png)
![](/patent/app/20190016719/US20190016719A1-20190117-C00008.png)
![](/patent/app/20190016719/US20190016719A1-20190117-C00009.png)
![](/patent/app/20190016719/US20190016719A1-20190117-C00010.png)
![](/patent/app/20190016719/US20190016719A1-20190117-C00011.png)
View All Diagrams
United States Patent
Application |
20190016719 |
Kind Code |
A1 |
Hilpert; Hans ; et
al. |
January 17, 2019 |
INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE
DERIVATIVES
Abstract
The present invention is concerned with indolin-2-one and
1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives of general
formula I wherein Ar.sup.1, A.sup.2, R.sup.1, R.sup.2, R.sup.3, X
and n are as described herein and pharmaceutically acceptable salts
thereof for treatment of central nervous system disorders
##STR00001##
Inventors: |
Hilpert; Hans;
(Muenchenstein, CH) ; Kolczewski; Sabine;
(Loerrach, DE) ; Limberg; Anja; (Basel, CH)
; Stoll; Theodor; (Binningen, CH) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Hoffmann-La Roche Inc. |
Little Falls |
NJ |
US |
|
|
Assignee: |
Hoffmann-La Roche Inc.
Little Falls
NJ
|
Family ID: |
50735996 |
Appl. No.: |
16/100181 |
Filed: |
August 9, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15353355 |
Nov 16, 2016 |
10112938 |
|
|
16100181 |
|
|
|
|
PCT/EP2015/060937 |
May 19, 2015 |
|
|
|
15353355 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 411/12 20130101;
C07D 471/04 20130101; C07D 417/14 20130101; A61P 25/16 20180101;
A61P 25/32 20180101; C07D 403/14 20130101; A61K 31/4439 20130101;
A61P 25/00 20180101; C07D 401/14 20130101; A61P 25/20 20180101;
A61K 31/4178 20130101; A61P 25/24 20180101; A61P 25/34 20180101;
A61P 19/02 20180101; A61P 25/18 20180101; C07D 413/14 20130101;
A61P 29/00 20180101; C07D 403/04 20130101; A61P 25/28 20180101;
A61P 25/36 20180101; A61K 45/06 20130101; A61K 31/506 20130101;
A61P 25/22 20180101; C07D 405/14 20130101; A61P 3/02 20180101; A61K
31/444 20130101; A61P 25/04 20180101 |
International
Class: |
C07D 471/04 20060101
C07D471/04; C07D 405/14 20060101 C07D405/14; A61K 45/06 20060101
A61K045/06; C07D 417/14 20060101 C07D417/14; C07D 411/12 20060101
C07D411/12; C07D 403/14 20060101 C07D403/14; C07D 401/14 20060101
C07D401/14; A61K 31/506 20060101 A61K031/506; A61K 31/444 20060101
A61K031/444; A61K 31/4439 20060101 A61K031/4439; A61K 31/4178
20060101 A61K031/4178; C07D 413/14 20060101 C07D413/14; C07D 403/04
20060101 C07D403/04 |
Foreign Application Data
Date |
Code |
Application Number |
May 22, 2014 |
EP |
14169477.8 |
Claims
1. A compound of formula (I) ##STR00238## wherein Ar.sup.1 is
phenyl, pyridinyl or pyrimidinyl; Ar.sup.2 is selected from the
group consisting of (i), (ii) and (iii) ##STR00239## R.sup.1 is
hydrogen, C.sub.1-7-alkyl, halogen or C.sub.1-7-alkoxy; R.sup.3 is
hydrogen, C.sub.1-7-alkyl, C.sub.1-7-alkyl substituted by hydroxy,
cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by
C.sub.1-7-alkyl, or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl;
X is CH or N; n is 1 or 2; or, or, a pharmaceutically acceptable
salt thereof, a racemic mixture, an enantiomer, an optical isomer,
a stereoisomer thereof.
2. The compound of claim 1 wherein said compound is of formula Ia
##STR00240##
3. The compound of claim 1 wherein said compound is of formula Ib
##STR00241##
4. The compound of claim 1 wherein said compound is of formula Ic
##STR00242##
5. The compound of claim 1 which compounds are selected from the
group consisting of:
1,3,3-Trimethyl-6-(4-(pyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one;
1,3,3-Trimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one;
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin--
2-one;
1,3,3-Trimethyl-6-(2-(pyridin-3-yl)oxazol-4-yl)indolin-2-one;
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-4-yl)-1H-pyrazol-1-yl)indolin--
2-one;
1,3,3-Trimethyl-6-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)indolin-2-one;
1,3,3-Trimethyl-6-(1-(pyridin-3-yl)-1H-pyrazol-4-yl)indolin-2-one;
3,3-Dimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one;
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2--
one;
1,3,3-Trimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-
-one;
1-Cyclopropyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1--
yl)indolin-2-one;
1,3,3-Trimethyl-6-(5-(pyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-one;
3,3-Dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one;
1,3,3-Trimethyl-6-(5-(2-methylpyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-one-
;
1,3,3-Trimethyl-6-(5-(pyridin-3-yl)-1H-pyrazol-3-yl)indolin-2-one;
1-Ethyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin--
2-one;
1,3,3-Trimethyl-6-(4-(6-methylpyridin-3-yl)-1H-pyrazol-1-yl)indolin-
-2-one;
1-Cyclopropyl-3,3-dimethyl-6-(4-(6-methylpyridin-3-yl)-1H-pyrazol--
1-yl)indolin-2-one;
3,3-Dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol--yl)-1-(oxetan-3-yl)i-
ndolin-2-one;
1,3,3-Trimethyl-6-(5-(6-methylpyridin-3-yl)-1H-pyrazol-3-yl)indolin-2-one-
;
1,3,3-Trimethyl-6-(1-methyl-5-(2-methylpyridin-4-yl)-1H-pyrazol-3-yl)ind-
olin-2-one;
1,3,3-Trimethyl-6-(4-methyl-3-(2-methylpyridin-4-yl)-1H-pyrazol-5-yl)indo-
lin-2-one; a pharmaceutically acceptable salt thereof.
6. The method of claim 1 comprising administering a compound of
formula I together with an antipsychotic, antidepressant,
anxiolytic or mood stabilizer.
7. A method for the treatment of central nervous system disorders
including positive (psychosis) and negative symptoms of
schizophrenia, substance abuse, alcohol and drug addiction,
obsessive-compulsive disorders, cognitive impairment, bipolar
disorders, mood disorders, major depression, treatment resistant
depression, anxiety disorders, autism, Parkinson's disease, chronic
pain, borderline personality disorder, sleep disturbances, chronic
fatigue syndrome, stiffness, antiinflammatory effects in arthritis
and balance problems comprising administering to a patient in need
thereof a therapeutically effective amount of a compound of formula
I. ##STR00243## wherein Ar.sup.1 is phenyl, pyridinyl or
pyrimidinyl; Ar.sup.2 is a pyrazole or imidazole; R.sup.1 is
hydrogen, C.sub.1-7-alkyl, halogen or C.sub.1-7-alkoxy; R.sup.2 is
hydrogen or C.sub.1-7-alkyl; R.sup.3 is hydrogen, C.sub.1-7-alkyl,
C.sub.1-7-alkyl substituted by hydroxy, cycloalkyl, oxetan-3-yl,
pyridinyl, imidazolyl, pyrazolyl, pyrimidinyl, which rings may
optionally substituted by C.sub.1-7-alkyl, or is
--(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; X is CH or N; n is 1 or
2; or a pharmaceutically acceptable salt thereof, a racemic
mixture, an enantiomer, an optical isomer, a stereoisomer
thereof.
8. The method of claim 7 wherein the compound is selected from the
group consisting of:
1-Cyclopropyl-6-(5-(4-fluorophenyl)-1H-imidazol-2-yl)-3,3-dimethylindolin-
-2-one: 1,3,3-Trimethyl-6-(5-phenyl-1H-imidazol-2-yl)indolin-2-one:
1,3,3-Trimethyl-6-(2-(pyridin-4-yl)-1H-imidazol-5-yl)indolin-2-one:
1-Cyclopropyl-3,3-dimethyl-6-(3-(pyridin-4-yl))-1,2,4-oxadiazol-5-yl)indo-
lin-2-one;
1,3,3-Trimethyl-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-2--
one;
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)ind-
olin-2-one;
3,3-Dimethyl-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-2-one;
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl)indolin-
-2-one;
3,3-Dimethyl-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl)indolin-2-one;
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-2-
-one;
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl)indo-
lin-2-one;
1,3,3-Trimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2--
one;
1,3,3-Trimethyl-6-(1-(pyridin-4-yl)-1H-imidazol-4-yl)indolin-2-one;
1,3,3-Trimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)indolin-2-on-
e;
6-[1-(2-Fluoropyridin-4-yl)imidazol-4-yl]-1,3,3-trimethylindol-2-one;
1-Cyclopropyl-3,3-dimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2-
-one;
1-Cyclopropyl-3,3-dimethyl-6-(1-(pyridin-4-yl)-1H-imidazol-4-yl)indo-
lin-2-one;
6-(1-(3-Fluoropyridin-4-yl)-1H-imidazol-4-yl)-1,3,3-trimethylin-
dolin-2-one;
1-Cyclopropyl-3,3-dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)i-
ndolin-2-one;
1-Cyclopropyl-6-(1-(3-fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyli-
ndolin-2-one;
1,3,3-Trimethyl-6-(2-methyl-1-(pyridin-4-yl)-1H-imidazol-4-yl)indolin-2-o-
ne;
1,3,3-Trimethyl-6-(2-methyl-1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)-
indolin-2-one;
6-(1-(3-Fluoropyridin-4-yl)-2-methyl-1H-imidazol-4-yl)-1,3,3-trimethylind-
olin-2-one;
1-Cyclopropyl-3,3-dimethyl-6-(2-methyl-1-(2-methylpyridin-4-yl)-1H-imidaz-
ol-4-yl)indolin-2-one;
1-Cyclopropyl-6-(1-(3-fluoropyridin-4-yl)-2-methyl-1H-imidazol-4-yl)-3,3--
dimethylindolin-2-one;
1,3,3-Trimethyl-6-(1-(3-methylpyridin-4-yl)-1H-imidazol-4-yl)indolin-2-on-
e;
1-Cyclopropyl-3,3-dimethyl-6-(1-(3-methylpyridin-4-yl)-1H-imidazol-4-yl-
)indolin-2-one;
1-Cyclopropyl-3,3-dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)--
1H-pyrrolo[3,2-c]pyridin-2(3H)-one;
1-Cyclopropyl-6-(1-(3-fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyl--
1H-pyrrolo[3,2-c]pyridin-2(3H)-one;
3,3-Dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)indolin-2-one;
3,3-Dimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2-one;
6-(1-(5-Fluoro-2-methylpyridin-4-yl)-1H-imidazol-4-yl)-1,3,3-trimethylind-
olin-2-one;
6-(1-(2-Fluoro-5-methylpyridin-4-yl)-1H-imidazol-4-yl)-1,3,3-trimethylind-
olin-2-one;
6-[l-(3-Fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-1-(6-methyl-3-pyridy-
l)indolin-2-one;
6-[l-(3-Fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-1-(2-methyl-4-pyridy-
l)indolin-2-one;
3,3-Dimethyl-1-(6-methyl-3-pyridyl)-6-[1-(2-methyl-4-pyridyl)imidazol-4-y-
l]indolin-2-one;
3,3-Dimethyl-1-(6-methyl-3-pyridyl)-6-[1-(3-methyl-4-pyridyl)imidazol-4-y-
l]indolin-2-one;
3,3-Dimethyl-1-(2-methyl-4-pyridyl)-6-[1-(3-methyl-4-pyridyl)imidazol-4-y-
l]indolin-2-one;
3,3-Dimethyl-1-(2-methylpyridin-4-yl)-6-(1-(2-methylpyridin-4-yl)-1H-imid-
azol-4-yl)indolin-2-one;
6-(1-(3-Fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyl-1-(1-methyl-1H-
-imidazol-4-yl)indolin-2-one;
6-(1-(3-Fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyl-1-(1-methyl-1H-
-pyrazol-3-yl)indolin-2-one;
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-1-(2-methylpyrimidin-
-5-yl)indolin-2-one;
3,3-Dimethyl-1-(1-methylimidazol-4-yl)-6-[1-(2-methyl-4-pyridyl)imidazol--
4-yl]indolin-2-one;
3,3-Dimethyl-1-(1-methylpyrazol-3-yl)-6-[1-(2-methyl-4-pyridyl)imidazol-4-
-yl]indolin-2-one;
3,3-Dimethyl-6-[1-(2-methyl-4-pyridyl)imidazol-4-yl]-1-(2-methylpyrimidin-
-5-yl)indolin-2-one;
3,3-Dimethyl-1-(1-methylimidazol-4-yl)-6-[1-(3-methyl-4-pyridyl)imidazol--
4-yl]indolin-2-one;
3,3-Dimethyl-1-(1-methylpyrazol-3-yl)-6-[1-(3-methyl-4-pyridyl)imidazol-4-
-yl]indolin-2-one;
3,3-Dimethyl-6-[1-(3-methyl-4-pyridyl)imidazol-4-yl]-1-(2-methylpyrimidin-
-5-yl)indolin-2-one;
1-Cyclopropyl-3,3-dimethyl-6-(1-(2-methylpyrimidin-5-yl)-1H-imidazol-4-yl-
)indolin-2-one;
1-Cyclopropyl-3,3-dimethyl-6-(1-(5-methylpyrimidin-2-yl)-1H-imidazol-4-yl-
)indolin-2-one;
1,3,3-Trimethyl-6-(1-(5-methylpyrimidin-2-yl)-1H-imidazol-4-yl)indolin-2--
one;
1,3,3-Trimethyl-6-(1-(2-methylpyrimidin-5-yl)-1H-imidazol-4-yl)indoli-
n-2-one;
3,3-Dimethyl-6-(1-(2-methylpyrimidin-5-yl)-1H-imidazol-4-yl)indol-
in-2-one;
3,3-Dimethyl-6-(1-(5-methylpyrimidin-2-yl)-1H-imidazol-4-yl)indo-
lin-2-one;
3,3-Dimethyl-6-(1-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)indol-
in-2-one;
6-[4-(5-Fluoro-2-methyl-4-pyridyl)imidazol-1-yl]-1,3,3-trimethyl-
-indolin-2-one;
1,3,3-Trimethyl-6-[4-(3-methyl-4-pyridyl)imidazol-1-yl]indolin-2-one;
1,3,3-Trimethyl-6-[4-(2-methyl-4-pyridyl)imidazol-1-yl]indolin-2-one;
6-[4-(2-Fluoro-4-pyridyl)imidazol-1-yl]-1,3,3-trimethyl-indolin-2-one;
1-(3-Cyclopropylsulfonylpropyl)-6-[1-(3-fluoro-4-pyridyl)imidazol-4-yl]-3-
,3-dimethyl-indolin-2-one;
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-1-(2-hydroxyethyl)-3,3-dimethyl-i-
ndolin-2-one;
1-(3-Cyclopropylsulfonylpropyl)-6-[1-(5-fluoro-2-methyl-4-pyridyl)imidazo-
l-4-yl]-3,3-dimethyl-indolin-2-one;
6-[1-(5-Fluoro-2-methyl-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-indolin-2-o-
ne;
1,3,3-Trimethyl-6-(4-(pyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one;
1,3,3-Trimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one;
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin--
2-one;
1,3,3-Trimethyl-6-(2-(pyridin-3-yl)oxazol-4-yl)indolin-2-one;
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-4-yl)-1H-pyrazol-1-yl)indolin--
2-one;
1,3,3-Trimethyl-6-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)indolin-2-one;
1,3,3-Trimethyl-6-(1-(pyridin-3-yl)-1H-pyrazol-4-yl)indolin-2-one;
3,3-Dimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one;
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2--
one;
1,3,3-Trimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-
-one;
1-Cyclopropyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1--
yl)indolin-2-one;
1,3,3-Trimethyl-6-(5-(pyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-one;
3,3-Dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one;
1,3,3-Trimethyl-6-(5-(2-methylpyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-one-
;
1,3,3-Trimethyl-6-(5-(pyridin-3-yl)-1H-pyrazol-3-yl)indolin-2-one;
1-Ethyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin--
2-one;
1,3,3-Trimethyl-6-(4-(6-methylpyridin-3-yl)-1H-pyrazol-1-yl)indolin-
-2-one;
1-Cyclopropyl-3,3-dimethyl-6-(4-(6-methylpyridin-3-yl)-1H-pyrazol--
1-yl)indolin-2-one;
3,3-Dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)-1-(oxetan-3-yl)-
indolin-2-one;
1,3,3-Trimethyl-6-(5-(6-methylpyridin-3-yl)-1H-pyrazol-3-yl)indolin-2-one-
;
1,3,3-Trimethyl-6-(1-methyl-5-(2-methylpyridin-4-yl)-1H-pyrazol-3-yl)ind-
olin-2-one; and,
1,3,3-Trimethyl-6-(4-methyl-3-(2-methylpyridin-4-yl)-1H-pyrazol-5-yl)indo-
lin-2-one; a pharmaceutically acceptable salt thereof.
9. The method of claim 7 comprising administering a compound of
formula I together with an antipsychotic drug selected from
olanzapine (Zyprexa.RTM.), Clozapine.RTM. (Clozaril.RTM.),
risperidone (Risperdal.RTM.), aripiprazole (Abilify.RTM.) or
ziprasidone.
10. The method of claim 7 comprising administering a compound of
formula I together with an anti-depressive drug selected from
citalopram (Celexa.RTM.), escitalopram (Lexapro.RTM., Cipralex),
paroxetine (Paxil.RTM., Seroxat), fluoxetine (Prozac.RTM.),
sertraline (Zoloft.RTM., Lustral) duloxetine (Cymbalta.RTM.),
milnacipran (Ixel.RTM., Savella.RTM.), venlafaxine (Effexor.RTM.),
or mirtazapine (Remeron.RTM.)
11. The method of claim 7 comprising administering a compound of
formula I together with an anxiolytic drug selected from alprazolam
(Helex.RTM., Xanax.RTM., Xanor, Onax, Alprox, Restyl, Tafil,
Paxal), chlordiazepoxide (Librium.RTM., Risolid, Elenium),
clonazepam (Rivotril, Klonopin.RTM., Iktorivil, Paxam), diazepam
(Antenex, Apaurin, Apzepam, Apozepam, Hexalid, Pax, Stesolid,
Stedon, Valium.RTM., Vival, Valaxona), Estazolam (ProSom),
eszopiclone (Lunesta.RTM.), zaleplon (Sonata.RTM., Starnoc),
zolpidem (Ambien.RTM., Nytamel, Stilnoct, Stilnox.RTM., Zoldem,
Zolnod), pregabalin (Lyrica.RTM.) or gabapentin (Fanatrex,
Gabarone, Gralise.RTM., Neurontin.RTM., Nupentin).
12. The method of claim 7 comprising a compound of formula I
together with a mood stabilizer selected from Carbamazepine
(Tegretol.RTM.), Lamotrigine (Lamictal.RTM.), Lithium
(Eskalith.RTM., Lithane, Lithobid.RTM.), or Valproic Acid
(Depakote.RTM.).
13. A pharmaceutical composition comprising a compound in
accordance with claim 1 and at least one pharmaceutically
acceptable carrier, diluent or excipient for treating
therapeutically active carrier for the treatment of certain central
nervous system disorders which are positive (psychosis) and
negative symptoms of schizophrenia, substance abuse, alcohol and
drug addiction, obsessive-compulsive disorders, cognitive
impairment, bipolar disorders, mood disorders, major depression,
treatment resistant depression, anxiety disorders, autism,
Parkinson's disease, chronic pain, borderline personality disorder,
sleep disturbances, chronic fatigue syndrome, stiffness,
antiinflammatory effects in arthritis and balance problems.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 15/353,355 having a filing date of Nov. 16, 2016 which is a
continuation of International Application No. PCT/EP2015/060937
having an international filing date of May 19, 2015 and which
claims benefit under 35 U.S.C. .sctn. 119 to International
Application EP 14169477.8 filed May 22, 2014. The entire contents
of both are incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to novel compounds of formula
I, wherein Ar.sup.1, Ar.sup.2, R.sup.1, R.sup.2, R.sup.3, X and n
are as described herein, having pharmaceutical activity, their
manufacture, pharmaceutical compositions containing them and their
potential use as medicaments.
BACKGROUND OF THE INVENTION
[0003] Schizophrenia is a complex mental disorder typically
appearing in late adolescence or early adulthood with a world-wide
prevalence of approximately 1% of the adult population, which has
enormous social and economic impact. The criteria of the
Association of European Psychiatrists (ICD) and the American
Psychiatric Association (DSM) for the diagnosis of schizophrenia
require two or more characteristic symptoms to be present:
delusions, hallucinations, disorganized speech, grossly
disorganized or catatonic behavior (positive symptoms), or negative
symptoms (alogia, affective flattening, lack of motivation,
anhedonia). As a group, people with schizophrenia have functional
impairments that may begin in childhood, continue throughout adult
life and make most patients unable to maintain normal employment or
otherwise have normal social function. They also have a shortened
lifespan compared to the general population, and suffer from an
increased prevalence of a wide variety of other neuropsychiatric
syndromes, including substance abuse, obsessive-compulsive symptoms
and abnormal involuntary movements prior to antipsychotic
treatment. Schizophrenia is also associated with a wide range of
cognitive impairments, bipolar disorders, major depression and
anxiety disorders, the severity of which limits the functioning of
patients, even when psychotic symptoms are well controlled.
[0004] The primary treatment of schizophrenia is antipsychotic
medications. Antipsychotics, for example risperidone, olanzapine,
however, fail to significantly ameliorate the negative symptoms and
cognitive dysfunction.
[0005] Antipsychotic drugs have shown clinical efficacy for the
treatment of the following diseases:
[0006] Fibromyalgia, which is a syndrome characterized by chronic
generalized pain associated with different somatic symptoms, such
as sleep disturbances, fatigue, stiffness, balance problems,
hypersensitivity to physical and psychological environmental
stimuli, depression and anxiety (CNS Drugs, 2012 26(2):135-53).
[0007] Schizoaffective disorders: includes psychotic and affective
symptoms, this disorder falls on a spectrum between bipolar
disorders (with depressive and manic episodes, alcohol and drug
addiction, substance abuse) and schizophrenia. (J. Clin.
Psychiatry, 2010, 71, Suppl. 2, 14-9; Pediatr. Drugs 2011 13 (5),
291-302)
[0008] Major depression: BMC Psychiatry 2011 11; 86.
[0009] Treatment resistent depression: Journal of
Psychopharmacology 2012 26(5)587.
[0010] Anxiety: European Neuropsychopharmacology 2011
21:429-449.
[0011] Bipolar disorders: Encephale, International J. of
Neuropsychopharmacology 2011 14:1029-104, International J. of
Neuropsychopharmacology, 2012 p. 1-12, J. of
Neuropsychopharmacology, 2011 0(0), 1-15.
[0012] Mood disorders: J. Psychopharmacol 2012, Jan. 11, CNS Drugs
2010 Feb. 24(2):131-61.
[0013] Autism: Current opinion in pediatrics 2011 23:621-627; J.
Clin. Psychiatry 2011 72(9), 1270-1276.
[0014] Alzheimer's disease: J. Clin. Psychiatry 2012 73(1),
121-128.
[0015] Parkinson's disease: Movement Disorders 2011 Vol. 26, No.
6.
[0016] Chronic fatigue syndrome: European Neuropsychopharmacology
2011 21:282-286.
[0017] Borderline Personality disorder: J. Clin. Psychiatry 2011 72
(10), 1363-1365. J. Clin. Psychiatry 2011 72(10):1353-1362.
[0018] Anti-inflammatory effects in arthritis: European J. of
Pharmacology 2012 678:55-60.
BRIEF SUMMARY OF THE INVENTIONS
[0019] The present invention is concerned with indole-2-one and
1,4-dihydro-pyrrolo[3,2-c]pyridine-2-one derivatives of general
formula
##STR00002## [0020] wherein [0021] Ar.sup.1 is phenyl, pyridinyl or
pyrimidinyl; [0022] Ar.sup.2 is a 5 or 6 membered heteroaryl group,
containing 2 or 3 heteroatoms, selected from N, O or S; [0023]
R.sup.1 is hydrogen, C.sub.1-7-alkyl, halogen or C.sub.1-7-alkoxy;
[0024] R.sup.2 is hydrogen or C.sub.1-7-alkyl; [0025] R.sup.3 is
hydrogen, C.sub.1-7-alkyl, C.sub.1-7-alkyl substituted by hydroxy,
cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by
C.sub.1-7-alkyl, or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl;
[0026] X is CH or N; [0027] n is 1 or 2; [0028] or a
pharmaceutically acceptable salt thereof, a racemic mixture, an
enantiomer, an optical isomer, a stereoisomer thereof. [0029]
mixture, or with its corresponding enantiomer and/or optical isomer
and/or stereoisomer thereof.
[0030] The present invention further relates to central nervous
system disorders with compounds of formula I, compositions
containing compounds of formula I and methods of the preparation of
compounds of formula I.
BRIEF DESCRIPTION OF DRAWINGS
[0031] FIG. 1 depicts the SmartCube.RTM. signatures of compounds
13, 54, 58 and 71 (at 25 mg/kg) which are similar to those of
atypical antipsychotics.
[0032] FIG. 2 depicts the SmartCube.RTM. signatures of atypical
antipsychotics olanzapine and risperidone (each at two doses).
DETAILED DESCRIPTION OF THE INVENTION
[0033] The present invention is concerned with indolin-2-one and
1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives of general
formula (I)
##STR00003##
wherein [0034] Ar.sup.1 is phenyl, pyridinyl or pyrimidinyl; [0035]
Ar.sup.2 is selected from the group consisting of (i), (ii) and
(iii)
[0035] ##STR00004## [0036] R.sup.1 is hydrogen, C.sub.1-7-alkyl,
halogen or C.sub.1-7-alkoxy; [0037] R.sup.3 is hydrogen,
C.sub.1-7-alkyl, C.sub.1-7-alkyl substituted by hydroxy,
cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by
C.sub.1-7-alkyl, or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl;
[0038] X is CH or N; [0039] n is 1 or 2; or, [0040] or, a
pharmaceutically acceptable salt thereof, a racemic mixture, an
enantiomer, an optical isomer, a stereoisomer thereof.
[0040] ##STR00005## [0041] wherein [0042] Ar.sup.1 is phenyl,
pyridinyl or pyrimidinyl; [0043] Ar.sup.2 is a 5 or 6 membered
heteroaryl group, containing 2 or 3 heteroatoms, selected from N, O
or S; [0044] R.sup.1 is hydrogen, lower alkyl, halogen or lower
alkoxy; [0045] R.sup.2 is hydrogen or lower alkyl; [0046] R.sup.3
is hydrogen, lower alkyl, lower alkyl substituted by hydroxy,
cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0047] X is CH or
N; [0048] n is 1 or 2; as well as with a pharmaceutically
acceptable salts thereof, with a racemic mixture, or with its
corresponding enantiomer and/or optical isomer and/or stereoisomer
thereof, for use in the treatment of certain central nervous system
disorders which are positive (psychosis) and negative symptoms of
schizophrenia, substance abuse, alcohol and drug addiction,
obsessive-compulsive disorders, cognitive impairment, bipolar
disorders, mood disorders, major depression, treatment resistant
depression, anxiety disorders, Alzheimer's disease, autism,
Parkinson's disease, chronic pain, borderline personality disorder,
sleep disturbances, chronic fatigue syndrome, stiffness,
antiinflammatory effects in arthritis and balance problems.
[0049] WO9106545 describes a very close structure containing a
phenyl substituted imidazole moiety for Ar.sup.2 for prevention of
clumping of both erythrocytes and thrombocytes. EP2108641 and
WO2008046083 disclose a very broad scope of similar compounds which
are inhibitors of the p38 nitrogen activated protein kinase for the
treatment of inflammation diseases and benign prostatic
pyperplasia, respectively.
[0050] Now it has been found that the compounds of formula I may be
used for the treatment of CNS diseases. The described compounds
have been shown to reverse the L-687,414 ((3R,4R)-3
amino-1-hydroxy-4-methyl-pyrrolidin-2-one, a NMDA glycine site
antagonist) induced hyperlocomotion, a behavioral pharmacodynamic
mouse model for schizophrenia, described by D. Alberati et al. in
Pharmacology, Biochemistry and Behavior, 97 (2010), 185-191. The
authors described that hyperlocomotion induced by L-687,414 was
inhibited by a series of known antipsychotic drugs. The compounds
of formula I demonstrate marked activity in this model. These
findings predict antipsychotic activity for the present compounds,
making them useful for the treatment of positive (psychosis) and
negative symptoms of schizophrenia, substance abuse, alcohol and
drug addiction, obsessive-compulsive disorders, cognitive
impairment, bipolar disorders, mood disorders, major depression,
resistant depression, anxiety disorders, Alzheimer's disease,
autism, Parkinson's disease, chronic pain, borderline personality
disorder, sleep disturbances, chronic fatigue syndrome, stiffness,
antiinflammatory effects in arthritis and balance problems. The
results are shown in Table 1.
[0051] In addition to the reversal of L-687,414 induced
hyperlocomotion experiment as described above, some compounds of
the present invention have been tested in SmartCube.RTM., an
automated system in which the behaviors of compound-treated mice in
response to multiple challenges are captured by digital video and
analyzed with computer algorithms (Roberds et al., Frontiers in
Neuroscience, 2011, Vol. 5, Art. 103, 1-4). In this way, the
neuro-pharmacological effects of a test compound can be predicted
by similarity to major classes of compounds, such as
antipsychotics, anxiolytics and antidepressants. Examples 35, 47,
62 and 93 show similarity to atypical antipsychotics. The results
are shown in Table 2.
[0052] Objects of the present invention are compounds of formula I
for use in the treatment of CNS diseases related to positive
(psychosis) and negative symptoms of schizophrenia, substance
abuse, alcohol and drug addiction, obsessive-compulsive disorders,
cognitive impairment, bipolar disorders, mood disorders, major
depression, resistant depression, anxiety disorders, Alzheimer's
disease, autism, Parkinson's disease, chronic pain, borderline
personality disorder, sleep disturbances, chronic fatigue syndrome,
stiffness, antiinflammatory effects in arthritis and balance
problems. Further objects of the present invention are novel
compounds, medicaments containing such novel compounds as well as
methods for preparation of compounds of formula I, a combination of
compounds of formula I with marketed antipsychotics,
antidepressants, anxiolytics or mood stabilizers, and methods for
the treatment of CNS disorders as mentioned above.
[0053] Compounds of formula I for use in the treatment of the above
mentioned CNS diseases are the followings: [0054]
1-Cyclopropyl-6-(5-(4-fluorophenyl)-1H-imidazol-2-yl)-3,3-dimethylindolin-
-2-one [0055]
1,3,3-Trimethyl-6-(5-phenyl-1H-imidazol-2-yl)indolin-2-one [0056]
1,3,3-Trimethyl-6-(2-(pyridin-4-yl)-1H-imidazol-5-yl)indolin-2-one
[0057]
1-Cyclopropyl-3,3-dimethyl-6-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-y-
l)indolin-2-one [0058]
1-Cyclopropyl-3,3-dimethyl-6-(5-(pyridin-4-yl)-1,2,4-oxadiazol-3-yl)indol-
in-2-one [0059]
3,3-Dimethyl-1-oxetan-3-yl-6-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-1,3-d-
ihydro-indol-2-one [0060]
1,3,3-Trimethyl-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one [0061]
1-Cyclopropyl-3,3-dimethyl-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one
[0062]
1-Cyclopropyl-3,3-dimethyl-6-(5-(pyridin-3-yl)oxazol-2-yl)indolin--
2-one [0063]
1-Cyclopropyl-3,3-dimethyl-6-(2-(pyridin-4-yl)oxazol-5-yl)indolin-2-one
[0064]
3,3-Dimethyl-1-(oxetan-3-yl)-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-
-yl)indolin-2-one
1-Cyclopropyl-3,3-dimethyl-6-(2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin-
-2-one [0065]
1,3,3-Trimethyl-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)indolin-2-one
[0066]
1-Cyclopropyl-3,3-dimethyl-6-(2-(2-methylpyridin-4-yl)thiazol-5-yl-
)indolin-2-one [0067]
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)oxazol-2-yl)indolin-2-one
[0068]
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-4-yl)oxazol-2-yl)indolin--
2-one [0069]
1-Cyclopropyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)oxazol-2-yl)indolin-
-2-one [0070]
1,3,3-Trimethyl-6-(2-(2-methylpyridin-4-yl)thiazol-5-yl)indolin-2-one
[0071]
1-Cyclopropyl-3,3-dimethyl-6-(5-(2-methylpyridin-4-yl)oxazol-2-yl)-
indolin-2-one [0072]
1,3,3-Trimethyl-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl)indolin-2-one
[0073] 1,3,3-Trimethyl-6-(4-(pyridin-3-yl)oxazol-2-yl)indolin-2-one
[0074]
1,3,3-Trimethyl-6-(2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin-2-one
[0075]
3,3-Dimethyl-1-(oxetan-3-yl)-6-(2-(pyridin-3-yl)oxazol-5-yl)indoli-
n-2-one [0076]
3,3-Dimethyl-6-(2-(6-methylpyridin-3-yl)oxazol-5-yl)-1-(oxetan-3-yl)indol-
in-2-one [0077]
3,3-Dimethyl-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one [0078]
3,3-Dimethyl-6-(2-(2-methylpyridin-4-yl)oxazol-5-yl)-1-(oxetan-3-y-
l)indolin-2-one [0079]
3,3-Dimethyl-6-(2-(6-methylpyridin-3-yl)oxazol-5-yl)indolin-2-one
[0080]
1-(2-Hydroxyethyl)-3,3-dimethyl-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)-
indolin-2-one [0081]
1,3,3-Trimethyl-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-2-one
[0082]
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-
-2-one [0083]
1,3,3-Trimethyl-6-(4-methyl-2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one
[0084]
3,3-Dimethyl-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-2-one
[0085]
1-Cyclopropyl-3,3-dimethyl-6-(2-(6-methylpyridin-3-yl)oxazol-5-yl)-
indolin-2-one [0086]
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl)indolin-
-2-one [0087]
3,3-Dimethyl-6-(2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin-2-one
[0088]
1,3,3-Trimethyl-6-(4-methyl-2-(6-methylpyridin-3-yl)oxazol-5-yl)indolin-2-
-one [0089]
1-Cyclopropyl-3,3-dimethyl-6-(4-methyl-2-(6-methylpyridin-3-yl)oxazol-5-y-
l)indolin-2-one [0090]
1,3,3-Trimethyl-6-(4-methyl-2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin-2-
-one [0091]
1-Cyclopropyl-3,3-dimethyl-6-(4-methyl-2-(2-methylpyridin-4-yl)oxazol-5-y-
l)indolin-2-one [0092]
1,3,3-Trimethyl-6-(4-(pyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one
[0093]
1,3,3-Trimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one
[0094]
1,3,3-Trimethyl-6-(3-pyridin-4-yl-isoxazol-5-yl)-1,3-dihydro-indol-2-one
[0095]
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)i-
ndolin-2-one [0096]
1,3,3-Trimethyl-6-(2-(pyridin-3-yl)oxazol-4-yl)indolin-2-one [0097]
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-4-yl)-1H-pyrazol-1-yl)indolin--
2-one [0098]
1,3,3-Trimethyl-6-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)indolin-2-one
[0099]
3,3-Dimethyl-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl)indolin-2-one
[0100]
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-2-
-one [0101]
3,3-Dimethyl-6-(5-(2-methylpyridin-4-yl)-1,3,4-oxadiazol-2-yl)-1-(oxetan--
3-yl)indolin-2-one [0102]
1,3,3-Trimethyl-6-(1-(pyridin-3-yl)-1H-pyrazol-4-yl)indolin-2-one
[0103]
3,3-Dimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one
[0104]
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2--
one [0105]
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl-
)indolin-2-one [0106]
1,3,3-Trimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one
[0107]
1-Cyclopropyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol--
1-yl)indolin-2-one [0108]
1,3,3-Trimethyl-6-(5-(pyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-one
[0109]
1,3,3-Trimethyl-6-(4-(pyridin-4-yl)-1H-1,2,3-triazol-1-yl)indolin-2-one
[0110]
3,3-Dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-
-one [0111]
1,3,3-Trimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2-one
[0112]
1,3,3-Trimethyl-6-(1-(pyridin-4-yl)-1H-imidazol-4-yl)indolin-2-one
[0113]
1,3,3-Trimethyl-6-(5-(2-methylpyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-one
[0114]
1,3,3-Trimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)indol-
in-2-one [0115]
6-(2-(3-Methoxypyridin-4-yl)oxazol-5-yl)-3,3-dimethylindolin-2-one
[0116]
1,3,3-Trimethyl-6-(3-(2-methylpyridin-4-yl)isoxazol-5-yl)indolin-2-one
[0117]
1,3,3-Trimethyl-6-(5-(pyridin-3-yl)-1H-pyrazol-3-yl)indolin-2-one
[0118]
1-Ethyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)i-
ndolin-2-one [0119]
6-[1-(2-Fluoropyridin-4-yl)imidazol-4-yl]-1,3,3-trimethylindol-2-one
[0120]
1,3,3-Trimethyl-6-(4-(6-methylpyridin-3-yl)-1H-pyrazol-1-yl)indoli-
n-2-one [0121]
1-Cyclopropyl-3,3-dimethyl-6-(4-(6-methylpyridin-3-yl)-1H-pyrazol-1-yl)in-
dolin-2-one [0122]
3,3-Dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)-1-(oxetan-3-yl)-
indolin-2-one [0123]
1-Cyclopropyl-3,3-dimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2-
-one [0124]
1-Cyclopropyl-3,3-dimethyl-6-(1-(pyridin-4-yl)-1H-imidazol-4-yl)indolin-2-
-one [0125]
6-(1-(3-Fluoropyridin-4-yl)-1H-imidazol-4-yl)-1,3,3-trimethylindolin-2-on-
e [0126]
1-Cyclopropyl-3,3-dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazo-
l-4-yl)indolin-2-one [0127]
1-Cyclopropyl-3,3-dimethyl-6-(3-(2-methylpyridin-4-yl)isoxazol-5-yl)indol-
in-2-one [0128]
1-Cyclopropyl-6-(1-(3-fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyli-
ndolin-2-one [0129]
1,3,3-Trimethyl-6-(2-methyl-1-(pyridin-4-yl)-1H-imidazol-4-yl)indolin-2-o-
ne [0130]
1,3,3-Trimethyl-6-(2-methyl-1-(2-methylpyridin-4-yl)-1H-imidazol-
-4-yl)indolin-2-one [0131]
6-(1-(3-Fluoropyridin-4-yl)-2-methyl-1H-imidazol-4-yl)-1,3,3-trimethylind-
olin-2-one [0132]
1,3,3-Trimethyl-6-(5-(6-methylpyridin-3-yl)-1H-pyrazol-3-yl)indolin-2-one
[0133]
1,3,3-Trimethyl-6-(1-methyl-5-(2-methylpyridin-4-yl)-1H-pyrazol-3--
yl)indolin-2-one [0134]
1,3,3-Trimethyl-6-(2-(2-methylpyridin-4-yl)pyrimidin-4-yl)indolin-2-one
[0135]
1,3,3-Trimethyl-6-(2-(6-methylpyridin-3-yl)pyrimidin-4-yl)indolin--
2-one [0136]
1,3,3-Trimethyl-6-(4-methyl-3-(2-methylpyridin-4-yl)-1H-pyrazol-5-yl)indo-
lin-2-one [0137]
3,3-Dimethyl-6-(2-(6-methylpyridin-3-yl)pyrimidin-4-yl)-1-(oxetan-3-yl)in-
dolin-2-one [0138]
1-Cyclopropyl-3,3-dimethyl-6-(2-methyl-1-(2-methylpyridin-4-yl)-1H-imidaz-
ol-4-yl)indolin-2-one [0139]
1-Cyclopropyl-6-(1-(3-fluoropyridin-4-yl)-2-methyl-1H-imidazol-4-yl)-3,3--
dimethylindolin-2-one [0140]
1,3,3-Trimethyl-6-(1-(3-methylpyridin-4-yl)-1H-imidazol-4-yl)indolin-2-on-
e [0141]
1-Cyclopropyl-3,3-dimethyl-6-(1-(3-methylpyridin-4-yl)-1H-imidazo-
l-4-yl)indolin-2-one [0142]
1-Cyclopropyl-3,3-dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)--
1H-pyrrolo[3,2-c]pyridin-2(3H)-one [0143]
1-Cyclopropyl-6-(1-(3-fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyl--
1H-pyrrolo[3,2-c]pyridin-2(3H)-one [0144]
3,3-Dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)indolin-2-one
[0145]
3,3-Dimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2-one
[0146]
1-Cyclopropyl-3,3-dimethyl-6-[2-(2-methyl-pyridin-4-yl)-oxazol-5-y-
l]-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one [0147]
6-(1-(5-Fluoro-2-methylpyridin-4-yl)-1H-imidazol-4-yl)-1,3,3-trimethylind-
olin-2-one [0148]
6-(2-(5-Fluoro-2-methylpyridin-4-yl)oxazol-5-yl)-1,3,3-trimethylindolin-2-
-one [0149]
3,3-Dimethyl-6-[5-(2-methyl-pyridin-4-yl)-[1,3,4]oxadiazol-2-yl]-1-oxetan-
-3-yl-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one [0150]
6-(1-(2-Fluoro-5-methylpyridin-4-yl)-1H-imidazol-4-yl)-1,3,3-trimethylind-
olin-2-one [0151]
6-(2-(2-Fluoro-5-methylpyridin-4-yl)oxazol-5-yl)-1,3,3-trimethylindolin-2-
-one [0152]
6-(5-(5-Fluoro-2-methylpyridin-4-yl)-1,3,4-oxadiazol-2-yl)-1,3,3-trimethy-
lindolin-2-one [0153]
1,3,3-Trimethyl-6-(2-(6-methylpyridin-3-yl)pyrimidin-5-yl)indolin-2-one
[0154]
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-1-(6-methyl-3-
-pyridyl)indolin-2-one [0155]
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-1-(2-methyl-4-pyridy-
l)indolin-2-one [0156]
3,3-Dimethyl-1-(6-methyl-3-pyridyl)-6-[1-(2-methyl-4-pyridyl)imidazol-4-y-
l]indolin-2-one [0157]
3,3-Dimethyl-1-(6-methyl-3-pyridyl)-6-[1-(3-methyl-4-pyridyl)imidazol-4-y-
l]indolin-2-one [0158]
3,3-Dimethyl-1-(2-methyl-4-pyridyl)-6-[1-(3-methyl-4-pyridyl)imidazol-4-y-
l]indolin-2-one [0159]
3,3-Dimethyl-1-(2-methylpyridin-4-yl)-6-(1-(2-methylpyridin-4-yl)-1H-imid-
azol-4-yl)indolin-2-one [0160]
6-(1-(3-Fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyl-1-(1-methyl-1H-
-imidazol-4-yl)indolin-2-one [0161]
6-(1-(3-Fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyl-1-(1-methyl-1H-
-pyrazol-3-yl)indolin-2-one [0162]
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-1-(2-methylpyrimidin-
-5-yl)indolin-2-one [0163]
3,3-Dimethyl-1-(1-methylimidazol-4-yl)-6-[1-(2-methyl-4-pyridyl)imidazol--
4-yl]indolin-2-one [0164]
3,3-Dimethyl-1-(1-methylpyrazol-3-yl)-6-[1-(2-methyl-4-pyridyl)imidazol-4-
-yl]indolin-2-one [0165]
3,3-Dimethyl-6-[1-(2-methyl-4-pyridyl)imidazol-4-yl]-1-(2-methylpyrimidin-
-5-yl)indolin-2-one [0166]
3,3-Dimethyl-1-(1-methylimidazol-4-yl)-6-[1-(3-methyl-4-pyridyl)imidazol--
4-yl]indolin-2-one [0167]
3,3-Dimethyl-1-(1-methylpyrazol-3-yl)-6-[1-(3-methyl-4-pyridyl)imidazol-4-
-yl]indolin-2-one [0168]
3,3-Dimethyl-6-[1-(3-methyl-4-pyridyl)imidazol-4-yl]-1-(2-methylpyrimidin-
-5-yl)indolin-2-one [0169]
1-Cyclopropyl-3,3-dimethyl-6-(1-(2-methylpyrimidin-5-yl)-1H-imidazol-4-yl-
)indolin-2-one [0170]
1-Cyclopropyl-3,3-dimethyl-6-(1-(5-methylpyrimidin-2-yl)-1H-imidazol-4-yl-
)indolin-2-one [0171]
1,3,3-Trimethyl-6-(1-(5-methylpyrimidin-2-yl)-1H-imidazol-4-yl)indolin-2--
one [0172]
1,3,3-Trimethyl-6-(1-(2-methylpyrimidin-5-yl)-1H-imidazol-4-yl)-
indolin-2-one [0173]
3,3-Dimethyl-6-(1-(2-methylpyrimidin-5-yl)-1H-imidazol-4-yl)indolin-2-one
[0174]
3,3-Dimethyl-6-(1-(5-methylpyrimidin-2-yl)-1H-imidazol-4-yl)indoli-
n-2-one [0175]
3,3-Dimethyl-6-(1-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)indolin-2-one
[0176]
6-[4-(5-Fluoro-2-methyl-4-pyridyl)imidazol-1-yl]-1,3,3-trimethyl-i-
ndolin-2-one [0177]
1,3,3-Trimethyl-6-[5-(3-methyl-4-pyridyl)isoxazol-3-yl]indolin-2-one
[0178]
1,3,3-Trimethyl-6-[4-(3-methyl-4-pyridyl)imidazol-1-yl]indolin-2-o-
ne [0179]
1,3,3-Trimethyl-6-[4-(2-methyl-4-pyridyl)imidazol-1-yl]indolin-2-
-one [0180]
6-[4-(2-Fluoro-4-pyridyl)imidazol-1-yl]-1,3,3-trimethyl-indolin-2-one
[0181]
1-(3-Cyclopropylsulfonylpropyl)-6-[1-(3-fluoro-4-pyridyl)imidazol--
4-yl]-3,3-dimethyl-indolin-2-one [0182]
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-1-(2-hydroxyethyl)-3,3-dimethyl-i-
ndolin-2-one [0183]
1-(3-Cyclopropylsulfonylpropyl)-6-[1-(5-fluoro-2-methyl-4-pyridyl)imidazo-
l-4-yl]-3,3-dimethyl-indolin-2-one or [0184]
6-[1-(5-Fluoro-2-methyl-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-indolin-2-o-
ne.
[0185] One object of the present invention are novel compounds of
general formula (I)
##STR00006## [0186] wherein [0187] Ar.sup.1 is phenyl, pyridinyl or
pyrimidinyl; [0188] Ar.sup.2 is selected from the group consisting
of (i), (ii) and (iii)
[0188] ##STR00007## [0189] R.sup.1 is hydrogen, C.sub.1-7-alkyl,
halogen or C.sub.1-7-alkoxy; [0190] R.sup.3 is hydrogen,
C.sub.1-7-alkyl, C.sub.1-7-alkyl substituted by hydroxy,
cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by
C.sub.1-7-alkyl, or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl;
[0191] X is CH or N; [0192] n is 1 or 2; or, [0193] or, a
pharmaceutically acceptable salt thereof, a racemic mixture, an
enantiomer, an optical isomer, a stereoisomer thereof.
[0193] ##STR00008## [0194] wherein [0195] Ar.sup.1 is phenyl,
pyridinyl or pyrimidinyl; [0196] Ar.sup.2 is a 5 or 6 membered
heteroaryl group, containing 2 or 3 heteroatoms, selected from N, O
or S; [0197] R.sup.1 is hydrogen, lower alkyl, halogen or lower
alkoxy; [0198] R.sup.2 is hydrogen or lower alkyl; [0199] R.sup.3
is hydrogen, lower alkyl, lower alkyl substituted by hydroxy,
cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0200] X is CH or
N; [0201] n is 1 or 2; [0202] as well as pharmaceutically
acceptable salts thereof, racemic mixtures, or corresponding
enantiomers and/or optical isomers and/or stereoisomers thereof,
with the exception, that Ar.sup.2 is not
##STR00009##
[0203] For example the following compounds are with the scope of
the invention: [0204]
1-Cyclopropyl-3,3-dimethyl-6-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)indol-
in-2-one [0205]
1-Cyclopropyl-3,3-dimethyl-6-(5-(pyridin-4-yl)-1,2,4-oxadiazol-3-yl)indol-
in-2-one [0206]
3,3-Dimethyl-1-oxetan-3-yl-6-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-1,3-d-
ihydro-indol-2-one [0207]
1,3,3-Trimethyl-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one [0208]
1-Cyclopropyl-3,3-dimethyl-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one
[0209]
1-Cyclopropyl-3,3-dimethyl-6-(5-(pyridin-3-yl)oxazol-2-yl)indolin--
2-one [0210]
1-Cyclopropyl-3,3-dimethyl-6-(2-(pyridin-4-yl)oxazol-5-yl)indolin-2-one
[0211]
3,3-Dimethyl-1-(oxetan-3-yl)-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-
-yl)indolin-2-one [0212]
1-Cyclopropyl-3,3-dimethyl-6-(2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin-
-2-one [0213]
1,3,3-Trimethyl-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)indolin-2-one
[0214]
1-Cyclopropyl-3,3-dimethyl-6-(2-(2-methylpyridin-4-yl)thiazol-5-yl-
)indolin-2-one [0215]
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)oxazol-2-yl)indolin-2-one
[0216]
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-4-yl)oxazol-2-yl)indolin--
2-one [0217]
1-Cyclopropyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)oxazol-2-yl)indolin-
-2-one [0218]
1,3,3-Trimethyl-6-(2-(2-methylpyridin-4-yl)thiazol-5-yl)indolin-2-one
[0219]
1-Cyclopropyl-3,3-dimethyl-6-(5-(2-methylpyridin-4-yl)oxazol-2-yl)-
indolin-2-one [0220]
1,3,3-Trimethyl-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl)indolin-2-one
[0221] 1,3,3-Trimethyl-6-(4-(pyridin-3-yl)oxazol-2-yl)indolin-2-one
[0222]
1,3,3-Trimethyl-6-(2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin-2-one
[0223]
3,3-Dimethyl-1-(oxetan-3-yl)-6-(2-(pyridin-3-yl)oxazol-5-yl)indoli-
n-2-one [0224]
3,3-Dimethyl-6-(2-(6-methylpyridin-3-yl)oxazol-5-yl)-1-(oxetan-3-yl)indol-
in-2-one [0225]
3,3-Dimethyl-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one [0226]
3,3-Dimethyl-6-(2-(2-methylpyridin-4-yl)oxazol-5-yl)-1-(oxetan-3-y-
l)indolin-2-one [0227]
3,3-Dimethyl-6-(2-(6-methylpyridin-3-yl)oxazol-5-yl)indolin-2-one
[0228]
1-(2-Hydroxyethyl)-3,3-dimethyl-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)-
indolin-2-one [0229]
1,3,3-Trimethyl-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-2-one
[0230]
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-
-2-one [0231]
1,3,3-Trimethyl-6-(4-methyl-2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one
[0232]
3,3-Dimethyl-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-2-one
[0233]
1-Cyclopropyl-3,3-dimethyl-6-(2-(6-methylpyridin-3-yl)oxazol-5-yl)-
indolin-2-one [0234]
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl)indolin-
-2-one [0235]
3,3-Dimethyl-6-(2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin-2-one
[0236]
1,3,3-Trimethyl-6-(4-methyl-2-(6-methylpyridin-3-yl)oxazol-5-yl)indolin-2-
-one [0237]
1-Cyclopropyl-3,3-dimethyl-6-(4-methyl-2-(6-methylpyridin-3-yl)oxazol-5-y-
l)indolin-2-one [0238]
1,3,3-Trimethyl-6-(4-methyl-2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin-2-
-one [0239]
1-Cyclopropyl-3,3-dimethyl-6-(4-methyl-2-(2-methylpyridin-4-yl)oxazol-5-y-
l)indolin-2-one [0240]
1,3,3-Trimethyl-6-(4-(pyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one
[0241]
1,3,3-Trimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one
[0242]
1,3,3-Trimethyl-6-(3-pyridin-4-yl-isoxazol-5-yl)-1,3-dihydro-indol-2-one
[0243]
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)i-
ndolin-2-one [0244]
1,3,3-Trimethyl-6-(2-(pyridin-3-yl)oxazol-4-yl)indolin-2-one [0245]
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-4-yl)-1H-pyrazol-1-yl)indolin--
2-one [0246]
1,3,3-Trimethyl-6-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)indolin-2-one
[0247]
3,3-Dimethyl-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl)indolin-2-one
[0248]
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-2-
-one [0249]
3,3-Dimethyl-6-(5-(2-methylpyridin-4-yl)-1,3,4-oxadiazol-2-yl)-1-(oxetan--
3-yl)indolin-2-one [0250]
1,3,3-Trimethyl-6-(1-(pyridin-3-yl)-1H-pyrazol-4-yl)indolin-2-one
[0251]
3,3-Dimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one
[0252]
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2--
one [0253]
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl-
)indolin-2-one [0254]
1,3,3-Trimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one
[0255]
1-Cyclopropyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol--
1-yl)indolin-2-one [0256]
1,3,3-Trimethyl-6-(5-(pyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-one
[0257]
1,3,3-Trimethyl-6-(4-(pyridin-4-yl)-1H-1,2,3-triazol-1-yl)indolin-2-one
[0258]
3,3-Dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-
-one [0259]
1,3,3-Trimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2-one
[0260]
1,3,3-Trimethyl-6-(1-(pyridin-4-yl)-1H-imidazol-4-yl)indolin-2-one
[0261]
1,3,3-Trimethyl-6-(5-(2-methylpyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-one
[0262]
1,3,3-Trimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)indol-
in-2-one [0263]
6-(2-(3-Methoxypyridin-4-yl)oxazol-5-yl)-3,3-dimethylindolin-2-one
[0264]
1,3,3-Trimethyl-6-(3-(2-methylpyridin-4-yl)isoxazol-5-yl)indolin-2-one
[0265]
1,3,3-Trimethyl-6-(5-(pyridin-3-yl)-1H-pyrazol-3-yl)indolin-2-one
[0266]
1-Ethyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)i-
ndolin-2-one [0267]
6-[1-(2-Fluoropyridin-4-yl)imidazol-4-yl]-1,3,3-trimethylindol-2-one
[0268]
1,3,3-Trimethyl-6-(4-(6-methylpyridin-3-yl)-1H-pyrazol-1-yl)indoli-
n-2-one [0269]
1-Cyclopropyl-3,3-dimethyl-6-(4-(6-methylpyridin-3-yl)-1H-pyrazol-1-yl)in-
dolin-2-one [0270]
3,3-Dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)-1-(oxetan-3-yl)-
indolin-2-one [0271]
1-Cyclopropyl-3,3-dimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2-
-one [0272]
1-Cyclopropyl-3,3-dimethyl-6-(1-(pyridin-4-yl)-1H-imidazol-4-yl)indolin-2-
-one [0273]
6-(1-(3-Fluoropyridin-4-yl)-1H-imidazol-4-yl)-1,3,3-timethylindolin-2-one
[0274]
1-Cyclopropyl-3,3-dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-
-4-yl)indolin-2-one [0275]
1-Cyclopropyl-3,3-dimethyl-6-(3-(2-methylpyridin-4-yl)isoxazol-5-yl)indol-
in-2-one [0276]
1-Cyclopropyl-6-(1-(3-fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyli-
ndolin-2-one [0277]
1,3,3-Trimethyl-6-(2-methyl-1-(pyridin-4-yl)-1H-imidazol-4-yl)indolin-2-o-
ne [0278]
1,3,3-Trimethyl-6-(2-methyl-1-(2-methylpyridin-4-yl)-1H-imidazol-
-4-yl)indolin-2-one [0279]
6-(1-(3-Fluoropyridin-4-yl)-2-methyl-1H-imidazol-4-yl)-1,3,3-timethylindo-
lin-2-one [0280]
1,3,3-Trimethyl-6-(5-(6-methylpyridin-3-yl)-1H-pyrazol-3-yl)indolin-2-one
[0281]
1,3,3-Trimethyl-6-(1-methyl-5-(2-methylpyridin-4-yl)-1H-pyrazol-3--
yl)indolin-2-one [0282]
1,3,3-Trimethyl-6-(2-(2-methylpyridin-4-yl)pyrimidin-4-yl)indolin-2-one
[0283]
1,3,3-Trimethyl-6-(2-(6-methylpyridin-3-yl)pyrimidin-4-yl)indolin--
2-one [0284]
1,3,3-Trimethyl-6-(4-methyl-3-(2-methylpyridin-4-yl)-1H-pyrazol-5-yl)indo-
lin-2-one [0285]
3,3-Dimethyl-6-(2-(6-methylpyridin-3-yl)pyrimidin-4-yl)-1-(oxetan-3-yl)in-
dolin-2-one [0286]
1-Cyclopropyl-3,3-dimethyl-6-(2-methyl-1-(2-methylpyridin-4-yl)-1H-imidaz-
ol-4-yl)indolin-2-one
1-Cyclopropyl-6-(1-(3-fluoropyridin-4-yl)-2-methyl-1H-imidazol-4-yl)-3,3--
dimethylindolin-2-one
1,3,3-Trimethyl-6-(1-(3-methylpyridin-4-yl)-1H-imidazol-4-yl)indolin-2-on-
e [0287]
1-Cyclopropyl-3,3-dimethyl-6-(1-(3-methylpyridin-4-yl)-1H-imidazo-
l-4-yl)indolin-2-one [0288]
1-Cyclopropyl-3,3-dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)--
1H-pyrrolo[3,2-c]pyridin-2(3H)-one [0289]
1-Cyclopropyl-6-(1-(3-fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyl--
1H-pyrrolo[3,2-c]pyridin-2(3H)-one [0290]
3,3-Dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)indolin-2-one
[0291]
3,3-Dimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2-one
[0292]
1-Cyclopropyl-3,3-dimethyl-6-[2-(2-methyl-pyridin-4-yl)-oxazol-5-y-
l]-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one [0293]
6-(1-(5-Fluoro-2-methylpyridin-4-yl)-1H-imidazol-4-yl)-1,3,3-trimethylind-
olin-2-one [0294]
6-(2-(5-Fluoro-2-methylpyridin-4-yl)oxazol-5-yl)-1,3,3-trimethylindolin-2-
-one [0295]
3,3-Dimethyl-6-[5-(2-methyl-pyridin-4-yl)-[1,3,4]oxadiazol-2-yl]-1-oxetan-
-3-yl-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one [0296]
6-(1-(2-Fluoro-5-methylpyridin-4-yl)-1H-imidazol-4-yl)-1,3,3-trimethylind-
olin-2-one [0297]
6-(2-(2-Fluoro-5-methylpyridin-4-yl)oxazol-5-yl)-1,3,3-trimethylindolin-2-
-one [0298]
6-(5-(5-Fluoro-2-methylpyridin-4-yl)-1,3,4-oxadiazol-2-yl)-1,3,3-trimethy-
lindolin-2-one [0299]
1,3,3-Trimethyl-6-(2-(6-methylpyridin-3-yl)pyrimidin-5-yl)indolin-2-one
[0300]
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-1-(6-methyl-3-
-pyridyl)indolin-2-one [0301]
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-1-(2-methyl-4-pyridy-
l)indolin-2-one [0302]
3,3-Dimethyl-1-(6-methyl-3-pyridyl)-6-[1-(2-methyl-4-pyridyl)imidazol-4-y-
l]indolin-2-one [0303]
3,3-Dimethyl-1-(6-methyl-3-pyridyl)-6-[1-(3-methyl-4-pyridyl)imidazol-4-y-
l]indolin-2-one [0304]
3,3-Dimethyl-1-(2-methyl-4-pyridyl)-6-[1-(3-methyl-4-pyridyl)imidazol-4-y-
l]indolin-2-one [0305]
3,3-Dimethyl-1-(2-methylpyridin-4-yl)-6-(1-(2-methylpyridin-4-yl)-1H-imid-
azol-4-yl)indolin-2-one
6-(1-(3-Fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyl-1-(1-methyl-1H-
-imidazol-4-yl)indolin-2-one [0306]
6-(1-(3-Fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyl-1-(1-methyl-1H-
-pyrazol-3-yl)indolin-2-one [0307]
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-1-(2-methylpyrimidin-
-5-yl)indolin-2-one [0308]
3,3-Dimethyl-1-(1-methylimidazol-4-yl)-6-[1-(2-methyl-4-pyridyl)imidazol--
4-yl]indolin-2-one [0309]
3,3-Dimethyl-1-(1-methylpyrazol-3-yl)-6-[1-(2-methyl-4-pyridyl)imidazol-4-
-yl]indolin-2-one [0310]
3,3-Dimethyl-6-[1-(2-methyl-4-pyridyl)imidazol-4-yl]-1-(2-methylpyrimidin-
-5-yl)indolin-2-one [0311]
3,3-Dimethyl-1-(1-methylimidazol-4-yl)-6-[1-(3-methyl-4-pyridyl)imidazol--
4-yl]indolin-2-one [0312]
3,3-Dimethyl-1-(1-methylpyrazol-3-yl)-6-[1-(3-methyl-4-pyridyl)imidazol-4-
-yl]indolin-2-one [0313]
3,3-Dimethyl-6-[1-(3-methyl-4-pyridyl)imidazol-4-yl]-1-(2-methylpyrimidin-
-5-yl)indolin-2-one [0314]
1-Cyclopropyl-3,3-dimethyl-6-(1-(2-methylpyrimidin-5-yl)-1H-imidazol-4-yl-
)indolin-2-one [0315]
1-Cyclopropyl-3,3-dimethyl-6-(1-(5-methylpyrimidin-2-yl)-1H-imidazol-4-yl-
)indolin-2-one [0316]
1,3,3-Trimethyl-6-(1-(5-methylpyrimidin-2-yl)-1H-imidazol-4-yl)indolin-2--
one [0317]
1,3,3-Trimethyl-6-(1-(2-methylpyrimidin-5-yl)-1H-imidazol-4-yl)-
indolin-2-one [0318]
3,3-Dimethyl-6-(1-(2-methylpyrimidin-5-yl)-1H-imidazol-4-yl)indolin-2-one
[0319]
3,3-Dimethyl-6-(1-(5-methylpyrimidin-2-yl)-1H-imidazol-4-yl)indoli-
n-2-one [0320]
3,3-Dimethyl-6-(1-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)indolin-2-one
[0321]
6-[4-(5-Fluoro-2-methyl-4-pyridyl)imidazol-1-yl]-1,3,3-trimethyl-i-
ndolin-2-one [0322]
1,3,3-Trimethyl-6-[5-(3-methyl-4-pyridyl)isoxazol-3-yl]indolin-2-one
[0323]
1,3,3-Trimethyl-6-[4-(3-methyl-4-pyridyl)imidazol-1-yl]indolin-2-o-
ne [0324]
1,3,3-Trimethyl-6-[4-(2-methyl-4-pyridyl)imidazol-1-yl]indolin-2-
-one [0325]
6-[4-(2-Fluoro-4-pyridyl)imidazol-1-yl]-1,3,3-trimethyl-indolin-2-one
[0326]
1-(3-Cyclopropylsulfonylpropyl)-6-[1-(3-fluoro-4-pyridyl)imidazol--
4-yl]-3,3-dimethyl-indolin-2-one [0327]
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-1-(2-hydroxyethyl)-3,3-dimethyl-i-
ndolin-2-one [0328]
1-(3-Cyclopropylsulfonylpropyl)-6-[1-(5-fluoro-2-methyl-4-pyridyl)imidazo-
l-4-yl]-3,3-dimethyl-indolin-2-one or [0329]
6-[1-(5-Fluoro-2-methyl-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-indolin-2-o-
ne.
[0330] One further object of the present invention are compounds of
formula Ic
##STR00010## [0331] wherein [0332] Ar.sup.1 is phenyl, pyridinyl or
pyrimidinyl; [0333] R.sup.1 is hydrogen, lower alkyl, halogen or
lower alkoxy; [0334] R.sup.3 is hydrogen, lower alkyl, lower alkyl
substituted by hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl,
imidazolyl, pyrazolyl, pyrimidinyl, which rings may optionally
substituted by lower alkyl, or is
--(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0335] n is 1 or 2;
[0336] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or its corresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0337] One further object of the present invention are compounds of
formula Id
##STR00011## [0338] wherein [0339] Ar.sup.1 is phenyl, pyridinyl or
pyrimidinyl; [0340] R.sup.1 is hydrogen, lower alkyl, halogen or
lower alkoxy; [0341] R.sup.3 is hydrogen, lower alkyl, lower alkyl
substituted by hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl,
imidazolyl, pyrazolyl, pyrimidinyl, which rings may optionally
substituted by lower alkyl, or is
--(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0342] n is 1 or 2;
[0343] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or its corresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0344] One further object of the present invention are compounds of
formula Ie
##STR00012## [0345] wherein [0346] Ar.sup.1 is phenyl, pyridinyl or
pyrimidinyl; [0347] R.sup.1 is hydrogen, lower alkyl, halogen or
lower alkoxy; [0348] R.sup.2 is hydrogen or lower alkyl; [0349]
R.sup.3 is hydrogen, lower alkyl, lower alkyl substituted by
hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0350] n is 1 or
2; [0351] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or its corresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0352] One further object of the present invention are compounds of
formula If
##STR00013## [0353] Ar.sup.1 is phenyl, pyridinyl or pyrimidinyl;
[0354] R.sup.1 is hydrogen, lower alkyl, halogen or lower alkoxy;
[0355] R.sup.3 is hydrogen, lower alkyl, lower alkyl substituted by
hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0356] n is 1 or
2; [0357] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or itscorresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0358] One further object of the present invention are compounds of
formula Ig
##STR00014## [0359] Ar.sup.1 is phenyl, pyridinyl or pyrimidinyl;
[0360] R.sup.1 is hydrogen, lower alkyl, halogen or lower alkoxy;
[0361] R.sup.3 is hydrogen, lower alkyl, lower alkyl substituted by
hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0362] n is 1 or
2; [0363] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or itscorresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0364] One further object of the present invention are compounds of
formula Ih
##STR00015## [0365] Ar.sup.1 is phenyl, pyridinyl or pyrimidinyl;
[0366] R.sup.1 is hydrogen, lower alkyl, halogen or lower alkoxy;
[0367] R.sup.3 is hydrogen, lower alkyl, lower alkyl substituted by
hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0368] n is 1 or
2; [0369] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or itscorresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0370] One further object of the present invention are compounds of
formula Ik
##STR00016## [0371] Ar.sup.1 is phenyl, pyridiny or pyrimi mdinyl;
[0372] R.sup.1 is hydrogen, lower alkyl, halogen or lower alkoxy;
[0373] R.sup.3 is hydrogen, lower alkyl, lower alkyl substituted by
hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0374] n is 1 or
2; [0375] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or itscorresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0376] One further object of the present invention are compounds of
formula Ii
##STR00017## [0377] Ar.sup.1 is phenyl, pyridinyl or pyrimidinyl;
[0378] R.sup.1 is hydrogen, lower alkyl, halogen or lower alkoxy;
[0379] R.sup.3 is hydrogen, lower alkyl, lower alkyl substituted by
hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0380] n is 1 or
2; [0381] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or its corresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0382] One further object of the present invention are compounds of
formula II
##STR00018## [0383] Ar.sup.1 is phenyl, pyridinyl or pyrimidinyl;
[0384] R.sup.1 is hydrogen, lower alkyl, halogen or lower alkoxy;
[0385] R.sup.2 is hydrogen or lower alkyl; [0386] R.sup.3 is
hydrogen, lower alkyl, lower alkyl substituted by hydroxy,
cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0387] n is 1 or
2; [0388] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or its corresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0389] One further object of the present invention are compounds of
formula Im
##STR00019## [0390] Ar.sup.1 is phenyl, pyridinyl or pyrimidinyl;
[0391] R.sup.1 is hydrogen, lower alkyl, halogen or lower alkoxy;
[0392] R.sup.3 is hydrogen, lower alkyl, lower alkyl substituted by
hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0393] n is 1 or
2; [0394] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or its corresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0395] One further object of the present invention are compounds of
formula In
##STR00020## [0396] Ar.sup.1 is phenyl, pyridinyl or pyrimidinyl;
[0397] R.sup.1 is hydrogen, lower alkyl, halogen or lower alkoxy;
[0398] R.sup.3 is hydrogen, lower alkyl, lower alkyl substituted by
hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0399] n is 1 or
2; [0400] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or its corresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0401] One further object of the present invention are compounds of
formula Io
##STR00021## [0402] Ar.sup.1 is phenyl, pyridinyl or pyrimidinyl;
[0403] R.sup.1 is hydrogen, lower alkyl, halogen or lower alkoxy;
[0404] R.sup.3 is hydrogen, lower alkyl, lower alkyl substituted by
hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0405] n is 1 or
2; [0406] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or itscorresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0407] One further object of the present invention are compounds of
formula Ip
##STR00022## [0408] Ar.sup.1 is phenyl, pyridinyl or pyrimidinyl;
[0409] R.sup.1 is hydrogen, lower alkyl, halogen or lower alkoxy;
[0410] R.sup.2 is hydrogen or lower alkyl; [0411] R.sup.3 is
hydrogen, lower alkyl, lower alkyl substituted by hydroxy,
cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0412] n is 1 or
2; [0413] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or its corresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0414] One further object of the present invention are compounds of
formula Iq
##STR00023## [0415] Ar.sup.1 is phenyl, pyridinyl or pyrimidinyl;
[0416] R.sup.1 is hydrogen, lower alkyl, halogen or lower alkoxy;
[0417] R.sup.3 is hydrogen, lower alkyl, lower alkyl substituted by
hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0418] n is 1 or
2; [0419] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or its corresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0420] One further object of the present invention are compounds of
formula Ir
##STR00024## [0421] Ar.sup.1 is phenyl, pyridinyl or pyrimidinyl;
[0422] R.sup.1 is hydrogen, lower alkyl, halogen or lower alkoxy;
[0423] R.sup.2 is hydrogen or lower alkyl; [0424] R.sup.3 is
hydrogen, lower alkyl, lower alkyl substituted by hydroxy,
cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0425] n is 1 or
2; [0426] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or its corresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0427] One further object of the present invention are compounds of
formula Is
##STR00025## [0428] Ar.sup.1 is phenyl, pyridinyl or pyrimidinyl;
[0429] R.sup.1 is hydrogen, lower alkyl, halogen or lower alkoxy;
[0430] R.sup.3 is hydrogen, lower alkyl, lower alkyl substituted by
hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl,
pyrimidinyl, which rings may optionally substituted by lower alkyl,
or is --(CH.sub.2).sub.3--S(O).sub.2-cyclopropyl; [0431] n is 1 or
2; [0432] as well as a pharmaceutically acceptable salt thereof, a
racemic mixture, or its corresponding enantiomer and/or optical
isomer and/or stereoisomer thereof.
[0433] Encompassed by the present invention are corresponding
prodrugs of compounds of formula I.
[0434] A common antipsychotic drug for the treatment of
schizophrenia is olanzapine. Olanzapine (Zyprexa) belongs to a drug
class known as atypical antipsychotics. Other members of this class
include for example clozapine (Clozaril), risperidone (Risperdal),
aripiprazole (Abilify) and ziprasidone (Geodon).
[0435] Olanzapine is approved for the treatment of psychotic
disorders, long term treatment of bipolar disorders and in
combination with fluoxetine for the treatment of depressive
episodes associated with bipolar disorders and for the treatment of
resistant depression.
[0436] The compounds of the present invention may be combined with
antipsychotic drugs like olanzapine (Zyprexa), clozapine
(Clozaril), risperidone (Risperdal), aripiprazole (Abilify),
amisulpride (Solian), asenapine (Saphris), blonanserin (Lonasen),
clotiapine (Entumine), iloperidone (Fanapt), lurasidone (Latuda),
mosapramine (Cremin), paliperidone (Invega), perospirone (Lullan),
quetiapine (Seroquel), remoxipride (Roxiam), sertindole
(Serdolect), sulpiride (Sulpirid, Eglonyl), ziprasidone (Geodon,
Zeldox), zotepine (Nipolept), haloperidol (Haldol, Serenace),
droperidol (Droleptan), chlorpromazine (Thorazine, Largactil),
fluphenazine (Prolixin), perphenazine (Trilafon), prochlorperazine
(Compazine), thioridazine (Mellaril, Melleril), trifluoperazine
(Stelazine), triflupromazine (Vesprin), levomepromazine (Nozinan),
promethazine (Phenergan), pimozide (Orap) and cyamemazine
(Tercian).
[0437] One preferred embodiment of the invention is a combination,
wherein the marketed antipsychotic drug is olanzapine (Zyprexa),
clozapine (Clozaril), risperidone (Risperdal), aripiprazole
(Abilify) or ziprasidone.
[0438] Furthermore, the compounds of the present invention can be
combined with antidepressants such as selective serotonin reuptake
inhibitors [Citalopram (Celexa), Escitalopram (Lexapro, Cipralex),
Paroxetine (Paxil, Seroxat), Fluoxetine (Prozac), Fluvoxamine
(Luvox), Sertraline (Zoloft, Lustral)], serotonin-norepinephrine
reuptake inhibitors [Duloxetine (Cymbalta), Milnacipran (Ixel,
Savella), Venlafaxine (Effexor), Desvenlafaxine (Pristiq), Tramadol
(Tramal, Ultram), Sibutramine (Meridia, Reductil)], serotonin
antagonist and reuptake inhibitors [Etoperidone (Axiomin, Etonin),
Lubazodone (YM-992, YM-35,995), Nefazodone (Serzone, Nefadar),
Trazodone (Desyrel)], norepinephrine reuptake inhibitors
[Reboxetine (Edronax), Viloxazine (Vivalan), Atomoxetine
(Strattera)], norepinephrine-dopamine reuptake inhibitors
[Bupropion (Wellbutrin, Zyban), Dexmethylphenidate (Focalin),
Methylphenidate (Ritalin, Concerta)], norepinephrine-dopamine
releasing agents [Amphetamine (Adderall), Dextroamphetamine
(Dexedrine), Dextromethamphetamine (Desoxyn), Lisdexamfetamine
(Vyvanse)], tricyclic antidepressants [Amitriptyline (Elavil,
Endep), Clomipramine (Anafranil), Desipramine (Norpramin,
Pertofrane), Dosulepin [Dothiepin] (Prothiaden), Doxepin (Adapin,
Sinequan), Imipramine (Tofranil), Lofepramine (Feprapax, Gamanil,
Lomont), Nortriptyline (Pamelor), Protriptyline (Vivactil),
Trimipramine (Surmontil)], tetracyclic antidepressants [Amoxapine
(Asendin), Maprotiline (Ludiomil), Mianserin (Bolvidon, Norval,
Tolvon), Mirtazapine (Remeron)], monoamine oxidase inhibitors
[Isocarboxazid (Marplan), Moclobemide (Aurorix, Manerix),
Phenelzine (Nardil), Selegiline [L-Deprenyl] (Eldepryl, Zelapar,
Emsam), Tranylcypromine (Parnate), Pirlindole (Pirazidol)], 5-HT1A
Receptor Agonists [Buspirone (Buspar), Tandospirone (Sediel),
Vilazodone (Viibryd)], 5-HT2 Receptor Antagonists [Agomelatine
(Valdoxan), Nefazodone (Nefadar, Serzone), selective Serotonin
Reuptake Enhancers [Tianeptine].
[0439] A preferred embodiment of this invention is a combination,
wherein the marketed anti-depressive drug is citalopram (Celexa),
escitalopram (Lexapro, Cipralex), paroxetine (Paxil, Seroxat),
fluoxetine (Prozac), sertraline (Zoloft, Lustral) duloxetine
(Cymbalta), milnacipran (Ixel, Savella), venlafaxine (Effexor), or
mirtazapine (Remeron).
[0440] Compounds can also be combined with anxiolytics such as
Alprazolam (Helex, Xanax, Xanor, Onax, Alprox, Restyl, Tafil,
Paxal), Bretazenil, Bromazepam (Lectopam, Lexotanil, Lexotan,
Bromam), Brotizolam (Lendormin, Dormex, Sintonal, Noctilan),
Chlordiazepoxide (Librium, Risolid, Elenium), Cinolazepam
(Gerodorm), Clonazepam (Rivotril, Klonopin, Iktorivil, Paxam),
Clorazepate (Tranxene, Tranxilium), Clotiazepam (Veratran, Clozan,
Rize), Cloxazolam (Sepazon, Olcadil), Delorazepam (Dadumir),
Diazepam (Antenex, Apaurin, Apzepam, Apozepam, Hexalid, Pax,
Stesolid, Stedon, Valium, Vival, Valaxona), Estazolam (ProSom),
Etizolam (Etilaam, Pasaden, Depas), Flunitrazepam (Rohypnol,
Fluscand, Flunipam, Ronal, Rohydorm), Flurazepam (Dalmadorm,
Dalmane), Flutoprazepam (Restas), Halazepam (Paxipam), Ketazolam
(Anxon), Loprazolam (Dormonoct), Lorazepam (Ativan, Temesta, Tavor,
Lorabenz), Lormetazepam (Loramet, Noctamid, Pronoctan), Medazepam
(Nobrium), Midazolam (Dormicum, Versed, Hypnovel, Dormonid),
Nimetazepam (Erimin), Nitrazepam (Mogadon, Alodorm, Pacisyn,
Dumolid, Nitrazadon), Nordazepam (Madar, Stilny), Oxazepam
(Seresta, Serax, Serenid, Serepax, Sobril, Oxabenz, Oxapax),
Phenazepam (Phenazepam), Pinazepam (Domar), Prazepam (Lysanxia,
Centrax), Premazepam, Quazepam (Doral), Temazepam (Restoril,
Normison, Euhypnos, Temaze, Tenox), Tetrazepam (Mylostan),
Triazolam (Halcion, Rilamir), Clobazam (Frisium, Urbanol),
Eszopiclone (Lunesta), Zaleplon (Sonata, Starnoc), Zolpidem
(Ambien, Nytamel, Stilnoct, Stilnox, Zoldem, Zolnod), Zopiclone
(Imovane, Rhovane, Ximovan; Zileze; Zimoclone; Zimovane; Zopitan;
Zorclone), Pregabalin (Lyrica) and Gabapentin (Fanatrex, Gabarone,
Gralise, Neurontin, Nupentin).
[0441] One preferred embodiment of the invention is a combination,
wherein the marketed anxiolytic drug is alprazolam (Helex, Xanax,
Xanor, Onax, Alprox, Restyl, Tafil, Paxal), chlordiazepoxide
(Librium, Risolid, Elenium), clonazepam (Rivotril, Klonopin,
Iktorivil, Paxam), diazepam (Antenex, Apaurin, Apzepam, Apozepam,
Hexalid, Pax, Stesolid, Stedon, Valium, Vival, Valaxona), Estazolam
(ProSom), eszopiclone (Lunesta), zaleplon (Sonata, Starnoc),
zolpidem (Ambien, Nytamel, Stilnoct, Stilnox, Zoldem, Zolnod),
pregabalin (Lyrica) or gabapentin (Fanatrex, Gabarone, Gralise,
Neurontin, Nupentin).
[0442] A further object of the invention is a combination with mood
stabilizers such as Carbamazepine (Tegretol), Lamotrigine
(Lamictal), Lithium (Eskalith, Lithane, Lithobid), and Valproic
Acid (Depakote).
[0443] Compounds can also be combined with procognitive compounds
such as donepezil (Aricept), galantamine (Razadyne), rivastigmine
(Exelon) and memantine (Namenda).
[0444] The preferred indications using the compounds of the present
invention are psychotic diseases like schizophrenia.
[0445] As used herein, the term "lower alkyl" denotes a saturated
straight- or branched-chain group containing from 1 to 7 carbon
atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl,
i-butyl, 2-butyl, t-butyl and the like. Preferred alkyl groups are
groups with 1-4 carbon atoms.
[0446] As used herein, the term "lower alkoxy" denotes an alkyl
group as defined above, which alkyl group is bonded via an O
atom.
[0447] As used herein, the term "lower alkyl substituted by
hydroxy" denotes a group wherein the alkyl residue is as defined
above, wherein at least one hydrogen atom is replaced by a hydroxy
group.
[0448] The term "cycloalkyl" denotes an alkyl ring with 3-6 carbon
ring atoms.
[0449] The term "halogen" denotes chlorine, iodine, fluorine and
bromine.
[0450] The term "5 or 6 membered heteroaryl group, containing 2 or
3 heteroatoms, selected from N, O or S" denotes an aromatic ring,
for example the following groups:
##STR00026##
[0451] The term "pharmaceutically acceptable acid addition salts"
embraces salts with inorganic and organic acids, such as
hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid,
citric acid, formic acid, fumaric acid, maleic acid, acetic acid,
succinic acid, tartaric acid, methane-sulfonic acid,
p-toluenesulfonic acid and the like.
[0452] The present compounds of formula I and their
pharmaceutically acceptable salts can be prepared by methods known
in the art, for example, by processes described below, which
processes comprise [0453] a) reacting a compound of formula
##STR00027##
[0453] to a compound of formula
##STR00028##
##STR00029##
wherein the substituents have the meaning as described above
and,
[0454] if desired, converting the compounds obtained into
pharmaceutically acceptable acid addition salts; or [0455] b)
reacting a compound of formula
##STR00030##
[0455] with a compound of formula
(R.sup.1).sub.n--Ar.sup.1--B(OH).sub.2
to a compound of formula
##STR00031##
wherein the substituents have the meaning as described above
and,
[0456] if desired, converting the compounds obtained into
pharmaceutically acceptable acid addition salts; [0457] c) reacting
a compound of formula
##STR00032##
[0457] with a compound of formula
(R.sup.1).sub.n--Ar.sup.1--Br
to a compound of formula
##STR00033##
wherein the substituents have the meaning as described above and,
if desired, converting the compounds obtained into pharmaceutically
acceptable acid addition salts.
[0458] The preparation of compounds of formula I of the present
invention may be carried out in sequential or convergent synthetic
routes. Syntheses of the compounds of the invention are shown in
the following schemes. The skills required for carrying out the
reaction and purification of the resulting products are known to
those skilled in the art. The substituents and indices used in the
following description of the processes have the significance given
herein before unless indicated to the contrary.
[0459] In more detail, the compounds of formula I can be
manufactured by the methods given below, by the methods given in
the examples or by analogous methods. Appropriate reaction
conditions for the individual reaction steps are known to a person
skilled in the art. The reaction sequence is not limited to the one
displayed in the schemes, however, depending on the starting
materials and their respective reactivity the sequence of reaction
steps can be freely altered. Starting materials are either
commercially available or can be prepared by methods analogous to
the methods given below, by methods described in the examples, or
by methods known in the art.
[0460] Compounds of general formula 2 (X.dbd.CH) (Scheme 1) wherein
R.sup.3 is methyl can e.g. be prepared by trimethylation of
6-halo-oxindoles 1 (X.dbd.CH) with Me-LG with LG being a leaving
group like iodide, bromide, chloride, tosylate in the presence of a
base like sodium hydride and wherein Y is halogen, e.g.
bromide.
##STR00034##
[0461] Compounds of general formula 2 (X.dbd.CH) (Scheme 1) wherein
R.sup.3 is not methyl can e.g. be prepared by dimethylation of
6-halo-oxindoles 1 (X.dbd.CH) with Me-LG (LG being a leaving group
like iodide, bromide, chloride, tosylate) in the presence of a base
like potassium tert-butoxide and in the presence of
copper(I)bromide-dimethylsulfide complex to give the dialkylated
product 4 (X.dbd.CH). Compounds of general formula 2 (X.dbd.CH, N)
can be prepared by alkylation of compounds of general formula 4
(X.dbd.CH, N) with R.sup.3-LG in the presence of a base like sodium
hydride or cesium carbonate or by coupling of boronic acids
R.sup.3--B(OH).sub.2 or esters R.sup.3--B(OR').sub.2 (e.g.
R.sup.3-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane) under metal
catalysis (like e.g. palladium(0) or copper(II)catalysis) in the
presence of a base like e.g. sodium bis(trimethylsilyl)amide or
sodium carbonate.
[0462] Compounds of formula 5 (X.dbd.CH, N) (Scheme 1) can be
prepared from general formula 2 (X.dbd.CH, N) by carbonylation with
carbon monoxide in methanol and in the presence of a
ferrocene-palladium catalyst. Hydrolysis of methy esters 5
(X.dbd.CH) using e.g. sodium hydroxide yields acids 3 (X.dbd.CH).
Alternatively, for R.sup.3=methyl, acid 3 (X.dbd.CH) can be
prepared by reaction of the methylester 6 with excess of Me-LG in
the presence of excess of a base, e.g. sodium hydride in THF
followed by hydrolysis of the intermediate ester using e.g. sodium
hydroxide. For R.sup.3.dbd.H, acid 3 (X.dbd.CH) can be prepared by
reaction of the methylester 6 with 2 equivalents of Me-LG in the
presence of 2 equivalents of a base, e.g. sodium hydride in DMF
followed by hydrolysis of the ester group using e.g. sodium
hydroxide.
##STR00035##
[0463] Imidazoles of formula Ia (Scheme 2) can be prepared by
substituting bromides 2a with cyanide, e.g. zinc cyanide in the
presence of a palladium catalyst to give nitriles 7. Addition of
LiHMDS to nitriles 7 followed by acidic hydrolysis provides
amidines 8, which can be cyclized with .alpha.-bromomethylketones 9
in the presence of a base to afford imidazoles Ia.
##STR00036##
[0464] Imidazoles of formula Ib (Scheme 3) can be prepared starting
from bromides 2a, which can be reacted with N-butyl vinylether in
the presence of a palladium catalyst to give the methylketones 10.
Bromination of 10 with e.g. tetra-N-butylammonium tribromide
followed by condensation of the formed .alpha.-halomethylketones 11
with amidines 12 yields imidazoles Ib.
##STR00037##
[0465] 1,2,4-Oxadiazoles of formula Ic (Scheme 4) can be prepared
by condensation of acids 3 (X.dbd.CH) with N-hydroxy amidines 13,
e.g. in the presence of carbonyldiimidazole.
##STR00038##
[0466] 1,2,4-Oxadiazoles of formula Id (Scheme 5) can be prepared
by reaction of nitriles 7 with hydroxylamine followed by
condensation of the formed N-hydroxy amidines 14 with acids 15,
e.g. in the presence of carbonyldiimidazole.
##STR00039##
[0467] Oxazoles of formula Ie (X.dbd.CH) (Scheme 6) can be prepared
by reaction of bromides 11 with hexamethylenetetramine to give the
aminomethylketones 16, which can be acylated using acid chlorides
17 to give the amides 18. Cyclization of 18 with
(methoxycarbonylsulfamoyl) triethylammoniumhydroxid provides
oxazoles Ie (X.dbd.CH). Alternatively, oxazoles of formula Ie
(X.dbd.CH) can be prepared by substitution of bromides 11 with
sodium azide followed by reaction of the azide 19 with acid
chlorides 17 in the presence of triphenylphosphine. In a third
method, bromide 2 (X.dbd.CH, R.sup.3.dbd.H) can first be protected
with p-methoxybenzyl chloride to give 2 (X.dbd.CH, R.sup.3=PMB),
which can be coupled with oxazoles 20 in the presence of
triphenylphosphine, a ferrocene-palladium catalysts and silver
carbonate followed by deprotection using TFA to give oxazoles of
formula Ie (X.dbd.CH). In a fourth method, bromide 2 (X.dbd.N,
R.sup.3=cyclopropyl) can be reacted with oxazoles 20 in the
presence of a palladium catalyst, e.g. palladium diacetate and a
phosphine ligand, e.g. 2-(dicyclohexylphosphino)biphenyl and cesium
carbonate to afford oxazoles Ie (X.dbd.N).
##STR00040##
[0468] Oxazoles of formula If (Scheme 7) can be prepared starting
from acids 3 (X.dbd.CH), which can be activated to the intermediate
acid chlorides using thionyl chloride followed by coupling with
amine 21 to give the amide acetales 22. Deprotection of the acetale
group using hydrochloric acid and subsequent cyclization of the
formed ketones 23 in the presence of
(methoxycarbonylsulfamoyl)triethylammoniumhydroxid furnishes
oxazoles of formula If.
##STR00041##
[0469] Oxadiazoles of formula Ig (X.dbd.CH) (Scheme 8) can be
prepared starting from acids 3 (X .dbd.CH), which can be reacted
with hydrazides 24 in the presence of EDCI and
1H-benzo[d][1,2,3]triazol-1-ol furnishing acetylhydrazides 25
(X.dbd.CH). Alternatively, acids 3 (X.dbd.N) can be activated to
the intermediate acid chlorides using thionyl chloride followed by
reaction with hydrazine to give the hydrazides 26 (X.dbd.N), which
can be coupled with acids 15 to give the acetylhydrazides 25
(X.dbd.N). Cyclization of 25 using p-toluensulfonyl cloride affords
oxadiazoles of formula Ig.
##STR00042##
[0470] Thiazoles of formula Ih (Scheme 9) can be prepared by
coupling of bromides 2a with substituted thiazoles 29, in the
presence of triphenylphosphine, a ferrocene-palladium catalysts and
silver carbonate. Substituted thiazoles 29 can be obtained by
Suzuki coupling of boronic acid 27 with bromothiazole 28 in the
presence of a palladium catalyst, e.g. of
tetrakis(triphenylphosphine)palladium(0).
##STR00043##
[0471] Oxazoles of formula Ii (Scheme 10) can be prepared by
converting acids 3 (X.dbd.CH) into the in situ generated acid
chlorides followed by reaction with ammonia to give the amides 30,
which can be reacted with chloroacetyl chloride affording the
chloromethylketones 31. Conversion to the oxazole triflates 32 was
effected with a base, i.e. sodium hydride followed by reaction with
triflic anhydride in the presence of a base, i.e. triethylamine.
Suzuki coupling of 32 with boronic acids 27 in the presence of a
palladium catalyst, i.e.
bis(triphenylphosphine)palladium(II)chloride provided the oxazoles
of formula Ii.
##STR00044##
[0472] Imidazoles of formula Ik (Scheme 11) can be prepared by
coupling bromides 2a with substituted imidazoles 33 in the presence
of a catalyst, i.e. copper(I)chloride and 2-acetylcyclohexanon in
N-methylpyrrolidone. Substituted imidazoles 33 are known and can be
prepared e.g. according to Ganellin et al., J. Med. Chem. 38, 3342,
1995. Alternatively the reaction may be carried out with
4-bromoimidazole leading, which subsequently can be arylated with
the corresponding Ar.sup.1-boronic acids or Ar.sup.1-boronic acid
esters in the presence of a base like potassium carbonate or NaOtBu
and a catalyst like PdCl.sub.2(PPh.sub.3).sub.2 or Brettphos
palladacycle to give compounds of formula Ik.
##STR00045##
[0473] Pyrazoles of formula II (Scheme 12) can be prepared by
coupling bromides 2a with substituted pyrazoles 34 in the presence
of a catalyst, i.e. copper(I)chloride and L-proline in DMSO.
Substituted pyrazoles 34 are known and can be prepared e.g.
according to Bauer et al., J. Med. Chem. 11, 981, 1968.
##STR00046##
[0474] Isoxazoles of formula Im (Scheme 13) can be prepared by
reacting methylketones 10 with esters 35 in the presence of a base,
i.e. sodium hydride to give diketones 36, which can be cyclized
with hydroxylamine furnishing isoxazoles Im and/or Im'.
##STR00047##
[0475] Oxazoles of formula In (Scheme 14) can be prepared by
cyclizing bromomethylketones 11 with hydroxylamine to give oxazoles
37, which can be chlorinated using hexachloroethane and a base,
e.g. LiHMDS providing chloro-oxazoles 38. Suzuki coupling of 38
with boronic acids 27 in the presence of a palladium catalyst, e.g.
bis(triphenylphosphine)palladium(II)dichloride yielded oxazoles
In.
##STR00048##
[0476] Pyrazoles of formula Io (Scheme 15) can be prepared by
Suzuki coupling of bromides 2a with boronic ester 39 in the
presence of a palladium catalyst, e.g.
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) to
afford pyrazoles 40, which can be alkylated with bromides 41 in the
presence of copper(I)iodide and L-proline in DMSO to give pyrazoles
of formula Io.
##STR00049##
[0477] Imidazoles of formula Ip (Scheme 16) can be prepared from
diketones 36 and hydrazine in the presence of a base, e.g. DIPEA to
give imidazoles of formula Ip.
##STR00050##
[0478] Triazoles of formula Iq (Scheme 17) can be prepared from
bromides 2a and an azide, e.g. sodium azide in the presence of
ascorbic acid sodium salt and
trans-(1R,2R)--N,N'-bismethyl-1,2-cyclohexanediamine to give the
azides 42. Cyclization of 42 can be effected with acetylenes 43 in
the presence of ascorbic acid sodium salt and copper(II)sulfate in
water to give triazoles of formula Iq.
##STR00051##
[0479] Imidazoles of formula Ir (Scheme 18) can be prepared from
acids 3 (X.dbd.CH) by reduction with e.g. borane tetrahydrofuran
complex to give alcohols 44, which can be oxidized with e.g.
manganese dioxide to aldehydes 45. Cyclization of 45 with
tosylmethylisocyanide provides oxazoles 46, which can be converted
to imidazoles 47 in the presence of formamide. Coupling of 47 with
bromides 41 in the presence of copper(I)chloride and
2-acetylcyclohexanone in DMSO furnishes imidazoles of formula Ir.
Alternatively compounds of formula 47 may be reacted with 2- or
4-fluoropyridines or 2-chloropyrimidines in the presence of cesium
carbonate to give compounds of formula Ir as well.
##STR00052##
[0480] Pyrimidines of formula Is (Scheme 19) can be prepared from
bromides 2a by reaction with bis(pinacolato)diboron and a palladium
catalyst, e.g.
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) to give
boronic esters 48, which can be coupled with
4-bromo-2-chloropyrimidine or 5-bromo-2-chloropyrimidine in the
presence of
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
affording chloropyrimidines 50. Suzuki coupling of 50 with boronic
acids 27 in the presence of
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
afforded pyrimidines of formula Is
##STR00053##
[0481] Imidazoles of formula Ir (Scheme 20) can be prepared from
the known chloro-pyridine 4a (Woolford et al., WO 2012143726),
which can be alkylated with a boronic acid, e.g. cyclopropylboronic
acid in the presence of copper(II)acetate and a base, e.g. sodium
bis(trimethylsilyl)amide to give alkylated chloro-pyrrolopyridins
51, which can be coupled with
N,N-dimethyl-4-(tributylstannyl)-1H-imidazole-1-sulfonamide
(prepared according to Altenbach et al., J. Med. Chem. 51, 6571,
2008) and a palladium catalyst, e.g.
tetrakis(triphenylphosphine)palladium(0) furnishing sulfonamides
53. Cleveage of the sulfonamide group in 53 can be accomplished
with an acid, e.g. aqueous hydrochloric acid providing imidazoles
54, which can be coupled with an aromatic fluoride 55 and a base,
e.g. cesium carbonate to give imidazoles of formula Ir.
##STR00054##
[0482] Alternatively to Scheme 18, compounds of formula 56 may be
directly prepared from compounds of formula 11 by treatment with
formamide. These may be transferred to compounds of formula 57 and
Iu by methods depicted in Scheme 18. Compounds of formula 57 may be
transformed to compounds of formula Iu by treatment with TFA
(Scheme 21). Compounds of formula Iu can be transformed to
compounds of formula Ir by reaction with the corresponding
heteroaryl bromides in the presence of a base like potassium
carbonate, a copper(I) source like Cul and a suitable ligand like
N,N'-dimethylethylen-1,2-diamine. Compounds of formula Ir can be
obtained by treatment of compounds with formula Iu with a suitable
alkylating agent in the presence of a base like cesium
carbonate
Experimental Part
[0483] The following examples are provided for illustration of the
invention. They should not be considered as limiting the scope of
the invention, but merely as being representative thereof.
[0484] Abbreviations:
[0485] DIPEA, diisopropylethylamine; DMAP, dimethylaminopyridine;
DMF, dimethylformamide; DMSO, dimethylsulfoxide; EtOAc, ethyl
acetate; HATU,
O-(7-azabenzotriazole-1-yl)-N,N,N,N'-tetramethyluronium
hexafluorophosphate; LiHMDMS, lithium hexamethyldisilazide; MeOH,
methanol; PMB, p-methoxybenzyl; TBAF, tetrabutylammonium fluoride;
TBME, tert-butylmethylether; TFA, trifluoroacetic acid; THF,
tetrahydrofuran.
[0486] General:
[0487] Silica gel chromatography was either performed using
cartridges packed with silica gel (ISOLUTE.RTM. Columns, TELOS.TM.
Flash Columns) or silica-NH2 gel (TELOS.TM. Flash NH2 Columns) on
ISCO Combi Flash Companion or on glass columns on silica gel 60
(32-60 mesh, 60 .ANG.). MS: Mass spectra (MS) were measured with
ion spray positive or negative method on a Perkin-Elmer SCIEX API
300.
Example 1
1-Cyclopropyl-6-(5-(4-fluorophenyl)-1H-imidazol-2-yl)-3,3-dimethylindolin--
2-one
##STR00055##
[0488] a) 6-Bromo-3,3-dimethyl-indolin-2-one
[0489] To a suspension of potassium tert-butylate (12.8 g) in dry
THF (80 ml) was added portion wise at 0.degree. C.
6-bromoindolin-2-one (5.0 g,) followed by copper (I)
bromide-dimethylsulfide complex (470 mg). MeI (6.82 g) was added
drop wise within 45 min keeping the internal temperature below
8.degree. C., the mixture was warmed to 22.degree. C. and stirring
was continued for 16 h. hours. The mixture was quenched at
0.degree. C. with saturated aqueous ammonium chloride solution and
diluted with TBME and water. The organic layer was dried,
evaporated and the residue purified by flash chromatography (silica
gel, EtOAc/n-heptane, 1:1) to give the title compound (5.17 g) as a
brown solid (5.17 g, 91%). MS ESI (m/z): 240.4/242.4
[(M+H).sup.+].
b) 6-Bromo-1-cyclopropyl-3,3-dimethylindolin-2-one
[0490] To a black suspension of 6-bromo-3,3-dimethylindolin-2-one
(7.0 g), cyclopropylboronic acid (5.01 g), DMAP (10.7 g) and copper
(II) acetate (5.56 g) in toluene (400 ml) was added a solution of
sodium bis(trimethylsilyl)amide in THF (2 M, 15.3 ml) while
bubbling dry air through the mixture, which was followed by heating
to 95.degree. C. for 7 h. The mixture was partitioned between
aqueous HCl (2 M) and TBME, the organic layer was washed with
aqueous HCl (2 M), dried, evaporated and the residue purified by
flash chromatography (silica gel, gradient, 0% to 20% EtOAc in
n-heptane) to give the title compound (7.1 g, 87%) as a red solid.
MS (ESI, m/z): 280.4/282.4 [(M+H).sup.+].
c) 1-Cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carbonitrile
[0491] A suspension of
6-bromo-1-cyclopropyl-3,3-dimethylindolin-2-one (2.0 g) in DMF (36
ml) was flushed with argon, treated with dicyanozinc (1.04 g) and
tetrakis(triphenylphosphine)palladium(0) (825 mg) and stirring was
continued at 85.degree. C. for 16 h. The mixture was evaporated,
the residue partitioned between aqueous sodium carbonate (1 M) and
EtOAc, the organic layer was washed with aqueous sodium carbonate
(1 M), dried, evaporated and the residue purified by flash
chromatography (silica gel, gradient, 0% to 40% EtOAc in n-heptane)
to give the title compound (1.61 g, quant.) as a light yellow
solid. MS (ESI, m/z): 227.5 [(M+H).sup.+].
d) 1-Cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carboximidamide
[0492] To a brown solution of lithium bis(trimethylsilyl)amide in
THF (IM, 8.2 m) and dry diethyl ether (17 ml) was added at
0.degree. C. in 3 portions
1-cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carbonitrile (900 mg)
and stirring was continued at 22.degree. C. for 21 h. The mixture
was cooled to 0.degree. C., treated with hydrochloric acid (6 M,
4.0 ml) and stirring was continued at 0.degree. C. for 40 min and
at 22.degree. C. for 5 h. The mixture was partitioned between water
and diethyl ether, the pH of the aqueous layer was adjusted to 14
using solid NaOH and extracted with dichloromethane. The organic
layer was dried and evaporated to give the crude title compound
(537 mg, 56%) as an off-white solid, which was used without further
purification. MS (ESI, m/z): 244.5 [(M+H).sup.+].
e)
1-Cyclopropyl-6-(5-(4-fluorophenyl)-1H-imidazol-2-yl)-3,3-dimethylindol-
in-2-one (Example 1)
[0493] A mixture of
1-cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carboximidamide (130 mg)
and 2-bromo-1-(4-fluorophenyl)ethanone (151 mg) in an aqueous
sodium hydrogencarbonate solution (1 M, 1.9 ml) and THF (120 ml)
was heated to reflux temperature for 16 h. The mixture was
evaporated, the residue partitioned between water and EtOAc, the
organic layer was dried, evaporated and the residue purified by
flash chromatography (silica gel, gradient, 0% to 15% MeOH in
dichloromethane), which was followed by a second chromatography
(Si--NH2, gradient, 0% to 70% EtOAc in n-heptane) to give the title
compound (121 mg, 63%) as a white foam. MS (ESI, m/z): 362.6
[(M+H).sup.+].
Example 2
1,3,3-Trimethyl-6-(5-phenyl-1H-imidazol-2-yl)indolin-2-one
##STR00056##
[0494] a) 6-Bromo-1,3,3-trimethylindolin-2-one
[0495] Under an argon atmosphere NaH (60% on mineral oil, 7.32 g)
was suspended in dry THF (45 ml). A suspension of
6-bromoindolin-2-one (10.0 g) in dry THF (108 ml) was added in
portions during 10 min keeping the temperature below 27.degree. C.
The reaction mixture was warmed to 25.degree. C., MeI (11.4 ml) was
added drop wise during 1 h while the internal temperature was
carefully kept between 24 and 27.degree. C. and stirring was
continued for 18 h. Saturated aqueous NH.sub.4Cl solution (20 ml)
was carefully added at 10-15.degree. C., the mixture was diluted
with EtOAc and saturated aqueous NaHCO.sub.3 solution, the organic
layer was washed with saturated aqueous NaHCO.sub.3 solution, dried
and evaporated. The residue was purified by flash chromatography
(siliga gel, gradient 0% to 30% EtOAc in n-heptane) to give the
title compound (10.1 g, 84%) as a light red solid. MS (ESI, m/z):
254.1/256.2 [(M+H).sup.+].
b) 1,3,3-Trimethyl-6-(5-phenyl-1H-imidazol-2-yl)indolin-2-one
(Example 2)
[0496] 6-Bromo-1,3,3-trimethylindolin-2-one was converted in
analogy to example 1c-e using bromo-1-(phenyl)ethanone in step e to
give the title compound as white solid. MS (ESI, m/z): 318.1
[(M+H).sup.+].
Example 3
1,3,3-Trimethyl-6-(2-(pyridin-4-yl)-1H-imidazol-5-yl)indolin-2-one
##STR00057##
[0497] a) 6-Acetyl-1,3,3-trimethylindolin-2-one
[0498] A mixture of 6-bromo-1,3,3-trimethylindolin-2-one (1.0 g)
from example 2a, 1,3-bis(diphenylphosphino)propane (418 mg),
palladium (II) acetate (88 mg), N-butyl vinylether (1.63 g) and
potassium carbonate (653 mg) in DMF (14 ml) and water (1.4 ml) was
flushed with argon for 5 min and heated in a microwave oven at
120.degree. C. for 1 h. The mixture treated at 22.degree. C. with
aqueous hydrochloric acid (2 N, 7.5 ml) and stirring was continued
for 3 h. The mixture was partitioned between saturated aqueous
ammonium hydrogencarbonate and EtOAc, the organic layer was dried,
evaporated and the residue purified by flash chromatography (silica
gel, gradient, 0% to 50% EtOAc in n-heptane) to give the title
compound (660 mg, 77%) as a light yellow solid. MS (ESI, m/z):
218.5 [(M+H).sup.+].
b) 6-(2-Bromoacetyl)-1,3,3-trimethylindolin-2-one
[0499] To a solution of 6-acetyl-1,3,3-trimethylindolin-2-one (660
mg) in THF (20 ml) and MeOH (12 ml) was added a solution of
tetra-n-butylammonium tribromide (1.49 g) in THF (7 ml) and
stirring was continued at 45.degree. C. for 17 h. The mixture was
partitioned between water and EtOAc, the organic layer was dried,
evaporated and the residue purified twice by flash chromatography
(silica gel, gradient, 0% to 50% EtOAc in n-heptane) to give the
title compound (646 mg, 72%) as a light brown liquid. MS (ESI,
m/z): 296.3/298.3 [(M+H).sup.+].
c)
1,3,3-Trimethyl-6-(2-(pyridin-4-yl)-1H-imidazol-5-yl)indolin-2-one
(Example 3)
[0500] A mixture of isonicotinimidamide hydrochloride (511 mg) in
an aqueous sodium hydrogencarbonate solution (1 M, 4.3 ml) and THF
(225 ml) was stirred at 22.degree. C. for 20 min. A solution of
6-(2-bromoacetyl)-1,3,3-trimethylindolin-2-one (320 mg) in THF (16
ml) was added and heated to reflux temperature for 22 h. The
mixture was evaporated, the residue partitioned between water and
EtOAc, the organic layer was dried, evaporated and the residue
purified twice by flash chromatography (silica gel, gradient, 0% to
15% MeOH in dichloromethane containing 1% NH3), to give the title
compound (168 mg, 48%) as a light yellow foam. MS (ESI, m/z): 319.5
[(M+H).sup.+].
Example 4
1-Cyclopropyl-3,3-dimethyl-6-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)indoli-
n-2-one
##STR00058##
[0501] a) Methyl
1-cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carboxylate
[0502] To a solution of
6-bromo-1-cyclopropyl-3,3-dimethylindolin-2-one from example 1b
(3.0 g), triethylamine (2.18 g) in EtOAc (40 ml) and MeOH (40 ml)
was added
1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride
dichlormethane adduct (0.87 g) and the mixture was carbonylated at
50 bar CO pressure at 100.degree. C. for 48 h. The mixture was
evaporated and the residue purified by flash chromatography (silica
gel, EtOAc/n-heptane, 1:1) to give the title compound (2.79 g, 91%)
as a black solid. MS (ESI, m/z): 260.5 [(M+H).sup.+].
b) 1-Cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carboxylic acid
[0503] A mixture of methyl
1-cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carboxylate (3.6 g) in
MeOH (56 ml) and aqueous sodium hydroxide (1 M, 56 ml) was stirred
at 22.degree. C. for 5 h. The mixture was partitioned between water
and TBME, the pH of the aqueous layer was adjusted to 1 using
aqueous hydrochloric acid (25%), the aqueous layer was extracted
with dichloromethane, the organic layer was dried and evaporated to
give the title compound (3.33 g, 98%) as a light yellow solid,
which was used without further purification. MS (ESI, m/z): 246.5
[(M+H).sup.+].
c)
1-Cyclopropyl-3,3-dimethyl-6-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)ind-
olin-2-one (Example 4)
[0504] A solution of
1-cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carboxylic acid (140 mg)
and carbonyldiimidazole (111 mg) in dry THF (6 ml) was heated to
reflux temperature for 2 h. 4-pyridylamidoxime (94 mg) was added
and stirring was continued at reflux for 1.5 h. The mixture was
evaporated, the residue dissolved in acetic acid (6 ml) and heated
to reflux temperature for 1.5 h and stirring was continued at
22.degree. C. for 16 h. The mixture was evaporated, the residue
partitioned between aqueous sodium carbonate (1 M) and
dichloromethane, the organic layer was washed with aqueous sodium
carbonate (1 M), dried, evaporated and the residue purified by
flash chromatography (silica gel, gradient, 0% to 50% EtOAc in
dichloromethane) to give the title compound (189 mg, 96%) as a
white solid. MS (ESI, m/z): 347.5 [(M+H).sup.+].
Example 5
1-Cyclopropyl-3,3-dimethyl-6-(5-(pyridin-4-yl)-1,2,4-oxadiazol-3-yl)indoli-
n-2-one
##STR00059##
[0505] a)
1-Cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carbonitrile
[0506] A suspension of
6-bromo-1-cyclopropyl-3,3-dimethylindolin-2-one from example 1b
(2.0 g) in DMF (36 ml) was flushed with argon, treated with
dicyanozinc (1.04 g) and tetrakis(triphenylphosphine)palladium(0)
(825 mg) and stirring was continued at 85.degree. C. for 16 h. The
mixture was evaporated, the residue partitioned between aqueous
sodium carbonate (1 M) and EtOAc, the organic layer was washed with
aqueous sodium carbonate (1 M), dried, evaporated and the residue
purified by flash chromatography (silica gel, gradient, 0% to 40%
EtOAc in n-heptane) to give the title compound (1.61 g, quant.) as
a light yellow solid. MS (ESI, m/z): 227.5 [(M+H).sup.+].
b)
(Z)-1-Cyclopropyl-N'-hydroxy-3,3-dimethyl-2-oxoindoline-6-carboximidami-
de
[0507] A mixture of
1-cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carbonitrile (170 mg),
hydroxylamine hydrochloride (132 mg) and DIPEA (248 mg) in ethanol
(1.5 ml) was heated to 70.degree. C. for 4 h and evaporated. The
residue was partitioned between aqueous sodium carbonate (1 M) and
EtOAc, the organic layer was washed with aqueous sodium carbonate
(1 M), dried and evaporated to give the crude title compound (240
mg, ca. 80% pure, 99%) as a light green foam, which was used
without further purification. MS (ESI, m/z): 260.5
[(M+H).sup.+].
c)
1-Cyclopropyl-3,3-dimethyl-6-(5-(pyridin-4-yl)-1,2,4-oxadiazol-3-yl)ind-
olin-2-one (Example 5)
[0508] A solution of isonicotinic acid (91 mg) and
carbonyldiimidazole (130 mg) in dry THF (7.4 ml) was heated to
reflux temperature for 1.5 h,
(Z)-1-cyclopropyl-N'-hydroxy-3,3-dimethyl-2-oxoindoline-6-carboximidamide
(240 mg, 80% pure) was added and heating was continued for 1.5 h.
The mixture was evaporated, the residue dissolved in acetic acid
(7.4 ml) and heated to reflux temperature for 1 h. The mixture was
evaporated, the residue partitioned between aqueous sodium
carbonate (1 M) and EtOAc, the organic layer was washed with
aqueous sodium carbonate (1 M), dried, evaporated and the residue
purified by flash chromatography (silica gel, gradient, 0% to 5%
MeOH in dichloromethane) to give the title compound (171 mg, 67%)
as a pale yellow solid. MS (ESI, m/z): 347.5 [(M+H).sup.+].
Example 6
3,3-Dimethyl-1-oxetan-3-yl-6-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-1,3-di-
hydro-indol-2-one
##STR00060##
[0509] a) 6-Bromo-3,3-dimethyl-l-(oxetan-3-yl)indolin-2-one
[0510] A mixture of 6-bromo-3,3-dimethylindolin-2-one from example
1a (500 mg), 3-bromooxetane (594 mg) and cesium carbonate (1.36 g)
in DMF (17 ml) was flushed with argon for 5 min and heated to
60.degree. C. for 18 h. The mixture was partitioned between aqueous
HCl (1 M) and EtOAc, the organic layer was dried, evaporated and
the residue purified by flash chromatography (silica gel, gradient,
0% to 50% EtOAc in n-heptane) to give the title compound (550 mg,
80%) as an orange waxy solid. MS (ESI, m/z): 296.3/298.3
[(M+H).sup.+].
b) Methyl
3,3-dimethyl-1-(oxetan-3-yl)-2-oxoindoline-6-carboxylate
[0511] 6-Bromo-3,3-dimethyl-1-(oxetan-3-yl)indolin-2-one was
converted in analogy to example 4a to give the title compound (97%)
as a viscous brown oil. MS (ESI, m/z): 276.5 [(M+H).sup.+].
c) 3,3-Dimethyl-1-(oxetan-3-yl)-2-oxoindoline-6-carboxylic acid
[0512] Methyl
3,3-dimethyl-1-(oxetan-3-yl)-2-oxoindoline-6-carboxylate was
converted in analogy to example 4b to give the title compound (93%)
as an off-white solid. MS (ESI, m/z): 262.5 [(M+H).sup.+].
d)
3,3-Dimethyl-1-oxetan-3-yl-6-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-1,3-
-dihydro-indol-2-one (Example 6)
[0513] 3,3-Dimethyl-1-(oxetan-3-yl)-2-oxoindoline-6-carboxylic acid
was converted in analogy to example 4c to give the title compound
(52%) as a white solid. MS (ESI, m/z): 363.5 [(M+H).sup.+].
Example 7
1,3,3-Trimethyl-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one
##STR00061##
[0514] a) 2-Oxo-2-(1,3,3-trimethyl-2-oxoindolin-6-yl)ethanaminium
chloride
[0515] A suspension of
6-(2-bromoacetyl)-1,3,3-trimethylindolin-2-one from example 3b (400
mg) and hexamethylenetetramine (189 mg) in toluene (10 ml) was
heated to 40.degree. C. for 3 h. The mixture was filtered and the
residue washed with toluene and diethyl ether. The solid was
dissolved in EtOH (10 ml) and hydrochloric acid (25%, 3 ml),
stirred at 22.degree. C. for 2 h and evaporated to give the crude
title compound (475 mg, quant.) as a yellow solid, which was used
without further purification. MS (ESI, m/z): 233.5
[(M+H).sup.+].
b)
N-(2-Oxo-2-(1,3,3-trimethyl-2-oxoindolin-6-yl)ethyl)nicotinamide
[0516] To a solution of nicotinoyl chloride hydrochloride (237 mg)
and 2-oxo-2-(1,3,3-trimethyl-2-oxoindolin-6-yl)ethanaminium
chloride (470 mg) in dichloromethane (4 ml) was added at 0.degree.
C. DIPEA (740 mg) and stirring was continued at 22.degree. C. for 2
h. The mixture was partitioned between water and EtOAc, the organic
layer was dried and evaporated to give the title compound (333 mg,
77%) as an light brown foam, which was used without further
purification. MS (ESI, m/z): 338.5 [(M+H).sup.+].
c) 1,3,3-Trimethyl-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one
(Example 7)
[0517] A mixture of
N-(2-oxo-2-(1,3,3-trimethyl-2-oxoindolin-6-yl)ethyl)nicotinamide
(330 mg) and (methoxycarbonylsulfamoyl)triethylammoniumhydroxid
(699 mg) in THF (8 ml) was heated in a microwave oven at
100.degree. C. for 20 min. The mixture was evaporated and the
residue purified by flash chromatography (silica gel, gradient, 0%
to 10% MeOH in dichloromethane) to give the title compound (140 mg,
55%) as light brown foam. MS (ESI, m/z): 320.5 [(M+H).sup.+].
Example 8
1-Cyclopropyl-3,3-dimethyl-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one
##STR00062##
[0519] 6-Bromo-1-cyclopropyl-3,3-dimethylindolin-2-one from example
1b was converted in analogy to example 3a-b to
6-(2-bromoacetyl)-1-cyclopropyl-3,3-dimethyl-indolin-2-one, which
was converted in analogy to example 7a-c to give the title compound
as a light yellow solid. MS (ESI, m/z): 346.5 [(M+H).sup.+].
Example 9
1-Cyclopropyl-3,3-dimethyl-6-(5-(pyridin-3-yl)oxazol-2-yl)indolin-2-one
##STR00063##
[0520] a)
1-Cyclopropyl-N-(2,2-dimethoxy-2-(pyridin-3-yl)ethyl)-3,3-dimeth-
yl-2-oxoindoline-6-carboxamide
[0521] A solution of
1-cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carboxylic acid (150 mg)
from example 4b, thionyl chloride (109 mg) and DMF (9 mg) in
toluene (2 ml) was heated to 110.degree. C. for 3 h. The mixture
was evaporated, the residue diluted with dichloromethane (2 ml),
treated at 22.degree. C. with
2,2-dimethoxy-2-(pyridin-3-yl)ethanamine dihydrochloride (203 mg,
prepared according to Bouchet et al., WO 2000002875), which was
followed by the addition of DIPEA (592 mg) and stirring was
continued for 22.degree. C. The reaction mixture was partitioned
between aqueous sodium carbonate and dichloromethane, the organic
layer was dried and evaporated to give the crude title compound
(260 mg, quant.) as a viscous oil, which was used without further
purification. MS (ESI, m/z): 410.6 [(M+H).sup.+].
b)
1-Cyclopropyl-3,3-dimethyl-2-oxo-N-(2-oxo-2-(pyridin-3-yl)ethyl)indolin-
e-6-carboxamide
[0522] A solution of
1-cyclopropyl-N-(2,2-dimethoxy-2-(pyridin-3-yl)ethyl)-3,3-dimethyl-2-oxoi-
ndoline-6-carboxamide (260 mg) in hydrochloric acid (37%, 5 ml) was
stirred at 22.degree. C. for 2 h. The mixture was partitioned
between aqueous sodium carbonate solution and EtOAc, the organic
layer was dried, evaporated and the residue purified by flash
chromatography (silica gel, gradient, 0% to 7% MeOH in
dichloromethane) to give the title compound (110 mg, 48%) as white
foam. MS (ESI, m/z): 364.6 [(M+H).sup.+].
c)
1-Cyclopropyl-3,3-dimethyl-6-(5-(pyridin-3-yl)oxazol-2-yl)indolin-2-one
(Example 9)
[0523] A mixture of
1-cyclopropyl-3,3-dimethyl-2-oxo-N-(2-oxo-2-(pyridin-3-yl)ethyl)indoline--
6-carboxamide (110 mg) and
(methoxycarbonylsulfamoyl)triethylammoniumhydroxid (216 mg) in THF
(3 ml) was heated in a microwave oven at 100.degree. C. for 20 min.
The mixture was evaporated and the residue purified by flash
chromatography (silica gel, gradient, 0% to 10% MeOH in
dichloromethane) to give the title compound (55 mg, 53%) as light
yellow solid. MS (ESI, m/z): 346.5 [(M+H).sup.+].
Example 10
1-Cyclopropyl-3,3-dimethyl-6-(2-(pyridin-4-yl)oxazol-5-yl)indolin-2-one
##STR00064##
[0525] Example 10 was prepared in analogy to example 8 using
pyridine-4-carbonyl chloride to give the title compound as a yellow
viscous oil. MS (ESI, m/z): 346.5 [(M+H).sup.+].
Example 11
3,3-Dimethyl-1-(oxetan-3-yl)-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)indo-
lin-2-one
##STR00065##
[0526] a)
N'-Isonicotinoyl-3,3-dimethyl-1-(oxetan-3-yl)-2-oxoindoline-6-ca-
rbohydrazide
[0527] To a solution of
3,3-dimethyl-1-(oxetan-3-yl)-2-oxoindoline-6-carboxylic acid (170
mg) from example 6c, 1H-benzo[d][1,2,3]triazol-1-ol (141 mg),
Ni-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine
hydrochloride (200 mg) and triethylamine (165 mg) in
dichloromethane (10 ml) was added isonicotinohydrazide (125 mg) and
stirring was continued at 22.degree. C. for 19 h. The mixture was
evaporated and the residue purified by flash chromatography (silica
gel, gradient, 0% to 15% MeOH in dichloromethane with 1% NH3) to
give the title compound (150 mg, 59%) as a white solid. MS (ESI,
m/z): 381.5 [(M+H).sup.+].
b)
3,3-Dimethyl-1-(oxetan-3-yl)-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)i-
ndolin-2-one
Example 11
[0528] To a solution of
N'-isonicotinoyl-3,3-dimethyl-1-(oxetan-3-yl)-2-oxoindoline-6-carbohydraz-
ide (150 mg) and p-toluensulfonyl chloride (142 mg) in acetonitrile
(6 ml) was added triethylamine (150 mg) and stirring was continued
at 22.degree. C. for 4 h. The mixture was partitioned between
aqueous sodium hydrogencarbonate solution and EtOAc, the organic
layer was dried, evaporated and the residue purified by flash
chromatography (silica gel, gradient, 0% to 100% EtOAc in
n-heptane) to give the title compound (141 mg, 97%) as white solid.
MS (ESI, m/z): 363.5 [(M+H).sup.+].
Example 12
1-Cyclopropyl-3,3-dimethyl-6-(2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin--
2-one
##STR00066##
[0530] Example 12 was prepared in analogy to example 10 using
2-methylpyridine-4-carbonyl chloride to give the title compound as
a light yellow foam. MS (ESI, m/z): 360.5 [(M+H).sup.+].
Example 13
1,3,3-Trimethyl-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)indolin-2-one
##STR00067##
[0531] a) 1,3,3-Trimethyl-2-oxoindoline-6-carboxylic acid
[0532] To a suspension of NaH (12.6 g) in THF (260 ml) was added at
22.degree. C. methyl 2-oxoindoline-6-carboxylate (15.0 g) over 30
min, which was followed by the addition of Mel (44.5 g) using a
syringe-pump over 80 min keeping the temperature between
24-28.degree. C. and stirring was continued for 2.5 h. A solution
of NaOH (6.3 g) in water (20 ml) was added and stirring was
continued for 1 h. The mixture was partitioned between water and
TBME, the pH of the aqueous layer was adjusted to 1, the suspension
was filtered and the residue dried to give the title compound (16.0
g, 93%) as a brown solid.
b)
N'-Isonicotinoyl-1,3,3-trimethyl-2-oxoindoline-6-carbohydrazide
[0533] 1,3,3-Trimethyl-2-oxoindoline-6-carboxylic acid was
converted in analogy to example 11a to give the title compound
(93%) as a light yellow foam. MS (ESI, m/z): 339.5
[(M+H).sup.+].
c)
1,3,3-Trimethyl-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)indolin-2-one
(Example 13)
[0534]
N'-Isonicotinoyl-1,3,3-trimethyl-2-oxoindoline-6-carbohydrazide was
converted in analogy to example 11b to give the title compound
(84%) as an off-white solid. MS (ESI, m/z): 321.5
[(M+H).sup.+].
Example 14
1-Cyclopropyl-3,3-dimethyl-6-(2-(2-methylpyridin-4-yl)thiazol-5-yl)indolin-
-2-one
##STR00068##
[0535] a) 2-(2-Methylpyridin-4-yl)thiazole
[0536] Argon was bubbled through a mixture of
2-methylpyridin-4-ylboronic acid (614 mg), 2-bromothiazole (736 mg)
and aqueous sodium carbonate (2 M, 4.5 ml) in dioxane (8 ml), which
was followed by the addition of
tetrakis(triphenylphosphine)palladium(0) (259 mg) and the mixture
was heated to 90.degree. C. for 16 h. The reaction mixture was
filtered through dicalite, the filtrate was partitioned between
water and EtOAc, the organic layer was dried, evaporated and the
residue purified by flash chromatography (silica gel, gradient, 30%
to 50% EtOAc in n-heptane) to give the title compound (325 mg, 41%)
as light brown solid. MS (ESI, m/z): 177.5 [(M+H).sup.+].
b)
1-Cyclopropyl-3,3-dimethyl-6-(2-(2-methylpyridin-4-yl)thiazol-5-yl)indo-
lin-2-one (Example 14)
[0537] A mixture of 6-bromo-1-cyclopropyl-3,3-dimethylindolin-2-one
(220 mg), 2-(2-methylpyridin-4-yl)thiazole (152 mg),
triphenylphosphine (21 mg),
1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride
dichlormethane adduct (32 mg), and silver carbonate (433 mg), in
water (5 ml) was heated to 90.degree. C. for 4 d. The reaction
mixture was filtered over dicalite, the filtrate
[0538] was partitioned between brine and dichloromethane, the
organic layer was dried, evaporated and the residue purified by
flash chromatography (silica gel, gradient, 40% to 60% EtOAc in
n-heptane). The compound containing fraction was evaporated, the
residue partitioned between aqueous hydrochloric acid and EtOAc,
the pH of the aqueous layer was adjusted to 9 using aqueous sodium
hydroxide and the aqueous layer was extracted with dichloromethane.
The organic layer was dried and evaporated to give the title
compound (126 mg, 43%) as a yellow viscous oil. MS (ESI, m/z):
376.6 [(M+H).sup.+].
Example 15
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)oxazol-2-yl)indolin-2-one
##STR00069##
[0539] a)
1-Cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carboxamide
[0540] To a suspension of
1-cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carboxylic acid (1.2 g)
from example 4b in toluene (11 ml) was added thionyl chloride (698
mg) and DMF (36 mg) and stirring was continued at reflux
temperature for 2 h. The mixture was evaporated, the residue
dissolved in dichloromethane (27 ml), aqueous ammonia (25%, 18 ml)
was added and the mixture was vigorously stirred at 22.degree. C.
for 2 d. The mixture was partitioned between aqueous sodium
carbonate (1 M) and dichloromethane, the organic layer was dried
and evaporated to give the title compound (1.17 g, 98%) as a white
solid, which was used without further purification. MS (ESI, m/z):
245.5 [(M+H).sup.+].
b)
N-(2-Chloroacetyl)-1-cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carboxami-
de
[0541] A suspension of
1-cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carboxamide (1.17 g) and
chloroacetyl chloride (2.76 g) was heated to 110.degree. C. for 1
h. The mixture was purified by flash chromatography (silica gel,
gradient, 0% to 100% EtOAc in n-heptane) to give the title compound
(1.18 g, 77%) as a white solid. MS (ESI, m/z): 321.5
[(M+H).sup.+].
c) 2-(1-Cyclopropyl-3,3-dimethyl-2-oxoindolin-6-yl)oxazol-4-yl
trifluoromethanesulfonate
[0542] To a suspension of sodium hydride (174 mg) in 1,4-dioxane
(30 ml) was added at 22.degree. C. a solution of
N-(2-chloroacetyl)-1-cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carboxamide
(1.16 g) in 1,4-dioxane (30 ml) and stirring was continued at
reflux temperature for 0.5 h and at 22.degree. C. for 1 h. The
mixture was filtered, the filtrate evaporated and the residue
dissolved in dichloromethane (15 ml). To the solution was added at
-78.degree. C. triethylamine (732 mg) followed by triflic anhydride
(1.53 g) and stirring was continued at 22.degree. C. for 30 min.
The mixture was partitioned between saturated sodium
hydrogencarbonate and dichloromethane, the organic layer was dried,
evaporated and the residue purified by flash chromatography (silica
gel, gradient, 0% to 100% EtOAc in n-heptane) to give the title
compound (600 mg, 40%) as a white solid. MS (ESI, m/z): 417.5
[(M+H).sup.+].
d)
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)oxazol-2-yl)indolin-2-one
(Example 15)
[0543] A mixture of
2-(1-cyclopropyl-3,3-dimethyl-2-oxoindolin-6-yl)oxazol-4-yl
trifluoromethanesulfonate (200 mg), pyridin-3-ylboronic acid (65
mg) and aqueous sodium carbonate (1 M, 0.7 ml) in 1,4-dioxane (7
ml) was degassed with argon,
bis(triphenylphosphine)palladium(II)chloride (17 mg) was added and
the mixture heated in a microwave oven to 150.degree. C. for 20
min. The mixture was filtered over dicalite, the filtrate
evaporated and the residue purified by flash chromatography (silica
gel, gradient, 0% to 100% EtOAc in n-heptane) followed by
preparative HPLC purification (RP-18, gradient, acetonitrile/water)
to give the title compound (98 mg, 54%) as a white solid. MS (ESI,
m/z): 346.6 [(M+H).sup.+].
Example 16
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-4-yl)oxazol-2-yl)indolin-2-one
##STR00070##
[0545] Example 16 was prepared in analogy to example 15 using
pyridin-4-ylboronic acid to give the title compound as a white
solid. MS (ESI, m/z): 346.5 [(M+H).sup.+].
Example 17
1-Cyclopropyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)oxazol-2-yl)indolin--
2-one
##STR00071##
[0547] Example 17 was prepared in analogy to example 15 using
2-methylpyridin-4-ylboronic acid to give the title compound as a
white solid. MS (ESI, m/z): 360.6 [(M+H).sup.+].
Example 18
1,3,3-Trimethyl-6-(2-(2-methylpyridin-4-yl)thiazol-5-yl)indolin-2-one
##STR00072##
[0549] Example 18 was prepared in analogy to example 14 starting
from 6-bromo-1,3,3-trimethylindolin-2-one from example 2a to give
the title compound as a yellow foam. MS (ESI, m/z): 350.5
[(M+H).sup.+].
Example 19
1-Cyclopropyl-3,3-dimethyl-6-(5-(2-methylpyridin-4-yl)oxazol-2-yl)indolin--
2-one
##STR00073##
[0551] Example 19 was prepared in analogy to example 9 using
2,2-dimethoxy-2-(2-methylpyridin-4-yl)ethanamine to give the title
compound as a ligt yellow solid. MS (ESI, m/z): 360.6
[(M+H).sup.+].
Example 20
1,3,3-Trimethyl-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl)indolin-2-one
##STR00074##
[0553] A suspension of 6-bromo-1,3,3-trimethylindolin-2-one from
example 2a (110 mg), 4-(1H-imidazol-4-yl)pyridine hydrochloride (79
mg, prepared according to Ganellin et al., J. Med. Chem. 38, 3342,
1995), potassium carbonate (188 mg) and 2-acetylcyclohexanon (30
mg) in N-methylpyrrolidone (1.0 ml) was flushed with argon during 5
min, then copper(I)chloride (9 mg) was added and the mixture heated
at 130.degree. C. for 36 h. The mixture was partitioned between
saturated sodium hydrogencarbonate and EtOAc, the organic layer was
dried, evaporated and the residue purified by flash chromatography
(silica gel, gradient, 0% to 15% MeOH in dichloromethane). The
compound containing fraction was evaporated and the residue
triturated with diethyl ether and dried to give the title compound
(100 mg, 73%) as an off-white solid. MS (ESI, m/z): 319.2
[(M+H).sup.+].
Example 21
1,3,3-Trimethyl-6-(4-(pyridin-3-yl)oxazol-2-yl)indolin-2-one
##STR00075##
[0555] Example 21 was prepared in analogy to example 15 starting
from 1,3,3-trimethyl-2-oxoindoline-6-carboxylic acid from example
13a to give the title compound as a white solid. MS (ESI, m/z):
320.6 [(M+H).sup.+].
Example 22
1,3,3-Trimethyl-6-(2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin-2-one
##STR00076##
[0556] a) 2-(2-Methylpyridin-4-yl)oxazole
[0557] To a solution of oxazole (201 mg) in THF (3 ml) was added at
-78.degree. C. BuLi (1.6 M in hexane, 2.2 ml), which was followed
by the addition of zinc chloride (2 M in 2-methyltetrahydrofurane,
2.9 ml) and stirring was continued at 22.degree. C. for 30 min.
4-Bromo-2-methylpyridine (0.50 g) and
tetrakis(triphenylphosphine)palladium(0) (336 mg) were added and
stirring was continued at 60.degree. C. for 5 h. The mixture was
partitioned between water and EtOAc, the organic layer was dried,
evaporated and the residue purified by flash chromatography (silica
gel, gradient, 40% to 60% EtOAc in n-heptane) to give the title
compound (295 mg, 63%) as a yellow solid. MS (ESI, m/z): 161.5
[(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin-2-one
(Example 22)
[0558] 6-Bromo-1,3,3-trimethylindolin-2-one from example 2a was
reacted with 2-(2-methylpyridin-4-yl)oxazole in analogy to example
14b to give the title compound as an off-white foam. MS (ESI, m/z):
334.5 [(M+H).sup.+].
Example 23
3,3-Dimethyl-1-(oxetan-3-yl)-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one
##STR00077##
[0559] a) 2-(Pyridin-3-yl)oxazole
[0560] Oxazole was coupled with 3-bromopyridine in analogy to
example 22a to give the title compound (53%) as a light yellow
solid. MS (ESI, m/z): 147.2 [(M+H).sup.+].
b)
3,3-Dimethyl-1-(oxetan-3-yl)-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-o-
ne (Example 23)
[0561] 6-Bromo-3,3-dimethyl-1-(oxetan-3-yl)indolin-2-one from
example 6a was reacted with 2-(pyridin-3-yl)oxazole in analogy to
example 14b to give the title compound (31%) as a white foam. MS
(ESI, m/z): 362.6 [(M+H).sup.+].
Example 24
3,3-Dimethyl-6-(2-(6-methylpyridin-3-yl)oxazol-5-yl)-1-(oxetan-3-yl)indoli-
n-2-one
##STR00078##
[0562] a) 2-(6-Methylpyridin-3-yl)oxazole
[0563] Oxazole was coupled with 5-bromo-2-methylpyridine in analogy
to example 22a to give the title compound (59%) as a light yellow
solid. MS (ESI, m/z): 161.5 [(M+H).sup.+].
b)
3,3-Dimethyl-6-(2-(6-methylpyridin-3-yl)oxazol-5-yl)-1-(oxetan-3-yl)ind-
olin-2-one (Example 24)
[0564] 6-Bromo-3,3-dimethyl-1-(oxetan-3-yl)indolin-2-one from
example 6a was reacted with 2-(6-methylpyridin-3-yl)oxazole in
analogy to example 14b to give the title compound (24%) as a white
solid. MS (ESI, m/z): 376.5 [(M+H).sup.+].
Example 25
3,3-Dimethyl-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one
##STR00079##
[0565] a) 6-Bromo-1-(4-methoxybenzyl)-3,3-dimethylindolin-2-one
[0566] A mixture of 6-bromo-3,3-dimethylindolin-2-one from example
1a (250 mg) in DMF (8 ml) was flushed with argon.
1-(Bromomethyl)-4-methoxybenzene (209 mg) and cesium carbonate (679
mg) were added and stirring was continued at 80.degree. C. for 1 h.
The mixture was partitioned between water and EtOAc, the organic
layer was dried, evaporated and the residue purified by flash
chromatography (silica gel, gradient, 0% to 50% EtOAc in n-heptane)
to give the title compound (340 mg, 91%) as a red liquid. MS (ESI,
m/z): 360.0/362.5 [(M+H).sup.+].
b)
1-(4-Methoxybenzyl)-3,3-dimethyl-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-
-2-one
[0567] 6-Bromo-1-(4-methoxybenzyl)-3,3-dimethylindolin-2-one was
reacted with 2-(pyridin-3-yl)oxazole from example 23a in analogy to
example 14b to give the title compound (58%) as a yellow solid. MS
(ESI, m/z): 426.7 [(M+H).sup.+].
c) 3,3-Dimethyl-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one
(Example 25)
[0568] A solution of
1-(4-methoxybenzyl)-3,3-dimethyl-6-(2-(pyridin-3-yl)oxazol-5-yl)indolin-2-
-one (112 mg) in TFA (1 ml) was heated to 110.degree. C. for 2d.
The mixture was partitioned between aqueous sodium carbonate (2 M)
and EtOAc, the organic layer was dried, evaporated and the residue
purified by flash chromatography (silica gel, gradient, 50% to 80%
EtOAc in n-heptane). The compound containing fraction was
evaporated, the residue partitioned between aqueous hydrochloric
acid and EtOAc, the pH of the aqueous layer was adjusted to 9 using
aqueous sodium hydroxide and the aqueous layer was extracted with
dichloromethane. The organic layer was dried and evaporated to give
the title compound (42 mg, 52%) as an off-white solid. MS (ESI,
m/z): 306.5 [(M+H).sup.+].
Example 26
3,3-Dimethyl-6-(2-(2-methylpyridin-4-yl)oxazol-5-yl)-1-(oxetan-3-yl)indoli-
n-2-one
##STR00080##
[0570] 6-Bromo-3,3-dimethyl-1-(oxetan-3-yl)indolin-2-one from
example 6a was reacted with 2-(2-methylpyridin-4-yl)oxazole from
example 22a in analogy to example 14b to give the title compound
(30%) as a yellow foam. MS (ESI, m/z): 376.6 [(M+H).sup.+].
Example 27
3,3-Dimethyl-6-(2-(6-methylpyridin-3-yl)oxazol-5-yl)indolin-2-one
##STR00081##
[0572] Example 27 was prepared in analogy to example 25 using
2-(6-methylpyridin-3-yl)oxazole from example 24a to give the title
compound as a brown solid. MS (ESI, m/z): 320.6 [(M+H).sup.+].
Example 28
1-(2-Hydroxyethyl)-3,3-dimethyl-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)i-
ndolin-2-one
##STR00082##
[0573] a) 3,3-Dimethyl-2-oxoindoline-6-carboxylic acid
[0574] To a solution of methyl 2-oxoindoline-6-carboxylate (17.6 g)
in DMF (260 ml) was added MeI (26.1 g) followed by NaH (3.68 g)
keeping the temperature at 22.degree. C. After 30 min a second
portion of NaH (1.84 g) was added followed after 1 h by a third
portion (1.84 g) and stirring was continued at 22.degree. C. for 16
h. Water (7 ml) followed by sodium hydroxide (34.5 g) were added
and stirring was continued at 45.degree. C. for 1 h and at
22.degree. C. for 16 h. The mixture was partitioned between TBME
and water, the pH of the aqueous layer was adjusted to 3 using
aqueous hydrochloric acid (25%) and extracted with dichloromethane.
The organic layere was dried and evaporated to give the crude title
compound (17.9 g, 95%) as a red solid, which was used without
further purification. MS (ESI, m/z): 204.2 [(M-H).sup.-].
b)
3,3-Dimethyl-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)indolin-2-one
[0575] 3,3-Dimethyl-2-oxoindoline-6-carboxylic acid was converted
to the title compound (36%) in analogy to example 1 1a-b, obtained
as an orange solid. MS (ESI, m/z): 307.6 [(M+H).sup.+].
c)
1-(2-(Tert-butyldimethylsilyloxy)ethyl)-3,3-dimethyl-6-(5-(pyridin-4-yl-
)-1,3,4-oxadiazol-2-yl)indolin-2-one
[0576] A mixture of
3,3-dimethyl-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)indolin-2-one
(171 mg) in DMF (2.5 ml) was flushed with argon, then treated with
(2-bromoethoxy)(tert-butyl)dimethylsilane (267 mg) and cesium
carbonate (364 mg) and stirring was continued at 80.degree. C. for
16 h. The mixture was partitioned between water and EtOAc, the
organic layer was dried, evaporated and the residue purified by
flash chromatography (silica gel, gradient, 0% to 20%
MeOH/NH.sub.4OH in dichloromethane) to give the impure title
compound (307 mg) as a brown solid, which was further used without
further purification. MS (ESI, m/z): 465.7 [(M+H).sup.+].
d)
1-(2-Hydroxyethyl)-3,3-dimethyl-6-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-y-
l)indolin-2-one (Example 28)
[0577] To a solution of
1-(2-(tert-butyldimethylsilyloxy)ethyl)-3,3-dimethyl-6-(5-(pyridin-4-yl)--
1,3,4-oxadiazol-2-yl)indolin-2-one (307 mg) in THF (13 ml) was
added at 0.degree. C. TBAF (136 mg) and stirring was continued at
0.degree. C. for 10 min and at 22.degree. C. for 3 h. The mixture
was partitioned between water and EtOAc, the organic layer was
dried, evaporated and the residue purified by flash chromatography
(silica gel, gradient, 0% to 20% MeOH/NH.sub.4OH in
dichloromethane) to give the title compound (137 mg, 75%) as a
light yellow solid. MS (ESI, m/z): 351.6 [(M+H).sup.+].
Example 29
1,3,3-Trimethyl-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-2-one
##STR00083##
[0579] Example 29 was prepared in analogy to example 20 using
3-(1H-imidazol-4-yl)pyridine (prepared according to Denton et al.,
J. Med. Chem., 48, 224, 2005) to give the title compound (38%) as a
light yellow solid. MS (ESI, m/z): 319.6 [(M+H).sup.+].
Example 30
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin--
2-one
##STR00084##
[0581] Example 30 was prepared in analogy to example 20 using
6-bromo-3,3-dimethyl-1-(oxetan-3-yl)indolin-2-one from example 6a
and 3-(1H-imidazol-4-yl)pyridine (prepared according to Denton et
al., J. Med. Chem., 48, 224, 2005) to give the title compound (36%)
as a white solid. MS (ESI, m/z): 361.6 [(M+H).sup.+].
Example 31
1,3,3-Trimethyl-6-(4-methyl-2-(pyridin-3-yl)oxazol-5-yl)indolin-2-one
##STR00085##
[0583] 6-Bromo-1,3,3-trimethylindolin-2-one from example 2a was
reacted with 4-methyl-2-(pyridin-3-yl)oxazole (prepared according
to Dondoni et al., Synthesis (8), 693-6, 1987) in analogy to
example 14b to give the title compound (57%) as a white solid. MS
(ESI, m/z): 334.6 [(M+H).sup.+].
Example 32
3,3-Dimethyl-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-2-one
##STR00086##
[0585] Example 32 was prepared in analogy to example 20 using
6-Bromo-3,3-dimethyl-indolin-2-one from example 1a and
3-(1H-imidazol-4-yl)pyridine (prepared according to Denton et al.,
J. Med. Chem., 48, 224, 2005) to give the title compound (22%) as a
white solid. MS (ESI, m/z): 305.5 [(M+H).sup.+].
Example 33
1-Cyclopropyl-3,3-dimethyl-6-(2-(6-methylpyridin-3-yl)oxazol-5-yl)indolin--
2-one
##STR00087##
[0587] Example 33 was prepared in analogy to example 27 using
6-bromo-1-cyclopropyl-3,3-dimethylindolin-2-one from example 1b to
give the title compound as a white foam. MS (ESI, m/z): 360.6
[(M+H).sup.+].
Example 34
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl)indolin--
2-one
##STR00088##
[0589] Example 34 was prepared in analogy to example 20 using
6-bromo-3,3-dimethyl-1-(oxetan-3-yl)indolin-2-one from example 6a
to give the title compound as a white solid. MS (ESI, m/z): 361.6
[(M+H).sup.+].
Example 35
3,3-Dimethyl-6-(2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin-2-one
##STR00089##
[0591] Example 35 was prepared in analogy to example 22 using
6-bromo-3,3-dimethyl-indolin-2-one from example 1a to give the
title compound as a light yellow solid. MS (ESI, m/z): 320.5
[(M+H).sup.+].
Example 36
1,3,3-Trimethyl-6-(4-methyl-2-(6-methylpyridin-3-yl)oxazol-5-yl)indolin-2--
one
##STR00090##
[0592] a) 4-Methyl-2-(6-methylpyridin-3-yl)oxazole
[0593] To a solution of 4-methyloxazole (254 mg) in THF (2 ml) was
added at -78.degree. C. a solution of n-BuLi (1.6 M in THF, 2.3 ml)
followed by zinc chloride (2 M in 2-methyl-tetrahydrofuran, 2.3 ml)
and stirring was continued at 22.degree. C. for 30 min.
5-Bromo-2-methylpyridine (526 mg) and
tetrakis(triphenylphosphine)palladium(0) (353 mg) were added and
stirring was continued at 60.degree. C. for 2 h. The mixture was
partitioned between water and EtOAc, the organic layer was dried,
evaporated and the residue purified by flash chromatography (silica
gel, gradient, 20% to 70% EtOAc in n-heptane) to give the title
compound (283 mg, 53%) as a light yellow solid. MS (ESI, m/z):
175.5 [(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(4-methyl-2-(6-methylpyridin-3-yl)oxazol-5-yl)indolin-
-2-one (Example 36)
[0594] 6-Bromo-1,3,3-trimethylindolin-2-one from example 2a was
reacted with 4-methyl-2-(6-methylpyridin-3-yl)oxazole in analogy to
example 14b to give the title compound (57%) as a white solid. MS
(ESI, m/z): 334.6 [(M+H).sup.+].
Example 37
1-Cyclopropyl-3,3-dimethyl-6-(4-methyl-2-(6-methylpyridin-3-yl)oxazol-5-yl-
)indolin-2-one
##STR00091##
[0596] 6-Bromo-1-cyclopropyl-3,3-dimethylindolin-2-one from example
1b was reacted with 4-methyl-2-(6-methylpyridin-3-yl)oxazole from
example 36a in analogy to example 14b to give the title compound
(37%) as an off-white foam. MS (ESI, m/z): 374.6 [(M+H).sup.+].
Example 38
1,3,3-Trimethyl-6-(4-methyl-2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin-2--
one
##STR00092##
[0597] a) 4-Methyl-2-(2-methylpyridin-4-yl)oxazole
[0598] To a solution of 4-methyloxazole (254 mg) in THF (2 ml) was
added at -78.degree. C. n-BuLi (1.6 M in THF, 2.3 ml) and zinc
chloride (2 M in 2-methyl-tetrahydrofuran, 2.3 ml) and stirring was
continued at 22.degree. C. for 30 min. 4-Bromo-2-methylpyridine
(526 mg) and tetrakis(triphenylphosphine)palladium(0) (353 mg) were
added and stirring was continued at 60.degree. C. for 2 h. The
mixture was partitioned between water and EtOAc, the organic layer
was dried, evaporated and the residue purified by flash
chromatography (silica gel, gradient, 30% to 70% EtOAc in
n-heptane) to give the title compound (375 mg, 70%) as a light
yellow viscous oil. MS (ESI, m/z): 175.5 [(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(4-methyl-2-(2-methylpyridin-4-yl)oxazol-5-yl)indolin-
-2-one (Example 38)
[0599] 6-Bromo-1,3,3-trimethylindolin-2-one from example 2a was
reacted with 4-methyl-2-(2-methylpyridin-4-yl)oxazole in analogy to
example 14b to give the title compound (70%) as a light yellow
foam. MS (ESI, m/z): 348.6 [(M+H).sup.+].
Example 39
1-Cyclopropyl-3,3-dimethyl-6-(4-methyl-2-(2-methylpyridin-4-yl)oxazol-5-yl-
)indolin-2-one
##STR00093##
[0601] 6-Bromo-1-cyclopropyl-3,3-dimethylindolin-2-one from example
1b was reacted with 4-methyl-2-(2-methylpyridin-4-yl)oxazole from
example 38a in analogy to example 14b to give the title compound
(61%) as a light yellow foam. MS (ESI, m/z): 374.6
[(M+H).sup.+].
Example 40
1,3,3-Trimethyl-6-(4-(pyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one
##STR00094##
[0603] A suspension of 6-bromo-1,3,3-trimethylindolin-2-one (140
mg) from example 2a, 4-(1H-pyrazol-4-yl)pyridine (80 mg, prepared
according to Bauer et al., J. Med. Chem. 11, 981, 1968) and
potassium carbonate (190 mg) in dry DMSO (4 ml) was flushed with
argon. Copper(I)iodide (11 mg) and L-proline (25 mg) were added and
stirring was continued at 110.degree. C. for 16 h. The reaction
mixture was partitioned between water and dichloromethane, the
organic layer was dried, evaporated and the residue purified by
flash chromatography (silica gel, gradient, 0% to 10%
MeOH/NH.sub.4OH in dichloromethane) to give the title compound (74
mg, 42%) as a white solid. MS (ESI, m/z): 319.4 [(M+H).sup.+].
Example 41
1,3,3-Trimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one
##STR00095##
[0604] a) 3-(1H-Pyrazol-4-yl)pyridine
[0605] To a suspension of 3-bromopyridine (400 mg) and tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate
(745 mg) in 1,4-dioxane (12 ml) was added aqueous sodium carbonate
(1 M, 2.5 ml) and the mixture was flushed with argon for 5 min.
[1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (103
mg) was added and stirring was continued at 110.degree. C. for 16
h. The mixture was partitioned between aqueous sodium
hydrogencarbonate and EtOAc, the organic layer was dried,
evaporated and the residue purified by flash chromatography (silica
gel, gradient, 0% to 10% MeOH/NH.sub.4OH in dichloromethane) to
give the title compound (234 mg, 64%) as a light brown solid. MS
(ESI, m/z): 146.2 [(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one
(Example 41)
[0606] 6-Bromo-1,3,3-trimethylindolin-2-one from example 2a was
reacted with 3-(1H-pyrazol-4-yl)pyridine in analogy to example 40
to give the title compound (38%) as a white solid. MS (ESI, m/z):
319.4 [(M+H).sup.+].
Example 42
1,3,3-Trimethyl-6-(3-pyridin-4-yl-isoxazol-5-yl)-1,3-dihydro-indol-2-one
##STR00096##
[0607] a)
1-(Pyridin-4-yl)-3-(1,3,3-trimethyl-2-oxoindolin-6-yl)propane-1,-
3-dione
[0608] To a solution of 6-acetyl-1,3,3-trimethylindolin-2-one (1.22
g) from example 3a and methyl isonicotinate (770 mg) in dry THF (30
ml) was added at 22.degree. C. sodium hydride (515 mg) and stirring
was continued for 6 h. The mixture was evaporated and the residue
partitioned between water and EtOAc, the organic layer was dried,
evaporated and the residue triturated with n-pentane to give the
title compound (700 mg, 39%) as an orange solid. MS (ESI, m/z):
321.4 [(M-H).sup.-].
b)
1,3,3-Trimethyl-6-(3-pyridin-4-yl-isoxazol-5-yl)-1,3-dihydro-indol-2-on-
e (Example 42)
[0609] To a solution of
1-(pyridin-4-yl)-3-(1,3,3-trimethyl-2-oxoindolin-6-yl)propane-1,3-dione
(300 mg) in dry ethanol (6 ml) was added hydroxylamine
hydrochloride (65 mg) and stirring was continued at reflux
temperature for 16 h. The mixture was evaporated and the residue
partitioned between aqueous sodium hydrogencarbonate and EtOAc, the
organic layer was dried, evaporated and the residue purified by
supercritical fluid chromatography (Princeton, 4-ethylpyridine
20.times.250 mm 100 A, 5 um, 12% isopropanol/88% carbondioxide, 60
ml/min, 40.degree. C.) to give the title compound (141 mg, 47%) as
the slower eluting isomer as a white solid. MS (ESI, m/z): 320.4
[(M+H).sup.+].
[0610] The faster eluting regio isomer,
1,3,3-trimethyl-6-(5-pyridin-4-yl-isoxazol-3-yl)-1,3-dihydro-indol-2-one
(85 mg, 29%), was obtained as a white solid. MS (ESI, m/z): 320.4
[(M+H).sup.+].
Example 43
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-
-one
##STR00097##
[0612] 6-Bromo-3,3-dimethyl-1-(oxetan-3-yl)indolin-2-one from
example 6a was converted in analogy to example 41 to the title
compound (42%), obtained as a white solid. MS (ESI, m/z): 361.4
[(M+H).sup.+].
Example 44
1,3,3-Trimethyl-6-(2-(pyridin-3-yl)oxazol-4-yl)indolin-2-one
##STR00098##
[0613] a) 1,3,3-Trimethyl-6-(oxazol-4-yl)indolin-2-one
[0614] A suspension of
6-(2-bromoacetyl)-1,3,3-trimethylindolin-2-one (1.05 g) from
example 3b and formamide (14.4 g) was heated to 110.degree. C. for
2 h. The mixture was partitioned between saturated aqueous sodium
hydrogencarbonate and EtOAc, the organic layer was dried,
evaporated and the residue purified by flash chromatography (silica
gel, gradient, 0% to 50% EtOAc in n-heptane) to give the title
compound (335 mg, 39%) as a white solid. MS (ESI, m/z): 243.6
[(M+H).sup.+].
b) 6-(2-Chlorooxazol-4-yl)-1,3,3-trimethylindolin-2-one
[0615] To a solution of
1,3,3-trimethyl-6-(oxazol-4-yl)indolin-2-one (0.23 g) in dry THF (4
ml) was added at -78.degree. C. a solution of LiHMDS (1 M in THF,
1.0 ml) and the mixture was allowed to warm to 22.degree. C. The
mixture was cooled to -78.degree. C. and treated with
hexachloroethane (238 mg) and stirring was continued at 22.degree.
C. for 3 h. The mixture was partitioned between saturated aqueous
ammonium chloride and TBME, the organic layer was dried, evaporated
and the residue purified by flash chromatography (silica gel,
gradient, 0% to 50% EtOAc in n-heptane) to give the title compound
(195 mg, 74%) as a white solid. MS (ESI, m/z): 277.5
[(M+H).sup.+].
c) 1,3,3-Trimethyl-6-(2-(pyridin-3-yl)oxazol-4-yl)indolin-2-one
(Example 44)
[0616] A mixture of
6-(2-chlorooxazol-4-yl)-1,3,3-trimethylindolin-2-one (100 mg) and
pyridine-3-boronic acid (58 mg) in 1,4-dioxane (3 ml) and aqueous
sodium carbonate (2 M, 0.7 ml) was flushed with argon,
bis(triphenylphosphine)palladium(II)dichloride was added (26 mg)
and the mixture was heated to reflux temperature for 2 h. The
mixture was evaporated and the residue purified by flash
chromatography (silica gel, gradient, 0% to 100% EtOAc in
n-heptane) followed by HPLC purification (RP-18, gradient,
acetonitrile/water) to give the title compound (68 mg, 59%) as a
white solid. MS (ESI, m/z): 320.5 [(M+H).sup.+].
Example 45
3,3-Dimethyl-1-(oxetan-3-yl)-6-(4-(pyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-
-one
##STR00099##
[0618] 6-Bromo-3,3-dimethyl-1-(oxetan-3-yl)indolin-2-one from
example 6a was converted to the title compound (20%) in analogy to
example 40, obtained as a white solid. MS (ESI, m/z): 361.5
[(M+H).sup.+].
Example 46
1,3,3-Trimethyl-6-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)indolin-2-one
##STR00100##
[0619] a) 1,3,3-Trimethyl-6-(1H-pyrazol-4-yl)indolin-2-one
[0620] A mixture of 6-bromo-1,3,3-trimethylindolin-2-one (200 mg)
from example 2a and tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate
(232 mg) in 1,4-dioxane (4.5 ml) and aqueous sodium carbonate (2 M,
0.8 ml) was flushed with argon,
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (32 mg)
was added and stirring was continued in a microwave oven at
120.degree. C. for 30 min. The mixture was partitioned between
saturated aqueous sodium hydrogencarboante and EtOAc, the organic
layer was dried, evaporated and the residue purified by flash
chromatography (silica gel, gradient, 0% to 100% EtOAc in
n-heptane) to give the title compound (115 mg, 61%) as a brown
viscous oil. MS (ESI, m/z): 242.5 [(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(1-(pyridin-4-yl)-1H-pyrazol-4-yl)indolin-2-one
(Example 46)
[0621] A suspension of
1,3,3-trimethyl-6-(1H-pyrazol-4-yl)indolin-2-one (85 mg),
4-bromopyridine hydrochloride (103 mg) and potassium carbonate (166
mg) in dry DMSO (2.5 ml) was flushed with argon, then
copper(I)iodide (14 mg) and L-proline (32 mg) were added and
stirring was continued at 110.degree. C. for 16 h. The mixture was
partitioned between water and EtOAc, the organic layer was dried,
evaporated and the residue purified by flash chromatography (silica
gel, gradient, 0% to 5% MeOH in dichloromethane), which was
followed by a second flash chromatography (silica gel, gradient, 0%
to 100% EtOAc in n-heptane) to give the title compound (86 mg, 77%)
as a white solid. MS (ESI, m/z): 319.5 [(M+H).sup.+].
Example 47
3,3-Dimethyl-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl)indolin-2-one
##STR00101##
[0623] Example 47 was prepared in analogy to example 20 using
6-bromo-3,3-dimethyl-indolin-2-one from example 1a to give the
title compound (15%) as a white solid. MS (ESI, m/z): 305.5
[(M+H).sup.+].
Example 48
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)-1H-imidazol-1-yl)indolin-2--
one
##STR00102##
[0625] Example 48 was prepared in analogy to example 32 using
6-bromo-1-cyclopropyl-3,3-dimethylindolin-2-one from example 1b to
give the title compound (30%) as a white solid. MS (ESI, m/z):
345.6 [(M+H).sup.+].
Example 49
3,3-Dimethyl-6-(5-(2-methylpyridin-4-yl)-1,3,4-oxadiazol-2-yl)-1-(oxetan-3-
-yl)indolin-2-one
##STR00103##
[0627] Example 49 was prepared in analogy to example 11 using
2-methylisonicotinohydrazide to give the title compound (47%) as a
white solid. MS (ESI, m/z): 377.6 [(M+H).sup.+].
Example 50
1,3,3-Trimethyl-6-(1-(pyridin-3-yl)-1H-pyrazol-4-yl)indolin-2-one
##STR00104##
[0629] Example 50 was prepared in analogy to example 46 using
3-bromopyridine to give the title compound (52%) as a white solid.
MS (ESI, m/z): 319.6 [(M+H).sup.+].
Example 51
3,3-Dimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one
##STR00105##
[0631] Example 51 was prepared in analogy to example 40 using
6-bromo-3,3-dimethylindolin-2-one from example 1a and
3-(1H-pyrazol-4-yl)pyridine from example 41a to give the title
compound (52%) as a white foam. MS (ESI, m/z): 305.6
[(M+H).sup.+].
Example 52
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-o-
ne
##STR00106##
[0633] Example 52 was prepared in analogy to example 40 using
6-bromo-1-cyclopropyl-3,3-dimethylindolin-2-one from example 1b and
3-(1H-pyrazol-4-yl)pyridine from example 41a to give the title
compound (34%) as a white foam. MS (ESI, m/z): 345.5
[(M+H).sup.+].
Example 53
1-Cyclopropyl-3,3-dimethyl-6-(4-(pyridin-4-yl)-1H-imidazol-1-yl)indolin-2--
one
##STR00107##
[0635] Example 53 was prepared in analogy to example 20 using
6-bromo-1-cyclopropyl-3,3-dimethylindolin-2-one from example 1b to
give the title compound (11%) as a white solid. MS (ESI, m/z):
345.5 [(M+H).sup.+].
Example 54
1,3,3-Trimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one
##STR00108##
[0636] a) 2-Methyl-4-(1H-pyrazol-4-yl)pyridine
[0637] The title compound (64%), prepared in analogy to example 41a
using 4-bromo-2-methylpyridine, was obtained as a light yellow
solid. MS (ESI, m/z): 160.3 [(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-o-
ne (Example 54)
[0638] Example 54 was prepared in analogy to example 40 using
6-bromo-1,3,3-trimethylindolin-2-one from example 2a and
2-methyl-4-(1H-pyrazol-4-yl)pyridine to give the title compound
(25%) as a white solid. MS (ESI, m/z): 333.5 [(M+H).sup.+].
Example 55
1-Cyclopropyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)ind-
olin-2-one
##STR00109##
[0640] Example 55 was prepared in analogy to example 40 using
6-bromo-1-cyclopropyl-3,3-dimethylindolin-2-one from example 1b and
2-methyl-4-(1H-pyrazol-4-yl)pyridine from example 54a to give the
title compound (29%) as a white solid. MS (ESI, m/z): 359.5
[(M+H).sup.+].
Example 56
1,3,3-Trimethyl-6-(5-(pyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-one
##STR00110##
[0642] To a solution of
1-(pyridin-4-yl)-3-(1,3,3-trimethyl-2-oxoindolin-6-yl)propane-1,3-dione
(170 mg) from example 42a in dry ethanol (3.5 ml) was added DIPEA
(82 mg) and hydrazine (1 M in THF, 0.6 ml) and stirring was
continued at reflux temperature for 18 h. The reaction mixture was
evaporated and the residue purified by flash chromatography (silica
gel, gradient, 0% to 20% MeOH/NH.sub.4OH in dichloromethane)
followed by a second purification by preparative HPLC
chromatography (RP-18, gradient, acetonitrile/water) to give the
title compound (25 mg, 15%) as a light yellow solid. MS (ESI, m/z):
319.6 [(M+H).sup.+].
Example 57
1,3,3-Trimethyl-6-(4-(pyridin-4-yl)-1H-1,2,3-triazol-1-yl)indolin-2-one
##STR00111##
[0643] a) 6-Azido-1,3,3-trimethylindolin-2-one
[0644] A suspension of 6-bromo-1,3,3-trimethylindolin-2-one (500
mg) from example 2a, sodium azide (258 mg), L(+)-ascorbic acid
sodium salt (20 mg) and
trans-(1R,2R)--N,N'-bismethyl-1,2-cyclohexanediamine (42 mg) in
ethanol (3 ml) and water (1 ml) was flushed with argon.
Copper(I)iodide (38 mg) was added and stirring was continued at
reflux temperature for 1 h. The mixture was evaporated and the
residue purified by flash chromatography (silica gel, gradient, 0%
to 40% EtOAc in n-heptane) to give the title compound (366 mg, 86%)
as a light brown solid. MS (ESI, m/z): 217.5 [(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(4-(pyridin-4-yl)-1H-1,2,3-triazol-1-yl)indolin-2-one
(Example 57)
[0645] To a solution of 6-azido-1,3,3-trimethylindolin-2-one (100
mg) and 4-ethinylpyridine (54 mg) in t-BuOH (3 ml) was added
L(+)-ascorbic acid sodium salt (46 mg) and copper(II) sulfate
pentahydrate (12 mg) in water (3 ml) and stirring was continued at
22.degree. C. for 16 h. The mixture was partitioned between aqueous
sodium carbonate (1 M) and EtOAc, the organic layer was dried,
evaporated and the residue purified by flash chromatography (silica
gel, gradient, 0% to 7% MeOH in dichloromethane) to give the title
compound (133 mg, 90%) as a white solid. MS (ESI, m/z): 320.2
[(M+H).sup.+].
Example 58
3,3-Dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-one
##STR00112##
[0647] Example 58 was prepared in analogy to example 40 using
6-bromo-3,3-dimethylindolin-2-one from example 1a and
2-methyl-4-(1H-pyrazol-4-yl)pyridine from example 54a to give the
title compound (16%) as a light brown solid. MS (ESI, m/z): 319.5
[(M+H).sup.+].
Example 59
1,3,3-Trimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2-one
##STR00113##
[0648] a) 6-(Hydroxymethyl)-1,3,3-trimethylindolin-2-one
[0649] To a suspension of
1,3,3-trimethyl-2-oxoindoline-6-carboxylic acid (150 mg) from
example 13a in THF (1 ml) was added at 0.degree. C. borane
tetrahydrofuran complex (1 M in THF, 1 ml) and stirring was
continued at 22.degree. C. for 2 h. The mixture was partitioned
between aqueous sodium hydrogencarbonate and EtOAc, the organic
layer was washed with water, dried and evaporated to give the crude
title compound (140 mg, quant.) as a light yellow foam, which was
used without further purification. MS (ESI, m/z): 206.5
[(M+H).sup.+].
b) 1,3,3-Trimethyl-2-oxoindoline-6-carbaldehyde
[0650] A suspension of
6-(hydroxymethyl)-1,3,3-trimethylindolin-2-one (2.07 g) and
manganese dioxide (6.1 g) in dichloromethane (30 ml) was heated to
reflux 1 h and stirring was continued at 22.degree. C. 16 h. The
suspension was filtered and the filtrate evaporated to give the
crude title compound (1.85 g, 90%) as an orange solid, which was
used without further purification. MS (ESI, m/z): 204.5
[(M+H).sup.+].
c) 1,3,3-Trimethyl-6-(oxazol-5-yl)indolin-2-one
[0651] A suspension of 1,3,3-trimethyl-2-oxoindoline-6-carbaldehyde
(1.68 g), potassium carbonate (1.16 g) and tosylmethylisocyanide
(1.61 g) in MeOH (12 ml) was heated to 80.degree. C. for 16 h. The
mixture was partitioned between water and dichloromethane, the
organic layer was washed with water, dried and evaporated to give
the crude title compound (1.96 g, 98%) as a light brown solid,
which was used without further purification. MS (ESI, m/z): 243.5
[(M+H).sup.+].
d) 6-(1H-Imidazol-5-yl)-1,3,3-trimethylindolin-2-one
[0652] A solution of 1,3,3-trimethyl-6-(oxazol-5-yl)indolin-2-one
(700 mg) in formamide (24 ml) was heated to 190.degree. C. for 7 h.
The mixture was partitioned between water and EtOAc, the organic
layer was washed with water, dried, evaporated and the residue
purified by flash chromatography (silica gel, gradient, 0% to 10%
MeOH in dichloromethane) to give the title compound (390 mg, 56%)
as a brown foam. MS (ESI, m/z): 242.5 [(M+H).sup.+].
e)
1,3,3-Trimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2-one
(Example 59)
[0653] A suspension of
6-(1H-imidazol-5-yl)-1,3,3-trimethylindolin-2-one (210 mg),
3-bromopyridine (165 mg), potassium carbonate (361 mg) and
2-acetylcyclohexanone (61 mg) in DMSO (4 ml) was flushed with
argon, then copper(I)chloride (22 mg) was added and stirring was
continued at 130.degree. C. for 16 h. The mixture was partitioned
between water and EtOAc, the organic layer were washed with water,
dried, evaporated and the residue purified by flash chromatography
(silica gel, gradient, 0% to 10% MeOH in dichloromethane) to give
the title compound (189 mg, 68%) as a light yellow foam. MS (ESI,
m/z): 319.5 [(M+H).sup.+].
Example 60
1,3,3-Trimethyl-6-(1-(pyridin-4-yl)-1H-imidazol-4-yl)indolin-2-one
##STR00114##
[0655] Example 60 was prepared in analogy to example 59 using
4-bromopyridine in step e to give the title compound (60%) as a
light brown solid. MS (ESI, m/z): 319.5 [(M+H).sup.+].
Example 61
1,3,3-Trimethyl-6-(5-(2-methylpyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-one
##STR00115##
[0656] a)
1-(2-Methylpyridin-4-yl)-3-(1,3,3-trimethyl-2-oxoindolin-6-yl)pr-
opane-1,3-dione
[0657] 6-Acetyl-1,3,3-trimethylindolin-2-one from example 3a and
methyl 2-methylisonicotinate were reacted in analogy to example 42a
to give the title compound (47%) as an orange gum. MS (ESI, m/z):
337.5 [(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(5-(2-methylpyridin-4-yl)-1H-pyrazol-3-yl)indolin-2-o-
ne (Example 61)
[0658] Example 61 was prepared from
1-(2-methylpyridin-4-yl)-3-(1,3,3-trimethyl-2-oxoindolin-6-yl)propane-1,3-
-dione in analogy to example 56 to give the title compound (57%) as
a white solid. MS (ESI, m/z): 333.6 [(M+H).sup.+].
Example 62
1,3,3-Trimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)indolin-2-one
##STR00116##
[0660] Example 62 was prepared in analogy to example 59 using
4-bromo-2-methylpyridine in step e to give the title compound (81%)
as a light brown foam. MS (ESI, m/z): 333.5 [(M+H).sup.+].
Example 63
6-(2-(3-Methoxypyridin-4-yl)oxazol-5-yl)-3,3-dimethylindolin-2-one
##STR00117##
[0661] a) Methyl 3,3-dimethyl-2-oxoindoline-6-carboxylate
[0662] A mixture of 3,3-dimethyl-2-oxoindoline-6-carboxylic acid
(8.29 g) from example 28a in MeOH (30 ml) and sulfuric acid (825
mg) was heated to reflux temperature for 16 h. The mixture was
partitioned between aqueous sodium carbonate (2 M) and
dichloromethane, the organic layer was dried, evaporated, the
residue triturated with EtOAc and diisopropylether (1:1, 70 ml),
filtered and the residue dried to give the crude title compound
(4.50 g, 51%) as a light red solid, which was used without further
purification. MS (ESI, m/z): 220.5 [(M+H).sup.+].
b) 6-(Hydroxymethyl)-3,3-dimethylindolin-2-one
[0663] To a solution of methyl
3,3-dimethyl-2-oxoindoline-6-carboxylate (8.59 g) in THF (390 ml)
was added at 22.degree. C. LiBH4 (5.12 g) and stirring was
continued at 50.degree. C. for 60 h. The mixture was partitioned
between saturated aqueous ammonium chloride and EtOAc, the organic
layer was dried and evaporated to give the crude title compound
(8.32 g, quant.) as an yellow solid, which was used without further
purification. MS (ESI, m/z): 192.5 [(M+H).sup.+].
c) 3,3-Dimethyl-2-oxoindoline-6-carbaldehyde
[0664] A suspension of 6-(hydroxymethyl)-3,3-dimethylindolin-2-one
(7.55 g) and manganese dioxide (20.6 g) in dichloromethane (395 ml)
was heated to reflux temperature for 16 h. The mixture was filtered
and the residue purified by flash chromatography (silica gel,
gradient, 0% to 100% MeOH in dichloromethane) to give the title
compound (5.99 g, 80%) as a brown solid. MS (ESI, m/z): 190.4
[(M+H).sup.+].
d) 3,3-Dimethyl-6-(oxazol-5-yl)indolin-2-one
[0665] To a suspension of 3,3-dimethyl-2-oxoindoline-6-carbaldehyde
(5.90 g) and potassium carbonate (5.60 g) in methanol (43 ml) was
added tosylmethyl isocyanide (6.09 g) and stirring was continued at
80.degree. C. for 3 h. The mixture was partitioned between water
and dichloromethane, the organic layer was dried and evaporated to
give the crude title compound (6.45 g, 91%) as an orange solid,
which was used without further purification. MS (ESI, m/z): 229.5
[(M+H).sup.+].
e) 6-(2-Chlorooxazol-5-yl)-3,3-dimethylindolin-2-one
[0666] To a solution of 3,3-dimethyl-6-(oxazol-5-yl)indolin-2-one
(6.35 g) in THF (110 ml) was added at -78.degree. C. a solution of
LiHMDS (1 M in THF, 58 ml) and the mixture was warmed to 22.degree.
C. over 1.5 h. Hexachloroethane (7.00 g) was added and stirring was
continued for at RT for 1.5 h. The mixture was partitioned between
saturated aqueous sodium hydrogencarbonate and TBME, the organic
layer was dried, evaporated and the residue purified by flash
chromatography (silica gel, gradient, 0% to 100% EtOAc in
n-heptane) to give the title compound (4.90 g, 67%) as an orange
solid. MS (ESI, m/z): 263.4 [(M+H).sup.+].
f)
6-(2-Chlorooxazol-5-yl)-1-(4-methoxybenzyl)-3,3-dimethylindolin-2-one
[0667] A mixture of
6-(2-chlorooxazol-5-yl)-3,3-dimethylindolin-2-one (2.00 g),
1-(chloromethyl)-4-methoxybenzene (1.31 g) and cesium carbonate
(4.96 g) in DMF (51 ml) was heated to 80.degree. C. for 3 h. The
mixture was partitioned between water and EtOAc, the organic layer
was dried, evaporated and the residue purified by flash
chromatography (silica gel, gradient, 0% to 100% EtOAc in
n-heptane) to give the title compound (2.13 g, 73%) as a light
yellow semisolid. MS (ESI, m/z): 383.4 [(M+H).sup.+].
g)
1-(4-Methoxybenzyl)-6-(2-(3-methoxypyridin-4-yl)oxazol-5-yl)-3,3-dimeth-
ylindolin-2-one
[0668] A mixture of
6-(2-chlorooxazol-5-yl)-1-(4-methoxybenzyl)-3,3-dimethylindolin-2-one
(500 mg) and 3-methoxypyridin-4-ylboronic acid (367 mg) in
1,4-dioxane (10 ml) and aqueous sodium carbonate (2 M, 2.6 ml) was
flushed with argon, then
bis(triphenylphosphine)palladium(II)dichloride (141 mg) was added
and stirring was continued at reflux temperature for 16 h. The
mixture was evaporated and the residue purified by flash
chromatography (silica gel, gradient, 0% to 10% MeOH in
dichloromethane) to give the still impure title compound (274 mg,
46%) as a brown foam, which was used without further purification.
MS (ESI, m/z): 456.4 [(M+H).sup.+].
h)
6-(2-(3-Methoxypyridin-4-yl)oxazol-5-yl)-3,3-dimethylindolin-2-one
(Example 63)
[0669] A solution of
1-(4-methoxybenzyl)-6-(2-(3-methoxypyridin-4-yl)oxazol-5-yl)-3,3-dimethyl-
indolin-2-one (270 mg) in TFA (4 ml) was heated to 120.degree. C.
for 16 h. The mixture was partitioned between aqueous sodium
carbonate (2 M) and EtOAc, the organic layer was dried, evaporated
and the residue purified by flash chromatography (silica gel,
gradient, 0% to 10% MeOH in dichloromethane) to give the title
compound (71 mg, 36%) as a brown solid. MS (ESI, m/z): 336.5
[(M+H).sup.+].
Example 64
1,3,3-Trimethyl-6-(3-(2-methylpyridin-4-yl)isoxazol-5-yl)indolin-2-one
##STR00118##
[0670] a)
1-(2-Methylpyridin-4-yl)-3-(1,3,3-trimethyl-2-oxoindolin-6-yl)pr-
opane-1,3-dione
[0671] The title compound was prepared from
6-acetyl-1,3,3-trimethylindolin-2-one from example 3a and methyl
2-methylisonicotinate in analogy to example 42a to give the title
compound (76%) as an orange oil. MS (ESI, m/z): 337.5
[(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(3-(2-methylpyridin-4-yl)isoxazol-5-yl)indolin-2-one
(Example 64)
[0672] Example 64 was prepared from
1-(2-methylpyridin-4-yl)-3-(1,3,3-trimethyl-2-oxoindolin-6-yl)propane-1,3-
-dione in analogy to example 42b to give the title compound (18%)
as a light brown solid. MS (ESI, m/z): 334.2 [(M+H).sup.+].
Example 65
1,3,3-Trimethyl-6-(5-(pyridin-3-yl)-1H-pyrazol-3-yl)indolin-2-one
##STR00119##
[0673] a)
1-(Pyridin-3-yl)-3-(1,3,3-trimethyl-2-oxoindolin-6-yl)propane-1,-
3-dione
[0674] The title compound was prepared from
6-acetyl-1,3,3-trimethylindolin-2-one from example 3a and methyl
nicotinate in analogy to example 42a to give the title compound
(79%) as a yellow solid. MS (ESI, m/z): 323.5 [(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(5-(pyridin-3-yl)-1H-pyrazol-3-yl)indolin-2-one
(Example 65)
[0675] Example 65 was prepared from
1-(pyridin-3-yl)-3-(1,3,3-trimethyl-2-oxoindolin-6-yl)propane-1,3-dione
in analogy to example 56 to give the title compound (50%) as a
white solid. MS (ESI, m/z): 319.5 [(M+H).sup.+].
Example 66
1-Ethyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indolin-2-
-one
##STR00120##
[0676] a) 6-Bromo-1-ethyl-3,3-dimethylindolin-2-one
[0677] To a solution of 6-bromo-3,3-dimethylindolin-2-one (465 mg)
from example 1a in dry THF (12 ml) was added at 0.degree. C. a
solution of sodium bis(trimethylsilyl)amide (1M in THF, 6 ml)
followed by ethyl iodide (1.03 g) and stirring was continued at
0.degree. C. for 30 min and at 50.degree. C. for 16 h. The mixture
was partitioned between water and EtOAc, the organic layer was
dried, evaporated and the residue purified by flash chromatography
(silica gel, gradient, 0% to 100% EtOAc in n-heptane) to give the
title compound (490 mg, 94%) as a yellow oil. MS (ESI, m/z): 269.4
[(M+H).sup.+].
b)
1-Ethyl-3,3-dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)indoli-
n-2-one (Example 66)
[0678] Example 66 was prepared from
6-bromo-1-ethyl-3,3-dimethylindolin-2-one and
2-methyl-4-(1H-pyrazol-4-yl)pyridine from example 54a in analogy to
example 40 to give the title compound (55%) as a white solid. MS
(ESI, m/z): 347.6 [(M+H).sup.+].
Example 67
6-[1-(2-Fluoropyridin-4-yl)imidazol-4-yl]-1,3,3-trimethylindol-2-one
##STR00121##
[0680] Example 67 was prepared from
6-(1H-imidazol-5-yl)-1,3,3-trimethylindolin-2-one from example 59d
and 4-bromo-3-fluoropyridine hydrochloride in analogy to example
59e to give the title compound (9%) as a brown solid. MS (ESI,
m/z): 337.5 [(M+H).sup.+].
Example 68
1,3,3-Trimethyl-6-(4-(6-methylpyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-one
##STR00122##
[0681] a) 2-Methyl-5-(1H-pyrazol-4-yl)pyridine
[0682] The title compound was prepared from
5-bromo-2-methylpyridine and tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate
in analogy to example 41a and obtained as a brown solid (78%). MS
(ESI, m/z): 158.2 [(M-H).sup.-].
b)
1,3,3-Trimethyl-6-(4-(6-methylpyridin-3-yl)-1H-pyrazol-1-yl)indolin-2-o-
ne (Example 68)
[0683] Example 68 was prepared from
6-bromo-1,3,3-trimethylindolin-2-one from example 2a and
2-methyl-5-(1H-pyrazol-4-yl)pyridine in analogy to example 40 to
give the title compound (30%) as a white solid. MS (ESI, m/z):
333.6 [(M+H).sup.+].
Example 69
1-Cyclopropyl-3,3-dimethyl-6-(4-(6-methylpyridin-3-yl)-1H-pyrazol-1-yl)ind-
olin-2-one
##STR00123##
[0685] Example 69 was prepared from
6-bromo-1-cyclopropyl-3,3-dimethylindolin-2-one from example 1b and
2-methyl-5-(1H-pyrazol-4-yl)pyridine from example 68a in analogy to
example 40 to give the title compound (34%) as a white foam. MS
(ESI, m/z): 359.6 [(M+H).sup.+].
Example 70
3,3-Dimethyl-6-(4-(2-methylpyridin-4-yl)-1H-pyrazol-1-yl)-1-(oxetan-3-yl)i-
ndolin-2-one
##STR00124##
[0687] Example 70 was prepared from
6-bromo-3,3-dimethyl-1-(oxetan-3-yl)indolin-2-one from example 6a
and 2-methyl-4-(1H-pyrazol-4-yl)pyridine from example 54a in
analogy to example 40 to give the title compound (30%) as an
off-white solid. MS (ESI, m/z): 375.2 [(M+H).sup.+].
Example 71
1-Cyclopropyl-3,3-dimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2--
one
##STR00125##
[0688] a)
1-Cyclopropyl-6-(1H-imidazol-5-yl)-3,3-dimethylindolin-2-one
[0689] The title compound was prepared from
1-cyclopropyl-3,3-dimethyl-2-oxoindoline-6-carboxylic from example
4b in analogy to example 59a-d and obtained as a light brown foam
(48%). MS (ESI, m/z): 268.5 [(M+H).sup.+].
b)
1-Cyclopropyl-3,3-dimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-
-2-one (Example 71)
[0690] Example 71 was prepared from
1-cyclopropyl-6-(1H-imidazol-5-yl)-3,3-dimethylindolin-2-one and
3-bromopyridine in analogy to example 59e to give the title
compound (61%) as an off-white foam. MS (ESI, m/z): 345.5
[(M+H).sup.+].
Example 72
1-Cyclopropyl-3,3-dimethyl-6-(1-(pyridin-4-yl)-1H-imidazol-4-yl)indolin-2--
one
##STR00126##
[0692] Example 72 was prepared from
1-cyclopropyl-6-(1H-imidazol-5-yl)-3,3-dimethylindolin-2-one from
example 71a and 4-bromopyridine in analogy to example 59e to give
the title compound (38%) as an off-white foam. MS (ESI, m/z): 345.5
[(M+H).sup.+].
Example 73
6-(1-(3-Fluoropyridin-4-yl)-1H-imidazol-4-yl)-1,3,3-trimethylindolin-2-one
##STR00127##
[0694] Example 73 was prepared from
6-(1H-imidazol-5-yl)-1,3,3-trimethylindolin-2-one from example 59d
and 4-bromo-3-fluoropyridine hydrochloride in analogy to example
59e to give the title compound (59%) as a light brown solid. MS
(ESI, m/z): 337.2 [(M+H).sup.+].
Example 74
1-Cyclopropyl-3,3-dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)in-
dolin-2-one
##STR00128##
[0696] Example 74 was prepared from
1-cyclopropyl-6-(1H-imidazol-5-yl)-3,3-dimethylindolin-2-one form
example 71a and 4-bromo-2-methylpyridine in analogy to example 59e
to give the title compound (46%) as an off-white foam. MS (ESI,
m/z): 359.5 [(M+H).sup.+].
Example 75
1-Cyclopropyl-3,3-dimethyl-6-(3-(2-methylpyridin-4-yl)isoxazol-5-yl)indoli-
n-2-one
##STR00129##
[0697] a) 6-Acetyl-1-cyclopropyl-3,3-dimethylindolin-2-one
[0698] The title compound was prepared from
6-bromo-1-cyclopropyl-3,3-dimethylindolin-2-one from example 1b in
analogy to example 3a and obtained as a light yellow solid (76%).
MS (ESI, m/z): 344.5 [(M+H).sup.+].
b)
1-Cyclopropyl-3,3-dimethyl-6-(3-(2-methylpyridin-4-yl)isoxazol-5-yl)ind-
olin-2-one
Example 75
[0699] Example 75 was prepared from
1-(1-cyclopropyl-3,3-dimethyl-2-oxo-indolin-6-yl)-3-(2-methyl-4-pyridyl)p-
ropane-1,3-dione (obtained from
6-acetyl-1-cyclopropyl-3,3-dimethylindolin-2-one and methyl
2-methylpyridine-4-carboxylate in analogy to example 42a) in
analogy to example 42b to give the title compound (56%) as a white
foam. MS (ESI, m/z): 360.8 [(M+H).sup.+].
Example 76
1-Cyclopropyl-6-(1-(3-fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethylin-
dolin-2-one
##STR00130##
[0701] Example 76 was prepared from
1-cyclopropyl-6-(1H-imidazol-5-yl)-3,3-dimethylindolin-2-one from
example 71a and 4-bromo-3-fluoropyridine hydrochloride in analogy
to example 59e to give the title compound (23%) as an off-white
foam. MS (ESI, m/z): 363.2 [(M+H).sup.+].
Example 77
1,3,3-Trimethyl-6-(2-methyl-1-(pyridin-4-yl)-1H-imidazol-4-yl)indolin-2-on-
e
##STR00131##
[0702] a)
1,3,3-Trimethyl-6-(2-methyl-1H-imidazol-5-yl)indolin-2-one
[0703] To a solution of acetamidine (735 mg) in dichloromethane (50
ml) was added at 22.degree. C. a solution of
6-(2-bromoacetyl)-1,3,3-trimethylindolin-2-one (1.50 g) from
example 3b in dichloromethane (5 ml) and stirring was continued for
16 h. The mixture was partitioned between aqueous sodium carbonate
(2 M) and dichloromethane, the organic layer was dried, evaporated
and the residue purified by flash chromatography (silica gel,
gradient, 0% to 10% EtOAc in n-heptane) to give the title compound
(966 mg, 75%) as an off-white foam. MS (ESI, m/z): 256.5
[(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(2-methyl-1-(pyridin-4-yl)-1H-imidazol-4-yl)indolin-2-
-one (Example 77)
[0704] Example 77 was prepared from
1,3,3-trimethyl-6-(2-methyl-1H-imidazol-5-yl)indolin-2-one and
4-bromopyridine hydrochloride in analogy to example 59e to give the
title compound (50%) as a light yellow foam. MS (ESI, m/z): 333.5
[(M+H).sup.+].
Example 78
1,3,3-Trimethyl-6-(2-methyl-1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)indo-
lin-2-one
##STR00132##
[0706] Example 78 was prepared from
1,3,3-trimethyl-6-(2-methyl-1H-imidazol-5-yl)indolin-2-one from
example 77a and 4-bromo-2-metyhlpyridine in analogy to example 59e
to give the title compound (46%) as a light yellow foam. MS (ESI,
m/z): 347.5 [(M+H).sup.+].
Example 79
6-(1-(3-Fluoropyridin-4-yl)-2-methyl-1H-imidazol-4-yl)-1,3,3-trimethylindo-
lin-2-one
##STR00133##
[0708] Example 79 was prepared from
1,3,3-trimethyl-6-(2-methyl-1H-imidazol-5-yl)indolin-2-one from
example 77a and 4-bromo-3-fluoropyridine hydrochloride in analogy
to example 59e to give the title compound (23%) as a light brown
foam. MS (ESI, m/z): 351.5 [(M+H).sup.+].
Example 80
1,3,3-Trimethyl-6-(5-(6-methylpyridin-3-yl)-1H-pyrazol-3-yl)indolin-2-one
##STR00134##
[0709] a)
1-(6-Methylpyridin-3-yl)-3-(1,3,3-trimethyl-2-oxoindolin-6-yl)pr-
opane-1,3-dione
[0710] The title compound was prepared from
6-acetyl-1,3,3-trimethylindolin-2-one from example 3a and methyl
6-methylnicotinate in analogy to example 42a and obtained as a
yellow oil (48%). MS (ESI, m/z): 337.6 [(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(5-(6-methylpyridin-3-yl-1H-pyrazol-3-yl)indolin-2-on-
e (Example 80)
[0711] Example 80 was prepared from
1-(6-methylpyridin-3-yl)-3-(1,3,3-trimethyl-2-oxoindolin-6-yl)propane-1,3-
-dione in analogy to example 56 to give the title compound (69%) as
a yellow solid. MS (ESI, m/z): 333.8 [(M+H).sup.+].
Example 81
1,3,3-Trimethyl-6-(1-methyl-5-(2-methylpyridin-4-yl)-1H-pyrazol-3-yl)indol-
in-2-one
##STR00135##
[0713] Example 81 was prepared in analogy to example 61b using
methylhydrazine. The crude material was purified by flash
chromatography (silica gel, gradient, 0% to 5% MeOH in
dichloromethane) to give
1,3,3-trimethyl-6-(1-methyl-3-(2-methylpyridin-4-yl)-1H-pyrazol-5-yl)indo-
lin-2-one (67%) as the faster eluting isomer as a white solid. The
slower eluting isomer contained the title compound (29%) as a white
solid. MS (ESI, m/z): 347.5 [(M+H).sup.+].
Example 82
1,3,3-Trimethyl-6-(2-(2-methylpyridin-4-yl)pyrimidin-4-yl)indolin-2-one
##STR00136##
[0714] a)
1,3,3-Trimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)i-
ndolin-2-one
[0715] A mixture of 6-bromo-1,3,3-trimethylindolin-2-one (5.00 g)
from example 2a, bis(pinacolato)diboron (7.57 g) and potassium
acetate (3.90 g) in DMSO (66 ml) was flushed with argon, then
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (720
mg) was added and stirring was continued at 110.degree. C. for 16
h. The mixture was filtered, the filtrate partitioned between
aqueous hydrochloric acid (0.1 M) and EtOAc, the organic layer was
dried, evaporated and the residue purified by flash chromatography
(silica gel, 0% to 40% EtOAc in n-heptane) followed by trituration
with EtOAc/n-heptane (1:1) to give the title compound (4.16 g, 70%)
as a white solid. MS (ESI, m/z): 302.2 [(M+H).sup.+].
b) 6-(2-Chloropyrimidin-4-yl)-1,3,3-trimethylindolin-2-one
[0716] A mixture of
1,3,3-trimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2--
one (450 mg), 4-bromo-2-chloropyrimidine (578 mg) and aqueous
sodium carbonate (2 M, 1.5 ml) in 1,4-dioxane (8 ml) was flused
with argon, then
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (61 mg)
was added and stirring was continued at 80.degree. C. for 2 h. The
mixture was evaporated and the residue purified by flash
chromatography (Si--NH2, gradient, 0% to 50% EtOAc in n-heptane) to
give the title compound (367 mg, 85%) as a white solid. MS (ESI,
m/z): 288.4 [(M+H).sup.+].
c)
1,3,3-Trimethyl-6-(2-(2-methylpyridin-4-yl)pyrimidin-4-yl)indolin-2-one
(Example 82)
[0717] A mixture of
6-(2-chloropyrimidin-4-yl)-1,3,3-trimethylindolin-2-one (110 mg),
2-methylpyridin-4-ylboronic acid (106 mg) and cesium carbonate (500
mg) in THF (3 ml) and water (1.5 ml) was flushed with argon,
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (32 mg)
was added and stirring was continued at 80.degree. C. for 16 h. The
mixture was evaporated and the residue purified by flash
chromatography (Si--NH2, gradient, 0% to 40% EtOAc in n-heptane) to
give the title compound (90 mg, 68%) as a light yellow foam. MS
(ESI, m/z): 345.6 [(M+H).sup.+].
Example 83
1,3,3-Trimethyl-6-(2-(6-methylpyridin-3-yl)pyrimidin-4-yl)indolin-2-one
##STR00137##
[0719] Example 83 was prepared from
6-(2-chloropyrimidin-4-yl)-1,3,3-trimethylindolin-2-one from
example 82b and 6-methylpyridin-3-ylboronic acid in analogy to
example 82c to give the title compound (108 mg, 82%) as a white
solid. MS (ESI, m/z): 345.6 [(M+H).sup.+].
Example 84
1,3,3-Trimethyl-6-(4-methyl-3-(2-methylpyridin-4-yl)-1H-pyrazol-5-yl)indol-
in-2-one
##STR00138##
[0720] a)
2-Methyl-1-(2-methylpyridin-4-yl)-3-(1,3,3-trimethyl-2-oxoindoli-
n-6-yl)propane-1,3-dione
[0721] To a mixture of
1-(2-methylpyridin-4-yl)-3-(1,3,3-trimethyl-2-oxoindolin-6-yl)propane-1,3-
-dione from example 61a (433 mg) and potassium carbonate (267 mg)
DMF (1.5 ml) was added iodomethane (201 mg) and stirring was
continued at 60.degree. C. for 16 h. The mixture was evaporated and
the residue purified by flash chromatography (Si--NH2, gradient, 0%
to 100% EtOAc in n-heptane) to give the title compound (89 mg, 20%)
as a light brown solid. MS (ESI, m/z): 351.6 [(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(4-methyl-3-(2-methylpyridin-4-yl)-1H-pyrazol-5-yl)in-
dolin-2-one (Example 84)
[0722] A solution of
2-methyl-1-(2-methylpyridin-4-yl)-3-(1,3,3-trimethyl-2-oxoindolin-6-yl)pr-
opane-1,3-dione (89 mg), p-toluenesulfonic acid monohydrate (3 mg)
and hydrazine monohydrate (254 mg) in THF (1.2 ml) was stirred
70.degree. C. for 17 h. The mixture was evaporated and the residue
purified by flash chromatography (Si--NH2, gradient, 0% to 70%
EtOAc in n-heptane) to give the title compound (65 mg, 74%) as a
light yellow solid. MS (ESI, m/z): 347.5 [(M+H).sup.+].
Example 85
3,3-Dimethyl-6-(2-(6-methylpyridin-3-yl)pyrimidin-4-yl)-1-(oxetan-3-yl)ind-
olin-2-one
##STR00139##
[0723] a)
6-(2-Chloropyrimidin-4-yl)-3,3-dimethyl-1-(oxetan-3-yl)indolin-2-
-one
[0724] The title compound was prepared from
6-bromo-3,3-dimethyl-1-(oxetan-3-yl)indolin-2-one from example 6a
in analogy to example 82a-b and obtained as a light brown solid. MS
(ESI, m/z): 330.1 [(M+H).sup.+].
b)
3,3-Dimethyl-6-(2-(6-methylpyridin-3-yl)pyrimidin-4-yl)-1-(oxetan-3-yl)-
indolin-2-one
Example 85
[0725] Example 85 was prepared from
6-(2-chloropyrimidin-4-yl)-3,3-dimethyl-1-(oxetan-3-yl)indolin-2-one
and 6-methylpyridin-3-ylboronic acid in analogy to example 82c to
give the title compound (85%) as a brown solid. MS (ESI, m/z):
387.2 [(M+H).sup.+].
Example 86
1-Cyclopropyl-3,3-dimethyl-6-(2-methyl-1-(2-methylpyridin-4-yl)-1H-imidazo-
l-4-yl)indolin-2-one
##STR00140##
[0726] a) 6-Acetyl-1-cyclopropyl-3,3-dimethylindolin-2-one
[0727] The title compound was prepared from
6-bromo-1-cyclopropyl-3,3-dimethylindolin-2-one from example 1b in
analogy to example 3a and obtained as a light yellow solid (45%).
MS (ESI, m/z): 244.6 [(M+H).sup.+].
b) 6-(2-Bromoacetyl)-1-cyclopropyl-3,3-dimethylindolin-2-one
[0728] To a solution of
6-acetyl-1-cyclopropyl-3,3-dimethylindolin-2-one (1.00 g) in THF
(24 ml) and MeOH (16 ml) was added a solution of
tetra-n-butylammonium tribromide (2.02 g) in THF (8 ml) and
stirring was continued at 50.degree. C. for 5 h. The mixture was
evaporated and the residue purified by flash chromatography (silica
gel, 0% to 30% EtOAc in n-heptane) to give the crude title compound
(1.39 g, 87%) as a yellow viscous oil, which was used without
further purification. MS (ESI, m/z): 322.0/324.0 [(M+H).sup.+].
c)
1-Cyclopropyl-3,3-dimethyl-6-(2-methyl-1H-imidazol-5-yl)indolin-2-one
[0729] To a solution of acetamidine (631 mg) in dichloromethane (45
ml) was added at 22.degree. C. a solution of
6-(2-bromoacetyl)-1-cyclopropyl-3,3-dimethylindolin-2-one (1.40 g)
in dichloromethane (5 ml) and stirring was continued for 16 h. The
mixture was partitioned between aqueous sodium carbonate (2 M) and
EtOAc, the organic layer was dried, evaporated and the residue
purified by flash chromatography (silica gel, 0% to 10% MeOH in
dichloromethane) to give the title compound (543 mg, 44%) as a
purple foam. MS (ESI, m/z): 282.5 [(M+H).sup.+].
d)
1-Cyclopropyl-3,3-dimethyl-6-(2--(2-ml-1-(2-methylpyridin-4-yl)-1H-imid-
azol-4-yl)indolin-2-one (Example 86)
[0730] Example 86 was prepared from
1-cyclopropyl-3,3-dimethyl-6-(2-methyl-1H-imidazol-5-yl)indolin-2-one
and 4-bromo-2-methylpyridine in analogy to example 59e to give the
title compound (51%) as a brown solid. MS (ESI, m/z): 373.2
[(M+H).sup.+].
Example 87
1-Cyclopropyl-6-(1-(3-fluoropyridin-4-yl)-2-methyl-1H-imidazol-4-yl)-3,3-d-
imethylindolin-2-one
##STR00141##
[0732] Example 87 was prepared from
1-cyclopropyl-3,3-dimethyl-6-(2-methyl-1H-imidazol-5-yl)indolin-2-one
from example 86c and 4-bromo-3-fluoropyridine hydrochloride in
analogy to example 59e to give the title compound (25%) as a light
brown foam. MS (ESI, m/z): 377.2 [(M+H).sup.+].
Example 88
1,3,3-Trimethyl-6-(1-(3-methylpyridin-4-yl)-1H-imidazol-4-yl)indolin-2-one
##STR00142##
[0734] Example 88 was prepared from
6-(1H-imidazol-5-yl)-1,3,3-trimethylindolin-2-one from example 59d
and 4-bromo-3-picoline hydrochloride in analogy to example 59e to
give the title compound (58%) as a brown solid. MS (ESI, m/z):
333.2 [(M+H).sup.+].
Example 89
1-Cyclopropyl-3,3-dimethyl-6-(1-(3-methylpyridin-4-yl)-1H-imidazol-4-yl)in-
dolin-2-one
##STR00143##
[0736] Example 89 was prepared from
1-cyclopropyl-6-(1H-imidazol-5-yl)-3,3-dimethylindolin-2-one from
example 71a and 4-bromo-3-picoline hydrochloride in analogy to
example 59e to give the title compound (54%) as a light yellow
foam. MS (ESI, m/z): 359.2 [(M+H).sup.+].
Example 90
1-Cyclopropyl-3,3-dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)-1-
H-pyrrolo[3,2-c]pyridin-2(3H)-one
##STR00144##
[0737] a)
6-Chloro-1-cyclopropyl-3,3-dimethyl-1H-pyrrolo[3,2-c]pyridin-2(3-
H)-one
[0738] A mixture of
6-chloro-3,3-dimethyl-1H-pyrrolo[3,2-c]pyridin-2(3H)-one (600 mg,
prepared according to Woolford et al., WO 2012143726),
cyclopropylboronic acid (524 mg), copper(II)acetate (582 mg) and
DMAP (1.12 g) in toluene (50 ml) was flushed with argon, then
treated with sodium bis(trimethylsilyl)amide (2 M in THF, 1.6 ml)
and stirring was continued at 95.degree. C. for 16 h. The mixture
was partitioned between aqueous hydrochloric acid (1 M) and TBME,
the organic layer was dried, evaporated and the residue purified by
flash chromatography (silica gel, 0% to 30% EtOAc in n-heptane) to
give the title compound (547 mg, 76%) as a white solid. MS (ESI,
m/z): 237.5 [(M+H).sup.+].
b)
4-(1-Cyclopropyl-3,3-dimethyl-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-c]pyridi-
n-6-yl)-N,N-dimethyl-1H-imidazole-1-sulfonamide
[0739] A mixture of
6-chloro-1-cyclopropyl-3,3-dimethyl-1H-pyrrolo[3,2-c]pyridin-2(3H)-one
(195 mg) and
N,N-dimethyl-4-(tributylstannyl)-1H-imidazole-1-sulfonamide (478
mg, prepared according to Altenbach et al., J. Med. Chem. 51, 6571,
2008) in dry DMF (4 ml) was flusehd with argon, then
tetrakis(triphenylphosphine)palladium(0) (114 mg) was added and
stirring was continued at 80.degree. C. for 16 h. The mixture was
partitioned between saturated aqueous sodium hydrogencarbonate and
EtOAc, the organic layer was dried, evaporated and the residue
purified by flash chromatography (silica gel, 0% to 100% EtOAc in
n-heptane) to give the title compound (193 mg, 62%) as a white
solid.
c)
1-Cyclopropyl-6-(1H-imidazol-4-yl)-3,3-dimethyl-1H-pyrrolo[3,2-c]pridin-
-2(3H)-one
[0740] A suspension of
4-(1-cyclopropyl-3,3-dimethyl-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin--
6-yl)-N,N-dimethyl-1H-imidazole-1-sulfonamide (193 mg) in aqueous
hydrochloric acid (2 M, 8 ml) was heated to 100.degree. C. for 2 h.
The mixture was evaporated and the residue purified by flash
chromatography (silica gel, 0% to 10% MeOH in dichloromethane
containing NH.sub.4OH) to give the title compound (123 mg, 89%) as
a white foam. MS (ESI, m/z): 269.2 [(M+H).sup.+].
d)
1-Cyclopropyl-3,3-dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl-
)-1H-pyrrolo[3,2-c]pyridin-2(3H)-one (Example 90)
[0741] A suspension of
1-cyclopropyl-6-(1H-imidazol-4-yl)-3,3-dimethyl-1H-pyrrolo[3,2-c]pyridin--
2(3H)-one (80 mg), 4-fluoro-2-methylpyridine (42 mg) and cesium
carbonate (185 mg) in acetonitrile (1 ml) was heated to reflux
temperature for 3 h. The mixture was evaporated and the residue
purified by flash chromatography (silica gel, 0% to 10% MeOH in
dichloromethane) to give the title compound (59 mg, 55%) as a white
foam. MS (ESI, m/z): 360.3 [(M+H).sup.+].
Example 91
1-Cyclopropyl-6-(1-(3-fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyl-1-
H-pyrrolo[3,2-c]pyridin-2(3H)-one
##STR00145##
[0743] Example 91 was prepared analogy to example 90d using
3,4-difluoropyridine to give the title compound (87%) as a white
foam. MS (ESI, m/z): 364.2 [(M+H).sup.+].
Example 92
3,3-Dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)indolin-2-one
##STR00146##
[0744] a) 6-(2-Bromoacetyl)-3,3-dimethylindolin-2-one
[0745] The title compound was prepared from
6-bromo-3,3-dimethylindolin-2-one from example 1a in analogy to
example 3a-b and obtained as a white solid. MS (ESI, m/z): 282/284
[(M+H).sup.+].
b) 6-(1H-Imidazol-4-yl)-3,3-dimethylindolin-2-one
[0746] A solution of 6-(2-bromoacetyl)-3,3-dimethylindolin-2-one
(1.00 g) in formamide (24 ml) was heated to 190.degree. C. for 5 h.
The mixture was partitioned between water and EtOAc, the organic
layer was dried, evaporated and the residue purified by flash
chromatography (silica gel, 0% to 15% MeOH in dichloromethane) to
give the impure title compound (967 mg) as a brown solid, which was
used without further purification. MS (ESI, m/z): 228.1
[(M+H).sup.+].
c)
3,3-Dimethyl-6-(1-(2-methylpyridin-4-yl)-1H-imidazol-4-yl)indolin-2-one
(Example 92)
[0747] A mixture of 6-(1H-imidazol-4-yl)-3,3-dimethylindolin-2-one
(100 mg), 4-fluoro-2-methylpyridine (86 mg) and cesium carbonate
(186 mg) in acetonitrile (1 ml) was heated to 110.degree. C. for 16
h. The mixture was evaporated and the residue purified by flash
chromatography (silica gel, 0% to 10% MeOH in dichloromethane)
followed by second flash chromatography (basic alumina, 0% to 10%
MeOH in dichloromethane) to give the title compound (59 mg, 57%) as
an off-white solid. MS (ESI, m/z): 319.3 [(M+H).sup.+].
Example 93
3,3-Dimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2-one
##STR00147##
[0748] a) 6-(1H-Imidazol-5-yl)-3,3-dimethylindolin-2-one
[0749] The title compound was prepared from
6-bromo-3,3-dimethylindolin-2-one in analogy to example 3a-b and
using formamide in example 3c and obtained as a brown solid. MS
(ESI, m/z): 228.1 [(M+H).sup.+].
b) 3,3-Dimethyl-6-(1-(pyridin-3-yl)-1H-imidazol-4-yl)indolin-2-one
(Example 93)
[0750] A suspension of
6-(1H-imidazol-5-yl)-3,3-dimethylindolin-2-one (120 mg),
3-bromopyridine (200 mg), potassium carbonate (219 mg) and
2-acetylcyclohexanone (37 mg) in DMSO (2.5 ml) was flushed with
argon, then copper(I)chloride (26 mg) was added and stirring was
continued at 130.degree. C. for 9 h. The mixture was partitioned
between water and EtOAc, the organic layer was dried, evaporated
and the residue purified by flash chromatography (silica gel, 0% to
10% MeOH in dichloromethane) followed by HPLC chromatography
(RP-18, gradient, acetonitrile/water) to give the title compound
(19 mg, 12%) as a white solid. MS (ESI, m/z): 305.1
[(M+H).sup.+].
Example 94
1-Cyclopropyl-3,3-dimethyl-6-[2-(2-methyl-pyridin-4-yl)-oxazol-5-yl]-1,3-d-
ihydro-pyrrolo[3,2-c]pyridin-2-one
##STR00148##
[0752] A mixture of 2-(2-methylpyridin-4-yl)oxazole (0.13 g) from
example 22a,
6-chloro-1-cyclopropyl-3,3-dimethyl-1H-pyrrolo[3,2-c]pyridin-2(3H)-o-
ne (0.384 g) from example 90a and cesium carbonate (0.52 g) in
dioxane (5 ml) was flushed with argon, then Pd(OAc)2 (18 mg) and
2-(dicyclohexylphosphino)biphenyl (57 mg) were added and stirring
was continued at 110.degree. C. for 16 h. The mixture was
partitioned between water and EtOAc, the organic layer was dried,
evaporated and the residue purified by flash chromatography (silica
gel, gradient, 0% to 30% EtOAc in n-heptane) to give the title
compound (70 mg, 24%) as a light yellow solid. MS (ESI, m/z): 361.2
[(M+H).sup.+].
Example 95
6-(1-(5-Fluoro-2-methylpyridin-4-yl)-1H-imidazol-4-yl)-1,3,3-trimethylindo-
lin-2-one
##STR00149##
[0754] Example 95 was prepared from
6-(1H-imidazol-5-yl)-1,3,3-trimethylindolin-2-one from example 59d
and 4-bromo-5-fluoro-2-methylpyridine in analogy to example 59e to
give the title compound (58%) as a light brown oil. MS (ESI, m/z):
351.2 [(M+H).sup.+].
Example 96
6-(2-(5-Fluoro-2-methylpyridin-4-yl)oxazol-5-yl)-1,3,3-trimethylindolin-2--
one
##STR00150##
[0755] a) 6-(2-Azidoacetyl)-1,3,3-trimethylindolin-2-one
[0756] To a solution of
6-(2-bromoacetyl)-1,3,3-trimethylindolin-2-one (1.75 g) from
example 3b in acetone (18 ml) was added at 22.degree. C. sodium
azide (767 mg) and stirring was continued for 6 h. The mixture was
partitioned between water and dichloromethane, the organic layer
was dried and evaporated to give the crude title compound (1.51 g,
99%) as a light yellow solid, which was used without further
purification. MS (ESI, m/z): 259.1 [(M+H).sup.+].
b)
6-(2-(5-Fluoro-2-methylpyridin-4-yl)oxazol-5-yl)-1,3,3-trimethylindolin-
-2-one (Example 96)
[0757] To a solution of triphenylphosphine (570 mg) in toluene (4
ml) was subsequently added at 22.degree. C.
6-(2-azidoacetyl)-1,3,3-trimethylindolin-2-one (330 mg) and a
solution of 5-fluoro-2-methylisonicotinoyl chloride (222 mg) in
toluene (2 ml) and stirring was continued for 2 h. The mixture was
evaporated and the residue purified by flash chromatography (silica
gel, gradient, 20% to 100% EtOAc in n-heptane) and by preparative
HPLC (RP-18, gradient, acetonitrile/water) to give the title
compound (50 mg, 11%) as light yellow solid. MS (ESI, m/z): 352.2
[(M+H).sup.+].
Example 97
3,3-Dimethyl-6-[5-(2-methyl-pyridin-4-yl)-[1,3,4]oxadiazol-2-yl]-1-oxetan--
3-yl-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one
##STR00151##
[0758] a)
6-Chloro-3,3-dimethyl-1-oxetan-3-1,3-dihydro-pyrrolo[3,2-c]pyrid-
in-2-one
[0759] A mixture of
6-chloro-3,3-dimethyl-1H-pyrrolo[3,2-c]pyridin-2(3H)-one (2.65 g,
prepared according to Woolford et al., WO 2012143726),
3-bromooxetane (1.85 ml) and cesium carbonate (8.78 g) in DMF (20
ml) was heated to 60.degree. C. for 16 h. The mixture was
partitioned between saturated aqueous ammonium chloride and EtOAc,
the organic layer was dried, evaporated and the residue purified by
flash chromatography (silica gel, gradient, 0% to 30% EtOAc in
n-heptane) to give the title compound (2.90 g, 85%) as a white
solid. MS (ESI, m/z): 252.8 [(M+H).sup.+].
b)
3,3-Dimethyl-1-oxetan-3-yl-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine--
6-carboxylic acid methyl ester
[0760] To a solution of
6-chloro-3,3-dimethyl-1-oxetan-3-yl-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-o-
ne (2.90 g) in MeOH (30 ml) and DMF (3 ml) was added
1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride
dichloromethane adduct (0.87 g) and the mixture was carbonylated at
100.degree. C. and 150 psi CO pressure for 16 h. The mixture was
evaporated and the residue partitioned between water and EtOAc, the
organic layer was dried, evaporated and the residue purified by
flash chromatography (silica gel, gradient, 0% to 100% EtOAc in
n-heptane) to give the title compound (2.90 g, 92%) as a brown gum.
MS (ESI, m/z): 276.8 [(M+H).sup.+].
c)
3,3-Dimethyl-1-oxetan-3-yl-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine--
6-carboxylic acid hydrazide
[0761] To a solution of
3,3-dimethyl-1-oxetan-3-yl-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-6
carboxylic acid methyl ester (0.50 g) in MeOH (10 ml) was added at
22.degree. C. hydrazinehydrate (0.88 ml) and stirring was continued
for 3 h. The mixture was evaporated and the residue partitioned
between water and dichloromethane, the organic layer was dried,
evaporated and the residue triturated with n-pentane to give the
crude title compound (0.34 g, 68%) as a brown solid, which was used
without further purification. MS (ESI, m/z): 276.8
[(M+H).sup.+].
d) 2-Methyl-isonicotinic acid
N'-(3,3-dimethyl-1-oxetan-3-yl-2-oxo-2,3-dihydro-1H-pyrrolol[3,2-c]pyridi-
ne-6-carbonyl)-hydrazide
[0762] To a solution of 2-methyl-isonicotinic acid (100 mg) and
thionyl chloride (3.0 ml) was added DMF (0.05 ml) and stirring was
continued at 80.degree. C. for 4 h. The mixture was evaporated, the
residue dissolved in dichloromethane (5 ml), then
3,3-dimethyl-1-oxetan-3-yl-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-6--
carboxylic acid hydrazide (180 mg) was added at 22.degree. C.
followed by triethylamine (0.2 ml) and stirring was continued 12 h.
The mixture was partitioned between aqueous sodium
hydrogencarbonate and dichloromethane, the organic layer was dried,
evaporated and the residue purified by flash chromatography (silica
gel, dichloromethane/MeOH 99:1)) to give the title compound (100
mg, 35%) as a brown solid. MS (ESI, m/z): 396.0 [(M+H).sup.+].
e)
3,3-Dimethyl-6-[5-(2-methyl-pyridin-4-yl)-[1,3,4]oxadiazol-2-yl]-1-oxet-
an-3-yl-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one (Example 97)
[0763] Example 97 was prepared from 2-methyl-isonicotinic acid
N'-(3,3-dimethyl-1-oxetan-3-yl-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-
e-6-carbonyl)-hydrazide in analogy to example 11b to give the title
compound (63%) as a white solid. MS (ESI, m/z): 378.3
[(M+H).sup.+].
Example 98
6-(1-(2-Fluoro-5-methylpyridin-4-yl)-1H-imidazol-4-yl)-1,3,3-trimethylindo-
lin-2-one
##STR00152##
[0765] Example 98 was prepared from
6-(1H-imidazol-5-yl)-1,3,3-trimethylindolin-2-one from example 59d
and 2-fluoro-4-iodo-5-methylpyridine in analogy to example 59e to
give the title compound (12%) as a light yellow solid. MS (ESI,
m/z): 351.2 [(M+H).sup.+].
Example 99
6-(2-(2-Fluoro-5-methylpyridin-4-yl)oxazol-5-yl)-1,3,3-trimethylindolin-2--
one
##STR00153##
[0767] Example 99 was prepared from
6-(2-azidoacetyl)-1,3,3-trimethylindolin-2-one from example 96a and
2-fluoro-5-methylisonicotinoyl chloride in analogy to example 96b
to give the title compound (21%) as a white solid. MS (ESI, m/z):
352.2 [(M+H).sup.+].
Example 100
6-(5-(5-Fluoro-2-methylpyridin-4-yl)-1,3,4-oxadiazol-2-yl)-1,3,3-trimethyl-
indolin-2-one
##STR00154##
[0768] a) Methyl 1,3,3-trimethyl-2-oxoindoline-6-carboxylate
[0769] To a solution of methyl 2-oxoindoline-6-carboxylate (4.08 g)
and MeI (6.12 g) in DMF (61 ml) was added at 22.degree. C. NaH
(1.71 g) over a period of 1.5 h and stirring was continued for 4 h.
The mixture was partitioned between aqueous hydrochloric acid (1 M)
and EtOAc, the organic layer was dried, evaporated and the residue
purified by flash chromatography (silica gel, gradient, 0% to 100%
EtOAc in n-heptane) to give the title compound (0.64 g, 13%) as a
brown solid. MS (ESI, m/z): 234.5 [(M+H).sup.+]. The second
fraction contained
3,3-dimethyl-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl
ester (3.82 g, 82%) as brown solid. MS (ESI, m/z): 220.5
[(M+H).sup.+].
b) 1,3,3-Trimethyl-2-oxoindoline-6-carbohydrazide
[0770] A solution of methyl
1,3,3-trimethyl-2-oxoindoline-6-carboxylate (350 mg) in methanol (4
ml) and hydrazine monohydrate (751 mg) was stirred at 22.degree. C.
for 20 h. The mixture was evaporated and the residue partitioned
between water and dichloromethane, the organic layer was dried and
evaporated to give the crude title compound (340 mg, 97%) as a
white foam, which was used without further purification. MS (ESI,
m/z): 234.1 [(M+H).sup.+].
c)
N'-(5-Fluoro-2-methylisonicotinoyl)-1,3,3-trimethyl-2-oxoindoline-6-car-
bohydrazide
[0771] To a mixture of 5-fluoro-2-methylisonicotinic acid (200 mg)
in dichloromethane (7 ml) und DMF (1 ml) was subsequently added at
22.degree. C. EDCI (198 mg), HOBT (158 mg) and triethylamine (163
mg) and stirring was continued for 15 min.
1,3,3-Trimethyl-2-oxoindoline-6-carbohydrazide (165 mg) was added
and stirring was continued for 18 h. The mixture was evaporated and
the residue purified by flash chromatography (silica gel, gradient,
0% to 10% MeOH in dichloromethane) to give the title compound (186
mg, 62%) as yellow oil. MS (ESI, m/z): 371.1 [(M+H).sup.+].
d)
6-(5-(5-Fluoro-2-methylpyridin-4-yl)-1,3,4-oxadiazol-2-yl)-1,3,3-trimet-
hylindolin-2-one (Example 100)
[0772] Example 100 was prepared from
N'-(5-fluoro-2-methylisonicotinoyl)-1,3,3-trimethyl-2-oxoindoline-6-carbo-
hydrazide in analogy to example 11b to give the title compound
(43%) as a white solid. MS (ESI, m/z): 353.1 [(M+H).sup.+].
Example 101
1,3,3-Trimethyl-6-(2-(6-methylpyridin-3-yl)pyrimidin-5-yl)indolin-2-one
##STR00155##
[0773] a)
6-(2-Chloropyrimidin-5-yl)-1,3,3-trimethylindolin-2-one
[0774] Example 101a was prepared from
1,3,3-trimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2--
one from example 82a and 5-bromo-2-chloropyrimidine in analogy to
example 82b to give the title compound as white solid (195 mg,
58%). MS (ESI, m/z): 288.5 [(M+H).sup.+].
b)
1,3,3-Trimethyl-6-(2-(6-methylpyridin-3-yl)pyrimidin-5-yl)indolin-2-one
(Example 101)
[0775] Example 101 was prepared from
6-(2-chloropyrimidin-5-yl)-1,3,3-trimethylindolin-2-one and
6-methylpyridin-3-ylboronic acid in analogy to example 82c to give
the title compound as white solid (85 mg 64%). MS (ESI, m/z): 345.5
[(M+H).sup.+].
Example 102
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-1-(6-methyl-3-pyridyl-
)indolin-2-one
##STR00156##
[0776] a)
6-(1H-Imidazol-4-yl)-1-(4-methoxybenzyl)-3,3-dimethylindolin-2-o-
ne
[0777] Example 102a was prepared from
6-bromo-1-(4-methoxybenzyl)-3,3-dimethylindolin-2-one (example 25a)
in analogy to example 3a-b, 92b. The title compound was obtained as
brown semi solid and was used without further purification. MS
(ESI, m/z): 348.3 [(M+H).sup.+].
b)
6-[1-(3-Fluoro-4-pyridvyl)imidazol-4-yl]-3,3-dimethyl-indolin-2-one
[0778] Example 102b was prepared from
6-(1H-imidazol-4-yl)-1-(4-methoxybenzyl)-3,3-dimethylindolin-2-one
in analogy to example 92c (using 3,4-difluoropyridine) and 63 h.
The title compound was obtained as off white solid. MS (ESI, m/z):
321.1 [(M+H).sup.+].
c)
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-1-(6-methyl-3-pyri-
dyl)indolin-2-one (Example 102)
[0779] To a stirred solution of
6-[1-(3-fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-indolin-2-one
(150 mg) in acetonitrile (10 ml) were added potassium carbonate
(141.4 mg) and 5-bromo-2-methyl-pyridine (96.7 mg). The apparatus
was evacuated and flushed with argon 3 times. The resulting mixture
was stirred at room temperature for -2 minutes. Then the mixture
was sparged with argon for 10 minutes, CuI (10.0 mg) and
N,N'-dimethylethylen-1,2-diamine (13.1 mg) were added and sparging
continued for 10 minutes. Then the reaction mixture was heated to
110.degree. C. for 5 hours. The reaction was poured into ice water
and ethyl acetate. The layers were separated and the aqueous layer
extracted with ethyl acetate. The combined organic layers were
dried over sodium sulfate, filtered and concentrated under vacuum
and the residue purified by flash column chromatography (silica
gel, 0% to 10% MeOH in ethyl acetae). The title compound was
obtained as off white solid (60 mg, 31%). MS (ESI, m/z): 414.2
[(M+H).sup.+].
Example 103
6-[1-(3-fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-1-(2-methyl-4-pyridyl-
)indolin-2-one
##STR00157##
[0781] Example 103 was prepared in analogy to example 102 using
3,4-difluoropyridine for imidazole arylation and
4-bromo-2-methylpyridine for lactam arylation. The title compound
was obtained as white solid (70 mg). MS (ESI, m/z): 414.4
[(M+H).sup.+].
Example 104
3,3-Dimethyl-1-(6-methyl-3-pyridyl)-6-[1-(2-methyl-4-pyridyl)imidazol-4-yl-
]indolin-2-one
##STR00158##
[0783] Example 104 was prepared in analogy to example 102 using
4-fluoro-2-methylpyridine for imidazole arylation and
5-bromo-2-methyl-pyridine for lactam arylation. The title compound
was obtained as yellow solid (60 mg). MS (ESI, m/z): 410.0
[(M+H).sup.+].
Example 105
3,3-Dimethyl-1-(6-methyl-3-pyridyl)-6-[1-(3-methyl-4-pyridyl)imidazol-4-yl-
]indolin-2-one
##STR00159##
[0785] Example 105 was prepared in analogy to example 102 using
4-fluoro-3-methylpyridine for imidazole arylation and
5-bromo-2-methyl-pyridine for lactam arylation. The title compound
was obtained as off white solid (55 mg). MS (ESI, m/z): 409.9
[(M+H).sup.+].
Example 106
3,3-Dimethyl-1-(2-methyl-4-pyridyl)-6-[1-(3-methyl-4-pyridyl)imidazol-4-yl-
]indolin-2-one
##STR00160##
[0787] Example 106 was prepared in analogy to example 102 using
4-fluoro-3-methylpyridine for imidazole arylation and
4-bromo-2-methyl-pyridine for lactam arylation. The title compound
was obtained as off white solid (52 mg). MS (ESI, m/z): 410.0
[(M+H).sup.+].
Example 107
3,3-Dimethyl-1-(2-methylpyridin-4-yl)-6-(1-(2-methylpyridin-4-yl)-1H-imida-
zol-4-yl)indolin-2-one
##STR00161##
[0789] Example 107 was prepared in analogy to example 102 using
4-fluoro-2-methylpyridine for imidazole arylation and
4-bromo-2-methyl-pyridine for lactam arylation. The title compound
was obtained as colorless amorphous solid (35 mg). MS (ESI, m/z):
410.2 [(M+H).sup.+].
Example 108
6-(1-(3-Fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyl-1-(1-methyl-1H--
imidazol-4-yl)indolin-2-one
##STR00162##
[0791] Example 108 was prepared in analogy to example 102 using
3,4-difluoropyridine for imidazole arylation and
4-bromo-1-methyl-1H-imidazole for lactam arylation. The title
compound was obtained as brown amorphous solid (25 mg). MS (ESI,
m/z): 403.2 [(M+H).sup.+].
Example 109
6-(1-(3-Fluoropyridin-4-yl)-1H-imidazol-4-yl)-3,3-dimethyl-1-(1-methyl-1H--
pyrazol-3-yl)indolin-2-one
##STR00163##
[0793] Example 109 was prepared in analogy to example 102 using
3,4-difluoropyridine for imidazole arylation and
3-bromo-1-methyl-1H-pyrazole for lactam arylation. The title
compound was obtained as off white solid (18 mg). MS (ESI, m/z):
403.2 [(M+H).sup.+].
Example 110
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-1-(2-methylpyrimidin--
5-yl)indolin-2-one
##STR00164##
[0795] Example 110 was prepared in analogy to example 102 using
3,4-difluoropyridine for imidazole arylation and
5-bromo-2-methyl-pyrimidine for lactam arylation The title compound
was obtained as light brown solid (65 mg). MS (ESI, m/z): 415.2
[(M+H).sup.+].
Example 111
3,3-Dimethyl-1-(1-methylimidazol-4-yl)-6-[1-(2-methyl-4-pyridyl)imidazol-4-
-yl]indolin-2-one
##STR00165##
[0797] Example 111 was prepared in analogy to example 102 using
4-fluoro-2-methylpyridine for imidazole arylation and
4-bromo-1-methyl-1H-imidazole for lactam arylation The title
compound was obtained as light yellow solid (60 mg). MS (ESI, m/z):
399.0 [(M+H).sup.+].
Example 112
3,3-Dimethyl-1-(1-methylpyrazol-3-yl)-6-[1-(2-methyl-4-pyridyl)imidazol-4--
yl]indolin-2-one
##STR00166##
[0799] Example 112 was prepared in analogy to example 102 using
4-fluoro-2-methylpyridine for imidazole arylation and
3-bromo-1-methyl-1H-pyrazole for lactam arylation The title
compound was obtained as orange solid (50 mg). MS (ESI, m/z): 399.4
[(M+H).sup.+].
Example 113
3,3-Dimethyl-6-[1-(2-methyl-4-pyridyl)imidazol-4-yl]-1-(2-methylpyrimidin--
5-yl)indolin-2-one
##STR00167##
[0801] Example 113 was prepared in analogy to example 102 using
4-fluoro-2-methylpyridine for imidazole arylation and
5-bromo-2-methyl-pyrimidine for lactam arylation The title compound
was obtained as light yellow solid (50 mg). MS (ESI, m/z): 411.3
[(M+H).sup.+].
Example 114
3,3-Dimethyl-1-(1-methylimidazol-4-yl)-6-[1-(3-methyl-4-pyridyl)imidazol-4-
-yl]indolin-2-one
##STR00168##
[0803] Example 114 was prepared in analogy to example 102 using
4-fluoro-3-methylpyridine for imidazole arylation and
4-bromo-1-methyl-1H-imidazole for lactam arylation The title
compound was obtained as off white solid (45 mg). MS (ESI, m/z):
399.4 [(M+H).sup.+].
Example 115
3,3-Dimethyl-1-(1-methylpyrazol-3-yl)-6-[1-(3-methyl-4-pyridyl)imidazol-4--
yl]indolin-2-one
##STR00169##
[0805] Example 115 was prepared in analogy to example 102 using
4-fluoro-3-methylpyridine for imidazole arylation and
3-bromo-1-methyl-1H-pyrazole for lactam arylation The title
compound was obtained as off white solid (45 mg). MS (ESI, m/z):
399.2 [(M+H).sup.+].
Example 116
3,3-Dimethyl-6-[1-(3-methyl-4-pyridyl)imidazol-4-yl]-1-(2-methylpyrimidin--
5-yl)indolin-2-one
##STR00170##
[0807] Example 116 was prepared in analogy to example 102 using
4-fluoro-3-methylpyridine for imidazole arylation and
5-bromo-2-methyl-pyrimidine for lactam arylation The title compound
was obtained as orange solid (70 mg). MS (ESI, m/z): 399.2
[(M+H).sup.+].
Example 117
1-Cyclopropyl-3,3-dimethyl-6-(1-(2-methylpyrimidin-5-yl)-1H-imidazol-4-yl)-
indolin-2-one
##STR00171##
[0809] Example 117 was prepared from
1-cyclopropyl-6-(1H-imidazol-5-yl)-3,3-dimethylindolin-2-one from
example 71a in analogy to example 59e using
5-bromo-2-methylpyrimidine. The title compound was obtained as
brown solid (164 mg, 81%). MS (ESI, m/z): 360.2 [(M+H).sup.+].
Example 118
1-Cyclopropyl-3,3-dimethyl-6-(1-(5-methylpyrimidin-2-yl)-1H-imidazol-4-yl)-
indolin-2-one
##STR00172##
[0811] In a sealed glass tube a suspension of
1-cyclopropyl-6-(1H-imidazol-5-yl)-3,3-dimethylindolin-2-one
(example 71a, 70 mg), 2-chloro-5-methylpyrimidine (37.0 mg) and
cesium carbonate (158 mg) in acetonitrile (1.05 ml) was heated to
120.degree. C. for 30 minutes under microwave irradiation. Then
again 18 mg 2-chloro-5-methylpyrimidine and 89 mg cesium carbonate
were added and the reaction mixture heated to 120.degree. C. under
conventional heating for 2 hours. The reaction mixture was
concentrated in vacuo and purified by flash chromatography (silica
gel, gradient, 0% to 100% EtOAc in n-heptane). The title compound
was obtained as off white solid (75 mg, 80%). MS (ESI, m/z): 360.2
[(M+H).sup.+].
Example 119
1,3,3-Trimethyl-6-(1-(5-methylpyrimidin-2-yl)-1H-imidazol-4-yl)indolin-2-o-
ne
##STR00173##
[0813] Example 119 was prepared from
6-(1H-imidazol-5-yl)-1,3,3-trimethylindolin-2-one from example 59d
in analogy to example 118. The title compound was obtained as white
solid (71 mg, 86%). MS (ESI, m/z): 334.2 [(M+H).sup.+].
Example 120
1,3,3-Trimethyl-6-(1-(2-methylpyrimidin-5-yl)-1H-imidazol-4-yl)indolin-2-o-
ne
##STR00174##
[0815] Example 120 was prepared from
6-(1H-imidazol-5-yl)-1,3,3-trimethylindolin-2-one from example 59d
in analogy to example 59e using 5-bromo-2-methylpyrimidine. The
title compound was obtained as white solid (109 mg, 53%). MS (ESI,
m/z): 334.2 [(M+H).sup.+].
Example 121
3,3-Dimethyl-6-(1-(2-methylpyrimidin-5-yl)-1H-imidazol-4-yl)indolin-2-one
##STR00175##
[0817] Example 121 was prepared from
6-(1H-imidazol-4-yl)-1-(4-methoxybenzyl)-3,3-dimethylindolin-2-one
(example 102a) in analogy to example 59e (using
5-bromo-2-methylpyrimidine) and example 63h. The title compound was
obtained as light yellow solid (27 mg). MS (ESI, m/z): 320.2
[(M+H).sup.+].
Example 122
3,3-Dimethyl-6-(1-(5-methylpyrimidin-2-yl)-1H-imidazol-4-yl)indolin-2-one
##STR00176##
[0819] Example 122 was prepared from
6-(1H-imidazol-4-yl)-1-(4-methoxybenzyl)-3,3-dimethylindolin-2-one
from example 102a in analogy to example 118 and 63 h. The title
compound was obtained as light yellow solid (30 mg). MS (ESI, m/z):
320.2 [(M+H).sup.+].
Example 123
3,3-Dimethyl-6-(1-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)indolin-2-one
##STR00177##
[0821] Example 123 was prepared in analogy to example 102a-b using
2-fluoro-6-methylpyridine for the imidazole arylation. The title
compound was obtained as light yellow solid (41 mg). MS (ESI, m/z):
319.2 [(M+H).sup.+].
Example 124
6-[4-(5-Fluoro-2-methyl-4-pyridyl)imidazol-1-yl]-1,3,3-trimethyl-indolin-2-
-one
##STR00178##
[0822] a)
6-(4-Bromoimidazol-1-yl)-1,3,3-trimethyl-indolin-2-one
[0823] To a stirred solution of
6-Bromo-1,3,3-trimethylindolin-2-one (example 2a, 1 g) in NMP (9
ml) were added 4-bromo-1H-imidazole (0.578 g), potassium carbonate
(1.71 g) and 2-acetylcyclohexanone (0.26 ml) and the mixture was
sparged with argon for 15 minutes. Then CuCl (0.08 g) was added to
the mixture and sparging was continued for another 10 minutes. The
reaction vessel was sealed and the reaction then heated to
130.degree. C. for 14 hours. The reaction mixture was diluted with
water and extracted with ethyl acetate. The combined organic layers
were washed with water followed by brine. The organic layer was
dried with sodium sulfate and concentrated under vacuum. The crude
material was purified by flash chromatography (silica gel, gradient
0-30% ethyl acetate in hexane). Rhe title compound was obtained as
off white solid (300 mg, 42%). MS (ESI, m/z): 320.1
[(M+H).sup.+].
b)
6-[4-(5-Fluoro-2-methyl-4-pyridyl)imidazol-1-yl]-1,3,3-trimethyl-indoli-
n-2-one (Example 124)
[0824] In a microwave vessel to a stirred solution of
6-(4-Bromoimidazol-1-yl)-1,3,3-trimethyl-indolin-2-one (100 mg) in
a mixture of DME (3 ml) and water (0.8 ml) were added
5-fluoro-2-methyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
(111 mg) and potassium carbonate (259 mg). The reaction mixture was
sparged with argon for 15 minutes. Then
PdCl.sub.2(PPh.sub.3).sub.2(11 mg) was then added to the reaction
mixture and sparging was continued for another 10 minutes. The
reaction mixture heated to 130.degree. C. for 30 minutes under
microwave irradiation. The resulting suspension was filtered and
the filtrate was concentrated under vacuum. The crude crude
material was purified by flash chromatography (silica gel, gradient
70-80% ethyl acetate in hexane) followed by purification using
preparative TLC using ethyl acetate as the mobile phase. The title
compound was obtained as off white solid (22 mg, 26%). MS (ESI,
m/z): 350.9 [(M+H).sup.+].
Example 125
1,3,3-Trimethyl-6-[5-(3-methyl-4-pyridyl)isoxazol-3-yl]indolin-2-one
##STR00179##
[0825] a)
1-(3-Methyl-4-pyridyl)-3-(1,3,3-trimethyl-2-oxo-indolin-6-yl)pro-
pane-1,3-dione
[0826] To a stirred solution of
6-acetyl-1,3,3-trimethyl-2,3-dihydro-1H-indol-2-one (example 3a,
100 mg) in THF (2 ml) was added NaH (60% in oil, 39 mg) at
0.degree. C. and stirred for 30 minutes at room temperature. Then
methyl 3-methylpyridine-4-carboxylate (63 mg) in THF (1 ml) was
added and stirring at room temperature continued for 21 hours. Then
the reaction mixture was heated for 1 hour to 50.degree. C. The
reaction mixture was quenched with aqueous saturated ammonium
chloride solution and extracted with EtOAc. The combined organic
layers were washed with brine, dried over anhydrous sodium sulfate
and concentrated under vacuum. The crude material was purified by
flash chromatography (silica gel, EtOAc in n-hexane 20%). The title
compound was obtained as off white solid (60 mg, 52% based on
recovered starting material). MS (ESI, m/z): 337.0
[(M+H).sup.+].
b)
1,3,3-trimethyl-6-[15-(3-methyl-4-pyridyl)isoxazol-3-yl]indolin-2-one
(Example 125)
[0827] Example 125 was prepared from
1-(3-methyl-4-pyridyl)-3-(1,3,3-trimethyl-2-oxo-indolin-6-yl)propane-1,3--
dione in analogy to example 42a. The title compound was obtained as
off white solid (45 mg, 46%). Only the given isomer was obtained.
MS (ESI, m/z): 334.1 [(M+H).sup.+].
Example 126
1,3,3-Trimethyl-6-[4-(3-methyl-4-pyridyl)imidazol-1-yl]indolin-2-one
##STR00180##
[0829] In a microwave vessel to a stirred solution of
6-(4-bromoimidazol-1-yl)-1,3,3-trimethyl-indolin-2-one (example
124a, 500 mg) in dioxane (5 ml) were added
(3-methyl-4-pyridyl)boronic acid (256 mg) and NaOtBu (180 mg) and
the mixture sparged with argon. Then Brettphos (84 mg) and
Brettphos palladacycle (125 mg) were added and again sparged with
argon. The reaction mixture was heated to 130.degree. C. under
microwave irradiation for 1 hour. Then the reaction mixture was was
cooled to room temperature, filtered and concentrated under vacuum.
The crude material was purified by flash chromatography (80% ethyl
acetate in hexane). The title compound was obtained as off white
solid (21.6 mg, 10% based on recovered starting material). MS (ESI,
m/z): 333.1 [(M+H).sup.+].
Example 127
1,3,3-Trimethyl-6-[4-(2-methyl-4-pyridyl)imidazol-1-yl]indolin-2-one
##STR00181##
[0831] Example 127 was prepared in analogy to example 126. The
title compound was obtained as off white solid (20 mg, 9%). MS
(ESI, m/z): 333.3 [(M+H).sup.+].
Example 128
6-[4-(2-Fluoro-4-pyridyl)imidazol-1-yl]-1,3,3-trimethyl-indolin-2-one
##STR00182##
[0833] Example 128 was prepared in analogy to example 126. The
title compound was obtained as off white solid (8 mg, 14%). MS
(ESI, m/z): 337.2 [(M+H).sup.+].
Example 129
1-(3-Cyclopropylsulfonylpropyl)-6-[1-(3-fluoro-4-pyridyl)imidazol-4-yl]-3,-
3-dimethyl-indolin-2-one
##STR00183##
[0834] a)
6-Bromo-1-(3-cyclopropylsulfonylpropyl)-3,3-dimethyl-indolin-2-o-
ne
[0835] Example 129a was prepared from
6-bromo-3,3-dimethyl-indolin-2-one (example 1a) in analogy to
WO2014/40969 A1, examples 65b and 70e. The title compound was
obtained as off white solid (1.01 g). MS (ESI, m/z): 385.8, 387.8
[(M+H).sup.+].
b)
1-(3-Cyclopropylsulfonylpropyl)-6-(1H-imidazol-4-yl)-3,3-dimethyl-indol-
in-2-one
[0836] Example 129b was prepared in analogy to example 3a-b and
92b. The title compound was obtained as brown solid (0.6 g). MS
(ESI, m/z): 374.1 [(M+H).sup.+].
c)
1-(3-Cyclopropylsulfonylpropyl)-6-[1-(3-fluoro-4-pyridyl)imidazol-4-yl]-
-3,3-dimethyl-indolin-2-one (Example 129)
[0837] Example 129 was prepared in analogy to example 92c using
3,4-difluoropyridine. The title compound was obtained as brown
sticky solid (22 mg, 18%). MS (ESI, m/z): 469.3 [(M+H).sup.+].
Example 130
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-1-(2-hydroxyethyl)-3,3-dimethyl-in-
dolin-2-one
##STR00184##
[0838] a) (2-Bromoethoxy)(tert-butyl)dimethylsilane
[0839] To a stirred solution of TBDMSCl (3.5 g) in DMF (10 ml) was
added imidazole (1.77 g). Then 2-bromoethan-1-ol (2.5 g) was added
slowly dropwise and the reaction mixture was stirred at room
temperature for 16 hours. The reaction was quenched with water and
extracted with hexane. The combined organic layers were dried over
anhydrous sodium sulfate and concentrated under reduced pressure.
The crude material was purified by flash chromatography (silica
gel, gradient 0-3% ethyl acetate in hexane). The title compound was
obtained as colourless oil (3.96 g, 83%). NMR complied with
literature data.
b)
1-[2-[tert-Butyl(dimethyl(silyl]oxethyl]-6-[1-(3-fluoro-4-pyridyl)imida-
zol-4-v]-3,3-dimethyl-indolin-2-one
[0840] To a solution of compound
6-[1-(3-gluoro-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-indolin-2-one
(example 102b, 430 mg) in DMF (3 ml) was added Cs.sub.2CO.sub.3
(869.3 mg) and a solution of
2-(2-bromoethoxy)(tert-butyl)dimethylsilane (638.3 mg) in DMF (2
ml). The tube was sealed and the reaction mixture heated to
70.degree. C. for 5 hours. The reaction mixture was poured into ice
water and ethyl acetate. The layers were separated and the aqueous
layer extracted with ethyl acetate. The combined organic layers
were washed with water, dried over anhydrous sodium sulfate and
concentrated under reduced pressure. The crude material was
purified by flash chromatography (silica gel, gradient 0-50% EtOAc
in hexane). The title compound was obtained as brown solid (260 mg,
33%). MS (ESI, m/z): 481.0 [(M+H).sup.+].
c)
6-[1-(3-Fluoro-4-pyridyl)imidazol-4-yl]-1-(2-hydroxyethyl)-3,3-dimethyl-
-indolin-2-one (Example 130)
[0841] To a solution of
1-[2-[tert-Butyl(dimethyl)silyl]oxyethyl]-6-[1-(3-fluoro-4-pyridyl)imidaz-
ol-4-yl]-3,3-dimethyl-indolin-2-one (250 mg) in THF (10 ml) was
added TBAF solution (1 M in THF, 0.5 ml) at 0.degree. C. After 15
minutes the reaction mixture was allowed to reach room temperature
and was stirred for 3 hours. The reaction mixture was diluted with
water (30 ml) and extracted with ethyl acetate. The combined
organic layers were dried over anhydrous sodium sulfate and
concentrated under reduced pressure. The crude material was
purified by flash chromatography (silica gel, gradient 0-3%
methanol in dichloromethane). The title compound was obtained as
off white solid (71 mg, 37%). MS (ESI, m/z): 367.3
[(M+H).sup.+].
Example 131
1-(3-Cyclopropylsulfonylpropyl)-6-[1-(5-fluoro-2-methyl-4-pyridyl)imidazol-
-4-yl]-3,3-dimethyl-indolin-2-one
##STR00185##
[0843] In a sealed tube to a mixture of
4-bromo-5-fluoro-2-methylpyridine (66 mg), CsF (106 mg) and
tetramethylammonium fluoride (5 mg) in DMSO (1 ml) was heated to
120.degree. C. for 24 hours. Then the reaction mixture was cooled
to room temperature,
1-(3-cyclopropylsulfonylpropyl)-6-(1H-imidazol-4-yl)-3,3-dimethyl-indolin-
-2-one (example 129b, 100 mg) and Cs.sub.2CO.sub.3 (131 mg) were
added, the tube resealed and the reaction mixture heated to
50.degree. C. for 12 hours. The reaction mixture was diluted with
water and extracted with ethyl acetate. The combined organic layers
were washed with water and brine, dried over anhydrous sodium
sulfate and concentrated under vacuum. The crude material was
purified by flash chromatography (silica gel, gradient 0-80% ethyl
acetate in hexane) followed by purification by preparative TLC. The
title compound was obtained as white solid (31 mg, 16%). MS (ESI,
m/z): 483.1 [(M+H).sup.+].
Example 132
6-[1-(5-Fluoro-2-methyl-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-indolin-2-on-
e trifluoroacetate
##STR00186##
[0844] a)
6-[1-(5-Fluoro-2-methyl-4-pyridyl)imidazol-4-yl-1-(4-methoxyphen-
yl)methyl]-3,3-dimethyl-indolin-2-one
[0845] Example 132a was prepared in analogy to example 131 from
6-(1H-imidazol-4-yl)-1-(4-methoxybenzyl)-3,3-dimethylindolin-2-one
from example 102a. The title compound was obtained as brown solid
(57 mg, 31%). MS (ESI, m/z): 457.0 [(M+H).sup.+].
b)
6-[1-(5-Fluoro-2-methyl-4-pyridyl)imidazol-4-yl]-3,3-dimethyl-indolin-2-
-one trifluoroacetate (Example 132)
[0846] In a sealed tube a solution of
6-[1-(5-fluoro-2-methyl-4-pyridyl)imidazol-4-yl]-1-[(4-methoxyphenyl)meth-
yl]-3,3-dimethyl-indolin-2-one (50 mg) in TFA (3 ml) was heated to
110.degree. C. for 48 hours. The reaction mixture was concentrated
in vacuo and the residue triturated with ether and pentante to
afford the title compound as green sticky solid. MS (ESI, m/z):
337.1 [(M+H).sup.+].
Biological Assays and Data
[0847] Now it has been found that the compounds of formula I may be
used for the treatment of CNS diseases.
[0848] The described compounds of formula I reduce
L-687,414-induced hyperlocomotion. This was assessed by using a
computerized Digiscan 16 Animal Activity Monitoring System
(Omnitech Electronics, Columbus, Ohio) to quantify locomotor
activity. Animals were kept under a 12 h light/dark cycle and
experiments were performed during the light period. Each activity
monitoring chamber consisted of a Plexiglas box
(41.times.41.times.28 cm; W.times.L.times.H) with sawdust bedding
on the floor surrounded by invisible horizontal and vertical
infrared sensor beams. The test boxes were divided by a Plexiglas
cross providing each mouse with 20.times.20 cm of moving space.
Cages were connected to a Digiscan Analyzer linked to a computer
that constantly collected the beam status information. Records of
photocell beam interruptions for individual animals were taken
every 5 min over the duration of the experimental session and the
sum of the first 6 periods was used as the final parameter.
Compounds were administered either p.o. 15 min before a s.c.
injection of 50 mg/kg of L-687,414, or i.p. at the same time as a
s.c. injection of 50 mg/kg of L-687,414. Mice were then transferred
from their home cage to the recording chambers for a 15-min
habituation phase allowing free exploration of the new environment.
Horizontal activity was then recorded for a 30-min time period. The
% inhibition of L-687,414-induced hyperlocomotion was calculated
according to the equation:
((Veh+L-687,414 horizontal activity-drug+L-687,414 horizontal
activity)/Veh+L-687,414 horizontal activity).times.100
[0849] ID.sub.50 values, defined as doses of each compound
producing 50% inhibition of L-687,414-induced hyperlocomotion, were
calculated by linear regression analysis of a dose-response data
using an Excel-based computer-fitting program.
[0850] As data was not presupposed to be normally distributed,
groups treated with test compounds were statistically compared with
the control (vehicle-treated) group using one-tailed Mann Whitney U
tests. In statistics, the Mann-Whitney U test (also called the
Mann-Whitney-Wilcoxon (MWW) or Wilcoxon rank-sum test) is a
non-parametric statistical hypothesis test for assessing whether
one of two samples of independent observations tends to have larger
values than the other. It is one of the most well-known
non-parametric significance tests. A p value gives the probability
that two groups are significantly different from each other and the
value of <0.05 is generally accepted as a criterion, it implies
that there is >95% chance that two groups are really different
from each other. P values given in table 1 are one-tailed since
only decreases in locomotion were expected and tested for (Mann, H.
B., Whitney, D. R. (1947), "On a Test of Whether one of Two Random
Variables is Stochastically Larger than the Other", Annals of
Mathematical Statistics, 18 (1), 50-60).
TABLE-US-00001 TABLE 1 Effects of compounds of formula I on
L-687,414-induced hyperlocomotion Inhibi- ID.sub.50 Dose tion,
Doses po po Lowest ip ip Expl. structure [mg/kg] [mg/kg] P value
[mg/kg] [%] P value 2 ##STR00187## 3-10-30 10.71 0.00131 3
##STR00188## 30 58.9 0.00738 7 ##STR00189## 30 83.9 0.000932 8
##STR00190## 30 80.5 0.00521 10 ##STR00191## 30 78.8 0.00054 11
##STR00192## 30 80.9 0.003497 12 ##STR00193## 30 49.1 0.01896 19
##STR00194## 30 55.9 0.03248 20 ##STR00195## 30 64.4 0.01406 22
##STR00196## 30 55.9 0.03247 29 ##STR00197## 30 80.3 0.000932 33
##STR00198## 1-3-10 po 3.36 0.01405 35 ##STR00199## 1-3-10 po 5.82
0.0189 41 ##STR00200## 30 50.3 0.05244 42 ##STR00201## 30 58.4
0.00738 43 ##STR00202## 30 47.3 0.03248 44 ##STR00203## 30 52.1
0.03248 49 ##STR00204## 1-3-10 po 5.02 0.00349 (10 mg dose) 50
##STR00205## 30 44 0.04693 51 ##STR00206## 30 61 0.0035 52
##STR00207## 30 82.1 0.00008 54 ##STR00208## 30 41.6 0.05245 55
##STR00209## 30 42.7 0.03248 57 ##STR00210## 30 89.2 0.00008 62
##STR00211## 1-3-10 po 8.8 0.01409 63 ##STR00212## 30 75 0.001476
69 ##STR00213## 30 53.3 0.02424 73 ##STR00214## 1-3-10 po 2.97
0.0052 74 ##STR00215## 30 71.4 0.0035 76 ##STR00216## 1-3-10 po
<1 0.01033 77 ##STR00217## 30 89.4 0.00008 80 ##STR00218## 30
62.6 0.00738 88 ##STR00219## 30 93.1 0.00008 89 ##STR00220## 30
58.5 0.01896 101 ##STR00221## 30 78.4 0.00194 102 ##STR00222## 30
65.6 0.0037 104 ##STR00223## 30 64.8 0.00194 105 ##STR00224## 30
40.6 0.02028 106 ##STR00225## 30 68.4 0.0037 110 ##STR00226## 30
85.4 0.00097 111 ##STR00227## 30 55.1 0.00906 112 ##STR00228## 30
52.5 0.01197 113 ##STR00229## 30 69.9 0.00138 114 ##STR00230## 30
64.9 0.00679 115 ##STR00231## 30 74.1 0.00194 116 ##STR00232## 30
74.3 0.00194 118 ##STR00233## 30 50.3 0.03304 119 ##STR00234## 30
48.1 0.02602 123 ##STR00235## 30 30.6 0.18602 130 ##STR00236## 30
74.5 0.00679 132 ##STR00237## 30 71.1 0.00906
[0851] As mentioned above, some compounds have been tested in
SmartCube.RTM., an analytical system developed by PsychoGenics
Inc.
[0852] SmartCube.RTM. was used to compare the behavioral signature
of a test compound to a database of behavioral signatures obtained
from a large set of clinically approved reference drugs, grouped
per indications. In this way, the neuro-pharmacological effects of
a test compound can be predicted by similarity to major classes of
compounds, such as antipsychotics, anxiolytics and antidepressants.
This approach is ideally suited to screen collections of existing
drugs or drug candidates with previously unknown neuropharmacology,
which could expedite the development of new and unexpected
treatments for psychiatric disorders.
[0853] Some compounds of the present invention were injected i.p.
at different doses 15 minutes before the test. At least 8 mice were
used in each treatment group. Digital videos of the subjects were
processed with computer vision algorithms to extract over 2000
dependent measures including frequency and duration of many
different behavioral states. The results of the classifications are
presented as bar charts for each compound and dose (mg/kg), the
Y-axis indicates the relative probability that the test compound
will show efficacy in the specific CNS indication.
[0854] The bar charts of example compounds 35, 47, 62 and 93 at a
dose of 25 mg/kg are shown in FIG. 1. For comparison, the
behavioral signatures of the atypical antipsychotics olanzapine and
risperidone are shown in FIG. 2. Compounds of the present invention
show similar signatures to those of atypical antipsychotics. An
independent analysis was performed on the unclassified data to
determine the similarity of the example compounds to active doses
of known atypical antipsychotics. For this analysis, we use
discrimination rate as the measure of separability between the two
drugs, i.e. one drug's "distinguishability" from another. A rate
equal to 50% (or 0.5) corresponds to zero distinguishability.
Empirical data has shown that a threshold rate for reliable
separation lies above 70% i.e., two drugs showing a discrimination
rate of 70% or lower are considered similar, whereas a
discrimination rate higher than 70% indicates that two drugs are
dissimilar. The table below shows the similarity analysis of
selected compounds of the present invention to several atypical
antipsychotics. In most cases, the example compounds show a
similarity to risperidone, clozapine and olanzapine with a
discrimination rate of <0.70.
TABLE-US-00002 TABLE 2 Similarity analysis of compounds of formula
I (at 25 mg/kg) showing effects in SmartCube .RTM. Clozapine
Olanzapine Risperidone Example 35 0.69 0.75 0.60 Example 47 0.70
0.68 0.64 Example 62 0.59 0.62 0.58 Example 93 0.63 0.68 0.60
[0855] Therefore, it can be assumed that the present compounds have
similar efficacies as known atypical antipsychotics.
[0856] FIG. 1: SmartCube.RTM. signatures of compounds 35, 47, 62
and 93 (at 25 mg/kg)--are similar to those of atypical
antipsychotics.
[0857] FIG. 2: SmartCube.RTM. signatures of atypical antipsychotics
Clozapine, Olanzapine and Risperidone (each at two doses).
[0858] The compounds of formula (I) and pharmaceutically acceptable
salts thereof can be used as medicaments, e.g. in the form of
pharmaceutical preparations. The pharmaceutical preparations can be
administered orally, e.g. in the form of tablets, coated tablets,
dragees, hard and soft gelatine capsules, solutions, emulsions or
suspensions. However, the administration can also be effected
rectally, e.g. in the form of suppositories, or parenterally, e.g.
in the form of injection solutions.
[0859] The compounds of formula (I) and pharmaceutically acceptable
salts thereof can be processed with pharmaceutically inert,
inorganic or organic carriers for the production of pharmaceutical
preparations. Lactose, corn starch or derivatives thereof, talc,
stearic acid or its salts and the like can be used, for example, as
such carriers for tablets, coated tablets, dragees and hard
gelatine capsules. Suitable carriers for soft gelatine capsules
are, for example, vegetable oils, waxes, fats, semi-solid and
liquid polyols and the like; depending on the nature of the active
substance no carriers are, however, usually required in the case of
soft gelatine capsules. Suitable carriers for the production of
solutions and syrups are, for example, water, polyols, sucrose,
invert sugar, glucose and the like. Adjuvants, such as alcohols,
polyols, glycerol, vegetable oils and the like, can be used for
aqueous injection solutions of water-soluble salts of compounds of
formula (I), but as a rule are not necessary. Suitable carriers for
suppositories are, for example, natural or hardened oils, waxes,
fats, semi-liquid or liquid polyols and the like.
[0860] In addition, the pharmaceutical preparations can contain
preservatives, solubilizers, stabilizers, wetting agents,
emulsifiers, sweeteners, colorants, flavorants, salts for varying
the osmotic pressure, buffers, masking agents or antioxidants. They
can also contain still other therapeutically valuable
substances.
[0861] As mentioned earlier, medicaments containing a compound of
formula (I) or pharmaceutically acceptable salts thereof and a
therapeutically inert excipient are also an object of the present
invention, as is a process for the production of such medicaments
which comprises bringing one or more compounds of formula I or
pharmaceutically acceptable salts thereof and, if desired, one or
more other therapeutically valuable substances into a galenical
dosage form together with one or more therapeutically inert
carriers. The active compounds may also be used in form of their
prodrugs.
[0862] As further mentioned earlier, the use of the compounds of
formula (I) for the preparation of medicaments useful in the
prevention and/or the treatment of the above recited diseases is
also an object of the present invention.
[0863] The dosage can vary within wide limits and will, of course,
be fitted to the individual requirements in each particular case.
In general, the effective dosage for oral or parenteral
administration is between 0.01-20 mg/kg/day, with a dosage of
0.1-10 mg/kg/day being preferred for all of the indications
described. The daily dosage for an adult person weighing 70 kg
accordingly lies between 0.7-1400 mg per day, preferably between 7
and 700 mg per day.
[0864] Preparation of pharmaceutical compositions comprising
compounds of the invention:
[0865] Tablets of the following composition are manufactured in the
usual manner:
TABLE-US-00003 mg/tablet ingredient 5 25 100 500 Compound of
formula I 5 25 100 500 Lactose Anhydrous DTG 125 105 30 150 Sta-Rx
1500 6 6 6 60 Microcrystalline Cellulose 30 30 30 450 Magnesium
Stearate 1 1 1 1 Total 167 167 167 831
[0866] Manufacturing Procedure [0867] 1. Mix ingredients 1, 2, 3
and 4 and granulate with purified water. [0868] 2. Dry the granules
at 50.degree. C. [0869] 3. Pass the granules through suitable
milling equipment. [0870] 4. Add ingredient 5 and mix for three
minutes; compress on a suitable press.
[0871] Capsules of the following composition are manufactured:
TABLE-US-00004 mg/capsule ingredient 5 25 100 500 Compound of
formula I 5 25 100 500 Hydrous Lactose 159 123 148 -- Corn Starch
25 35 40 70 Talk 10 15 10 25 Magnesium Stearate 1 2 2 5 Total 200
200 300 600
[0872] Manufacturing Procedure [0873] 1. Mix ingredients 1, 2 and 3
in a suitable mixer for 30 minutes. [0874] 2. Add ingredients 4 and
5 and mix for 3 minutes. [0875] 3. Fill into a suitable
capsule.
[0876] A compound of formula I lactose and corn starch are firstly
mixed in a mixer and then in a comminuting machine. The mixture is
returned to the mixer; the talc is added thereto and mixed
thoroughly. The mixture is filled by machine into suitable
capsules, e.g. hard gelatin capsules.
[0877] Injection solutions of the following composition are
manufactured:
TABLE-US-00005 ingredient mg/injection solution. Compound of
formula I 3 Polyethylene Glycol 400 150 acetic acid q.s. ad pH 5.0
water for injection solutions ad 1.0 ml
[0878] Manufacturing Procedure
[0879] A compound of formula I is dissolved in a mixture of
Polyethylene Glycol 400 and water for injection (part). The pH is
adjusted to 5.0 by acetic acid. The volume is adjusted to 1.0 ml by
addition of the residual amount of water. The solution is filtered,
filled into vials using an appropriate overage and sterilized.
* * * * *